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Introduction 
Adapted from "Lymphangiogenesis in  
malignant tumors: does it occur?" 
R. Clarijs 
D.J. Ruiter  
R.M.W. de Waal 
J. Pathol. 2000; 193:143-146 
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Cancer is a common cause of death in Western society. A malignant tumor can 
arise in any organ and as long as it is confined to its organ of origin, patients 
can often be cured through surgical removal of the tumor. However, many 
cancers spread to other sites in the body and metastasis is the leading cause of 
death in cancer patients. Tumor cell extension can occur by different 
mechanisms such as direct invasion of surrounding tissues (per continuitatem), 
spread through body cavities, spread through lymphatic vessels (lymphatic 
metastasis) and via blood vessels (hematogenous metastasis). Despite its 
clinical relevance, the mechanisms leading to metastasis via the blood stream 
are only partly understood, and even much less is known about metastasis via 
lymphatic vessels. In addition, it appears that metastasis is not strictly 
dependent on dissemination via blood and lymphatic channels, but that also 
certain extracellular matrix deposition patterns may be involved. Therefore, we 
focused in this thesis on the role of the microvasculature and extracellular 
matrix patterns in progression and metastasis of human cancer with emphasis 
on cutaneous melanoma and, especially, uveal melanoma. 
 
Involvement of blood and lymphatic vessels in tumor growth and 
metastasis 
Solid tumors need blood supply for nutrition and growth.1 If a neovascular bed 
develops in and around the tumor, this process of angiogenesis is modulated 
by growth factors secreted by tumor cells or by an inflammatory infiltrate.2,3 
Next to facilitating tumor growth, the vascular bed is essential for metastasis. 
Indeed, in several types of tumors, a high mean vascular density was related 
to poor prognosis associated with a high rate of metastasis.4 This relationship 
may be explained by a simple, but hypothetical principle: the more vessels, the 
greater the probability that tumor cells invade the vascular bed and escape 
from the site of origin of the tumor. However, besides the number of vessels 
present in the tumor, other properties will determine metastatic spread as well. 
For example, proteolytic and migratory activity, the expression of adhesion 
molecules and deposition of extracellular matrix by stromal and/or tumor cells 
contribute importantly to tumor growth and rate of metastasis.5 
Many factors influence metastasis and could explain the aberrant findings in 
tumor types that do not obey the above-mentioned principle, like cutaneous 
melanoma and head-and-neck squamous cell carcinoma. In these types of 
malignant tumors, the microvascular density appears not to correlate with 
metastatic spread.6-8 Until now, the reason for this lack of correlation is unclear 
but it may be speculated that, next to several properties of tumor cells and 
tumor-associated stromal cells, the presence of a lymphatic vascular bed is an 
important factor. It is obvious that the preference of a tumor to spread initially 
via the lymphatic vascular bed may be dependent on a high intrinsic lymphatic 
density in the tissue where the tumor arose. 
 Lymphatics can be invaded by tumor cells when the tumor reaches pre-
existent vessels by outgrowth driven by angiogenesis or, alternatively, this 
might be accomplished by formation of new lymphatic vessels 
(lymphangiogenesis). In the first case, strong angiogenesis, reflected by high 
vascular density in the primary tumor, may increase lymphatic spread 
indirectly.9 By the lymphatic route, metastases are then formed in locoregional 
lymph nodes. Outgrowth of tumor metastases on its turn could invade both 
neighboring lymphatic and blood vessels in lymph nodes. As a result of lymph 
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node metastasis, the thoracic lymphatic duct would collect lymphatic fluid 
containing tumor cells and drain it into the blood stream in the superior vena 
cava. Tumor cells could easily be disseminated by this route to the blood 
stream. Moreover, shunts that may exist between lymphatic and blood vessels 
in lymph nodes could further facilitate hematogenous spread. By this 
hypothetical mechanism, the lymphatic vasculature could contribute to the 
formation of distant metastasis and explain the lack of correlation between 
high blood vessel density and prognosis found in cutaneous melanoma. In the 
second case, there is the possibility that occurrence of tumor-induced 
lymphangiogenesis contributes importantly to local metastasis. Indeed, by 
increasing peri- and intratumoral lymphatic density, tumor cells may become in 
close relationship with the lymphatic vasculature. 
 
Table I. Lymphatic markers and their expression pattern 
Markers Expression pattern 
CD31 expression on blood vessels 
Flt-4 re-expression on blood vessels in pathological conditions 
podoplanin expression in vascular tumors, kidney podocytes, osteoblasts 
and lung alveolar type I cells 
LYVE-1 expression in normal kidney, pancreas, adrenal and thyroid 
epithelia and in hepatic blood sinusoidal endothelial cells 
Prox-1 expression in the lens, heart, liver and nervous system 
β-chemokine 
receptor D6 
expression on a subset of the lymphatic vasculature 
desmoplakin expression in epithelia 
 
Evaluation of lymphatic vasculature 
Although in several studies blood and lymphatic vessels were discriminated by 
exploiting histo-morphological differences,10-12 lack of reliable lymphatic 
endothelial markers (Table I) has thus far hampered a consistent evaluation of 
the lymphatic vasculature in both normal and tumor tissues.13 Therefore, 
details of the anatomical relation between lymphatics and tumor cells on the 
one hand and the occurrence of lymphangiogenesis on the other, are 
essentially unknown. Recently, our group has developed a double staining 
protocol which differentially stains blood and lymphatic vasculature using the 
blood vessel endothelial marker PAL-E and the pan-endothelial marker CD31 in 
frozen sections of normal skin and cutaneous melanoma.9 Another possible 
candidate marker for lymphatic immuno-staining is Flt-4 (also known as 
vascular endothelium growth factor receptor-3 (VEGFR-3)).14 In adult life, Flt-4 
is restricted exclusively to lymphatic endothelium.14-17 However, recent studies 
demonstrated that this receptor is upregulated on blood vessels in 
carcinoma,18,19 making this marker less useful for detection of lymphatics in 
tumors. Lymphatics may also be detected by an antibody directed against 
podoplanin.20,21 Podoplanin is a membrane glycoprotein that was identified on 
podocytes in rat kidneys 22 and was expressed in endothelial cells of normal 
lymphatics and benign lymphatic tumors.20 LYVE-1 (lymphatic vessel 
endothelial hyaluronan receptor), the ß-chemokine receptor D6 and Prox-I 
have been recently reported to be lymph-specific.23-26 However, recent studies 
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showed that these markers may have their drawbacks as well (Table I).25,27 
Less well known antibodies that may be suitable for lymphatic detection are 
LyMAb 28 and a monoclonal antibody direct against desmoplakin-containing 
endothelial junctions.29-31 Finally, it has been reported that lymphatics can also 
be visualized by 5'-nucleotidase enzyme histochemistry.32-34 
 
Tumor-induced lymphangiogenesis 
Initially, Folkman raised the question whether intratumoral lymphatics are 
present, newly formed, and functional and whether they are part of the tumor 
vascular system.35 He asserted that tumors do not possess lymphatics which 
has lead to some discussion.35-37 However, lymphatics present both intra- and 
peritumorally have been reported.9 Although it could not be discriminated 
whether intratumoral lymphatics were pre-existent or newly formed, the 
occurrence of (tumor-induced) lymphangiogenesis in adults was initially 
suggested in the context of wound healing and head and neck cancer.17,38 
Further evidence of tumor-induced lymphangiogenesis in humans is provided 
by recent experimental animal studies.39-44 As a result of these pioneering 
publications, the role of lymphatics and the possible occurrence of 
lymphangiogenesis in cancer has become a hot topic.45-49 
It is not unlikely that the growth factors involved in vasculogenesis and 
lymphangiogenesis during embryogenesis (for review: see ref. 50) are also 
involved during tumor growth in adults, similar to what has been described for 
hemangiogenic factors. Members of the family of VEGFs are prime regulators of 
angiogenesis, via their interaction with the VEGF receptors Flt-1 (VEGFR-1) and 
KDR (VEGFR-2) (for extensive review: see ref. 51). In vessel walls in adults, 
Flt-1 and KDR are exclusively expressed on blood vascular endothelial cells 
whereas the third member of the VEGF-receptor family, Flt-4, is restricted to 
lymphatic endothelium.14 The role of Flt-4 in normal lymphatic vascular 
function is established by studies demonstrating that hereditary lymphoedema 
is caused by missense mutations in the Flt-4 encoding sequence.52,53 
Furthermore, Flt-4 has been implicated in both angiogenesis and 
lymphangiogenesis during embryogenesis.14 Overexpression of the ligand of 
Flt-4, VEGF-C 54,55 in the skin of transgenic mice resulted in lymphatic 
endothelial proliferation and vessel enlargement.56 Other studies 39,57,58 pointed 
at a role of VEGF-C and the other ligand of Flt-4, VEGF-D 59 as a specific 
lymphatic growth factor. Indeed, overexpression of VEGF-C and VEGF-D have 
been shown to induce lymphangiogenesis in a number of different murine and 
avian chorioallantoic membrane xenograft models,39-44 thereby pointing at an 
existence of tumor-induced lymphangiogenesis in human patients. This 
possibility is supported by the presence of both VEGF-C and Flt-4 expression 
19,60-64 and a relationship between VEGF-C expression and lymph node 
metastasis in different human tumor types.33,63,65-68 VEGF-A does not bind to 
Flt-4 and induces angiogenesis exclusively,56 indicating that the receptor 
mediating putative lymphangiogenesis must be Flt-4. This hypothesis is indeed 
confirmed by recent studies: first, it appeared that a soluble form of Flt-4 is a 
potent inhibitor of VEGF-C/-D signaling. Soluble Flt-4 expressed in the skin of 
transgenic mice, inhibits fetal lymphangiogenesis and induces a regression of 
already formed lymphatic vessels.69 Second, signaling via Flt-4 alone was 
sufficient for lymphangiogenic signals, since a mutated VEGF-C, which only 
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activates Flt-4 but not KDR, induced 
growth of lymphatic vessels in the 
skin of transgenic mice.39 
Next to specific lymphatic growth 
factors VEGF-C and VEGF-D (figure 
1), other factors may play a role in 
tumor-induced lymphangiogenesis. 
Due to a lack of detailed studies, 
the origin of lymphatic endothelial 
cells in adult angiogenesis is still 
unknown. It is likely that lymphatic endothelial cells originate from pre-existent 
lymphatics or from blood vasculature present at the tumor site. The gradual 
limitation of Flt-4 expression to only the lymphatic endothelial cells during late 
embryogenesis 14 and the induction of Flt-4 expression on angiogenic tumor 
blood vessels 18,19 support the generally accepted assumption that lymphatics 
are derived from blood vessels and in particular, from veins.70 Similar to the 
formation of blood vessels during embryogenesis, circulating (bone marrow-
derived) precursor cells in the blood or lymphatic stream could also participate 
in the formation of new lymphatics. 
 
The role of Flt-4 expression in tumor-induced angiogenesis 
During mouse embryogenesis, Flt-4 expression starts at embryonic day (E) 8 in 
developing blood vessels, but becomes largely restricted to the lymphatic 
endothelium after their formation from day E 12.5 onward.14,57 The essential 
involvement of Flt-4 in blood vessel formation during embryogenesis is further 
emphasized by a study which demonstrated that targeted disruption of Flt-4 in 
mouse embryos prevented the remodeling of the primary vascular network and 
caused death at day E 9.5.71 Flt-4 expression is also present on tumoral blood 
vessels, suggesting participation of Flt-4 in tumor angiogenesis as well.18,19,72,73 
Indeed, blocking of Flt-4 function resulted in impaired or absent branching of 
secondary and tertiary vessels in xenografted tumors,72 thereby indicating that 
Flt-4 may have a similar role in tumor-induced and embryogenetic 
angiogenesis: remodelling of the primitive plexus into a higher-ordered 
architecture. Angiogenesis mediated by Flt-4 signal transduction is likely to 
occur after binding of its known receptors VEGF-C and VEGF-D (figure 1). 
Initially, it was reported that VEGF-C is able to induce angiogenesis in adult life 
Figure 1. Schematic drawing of a 
hypothetical mechanism by which 
malignant tumors can induce 
lymphangiogenesis. Briefly, tumor cells 
express and release VEGF-C and -D. 
Both grow factors activate Flt-4 
expressed on endothelial cells (EC) of 
both blood and lymphatic vessels. Both 
types of vessels could serve as possible 
sources of lymphatic endothelial cells,70 
necessary for lymphangiogenesis. 
Angiogenesis via VEGF-C and -D release 
can be mediated by binding to Flt-4 and 
KDR on blood vessel endothelium. 
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in the mouse cornea, ischemic muscle and a xenograft model.43,74,75 However, 
overexpression of a Flt-4-specific mutant of VEGF-C and VEGF-D induced the 
growth of lymphatic vessels in the skin of transgenic mice,39 thereby indicating 
that VEGF-C and VEGF-D induced angiogenesis is mediated predominantly by 
KDR, rather than by Flt-4. 
If Flt-4 expression on blood vessels is restricted to malignant tumors, it may 
have diagnostic, prognostic and even therapeutic implications. In case of 
histological diagnostic difficulties, immunohistochemical analysis of Flt-4 
expression may provide additional support in determining whether a tumor is 
benign or malignant and, perhaps, what its grade of malignancy is. Anti-
angiogenic therapy aimed at Flt-4 may selectively destroy tumor blood vessels 
and reduce angiogenesis, whereas the normal blood vasculature remains 
unaffected. Also, lymphatic spread may be inhibited by destruction of lymphatic 
vessels and preventing lymphangiogenesis. 
Although there are clear indications for the function of Flt-4 expression on 
tumor blood vessels,72 it is yet unknown how this reappearance of Flt-4 is 
mediated. It is likely that factors released by the tumor cells themselves induce 
Flt-4 expression in a paracrine manner since the expression is present on blood 
vessels which are directly adjacent to tumor cell nests.19 So, identifying the key 
players involved in Flt-4 induction would be of significant importance for our 
understanding of the mechanism of tumor-induced angiogenesis. 
 
Absence of lymphatic vasculature in uveal melanoma 
Melanoma of the uvea is the most common primary malignant intraocular 
tumor in adults,76 originating from neuroectodermally derived melanocytes in 
the iris, ciliary body or choroid (figure 2). The highly vascularised choroid is the 
largest part of the uveal tract and the most common site for intraocular 
melanoma (80%).77 These posterior melanoma lesions disseminate exclusively 
by a hematogenous route to the liver,78 whereas anterior (iris) uveal 
melanomas may also metastasize to local cervical lymph nodes after invasion 
of conjunctival lymphatics.79,80 The pure hematogenous spread of posterior 
tumors is generally explained by the assumption that lymphatic channels are 
absent from the eye and its derived melanoma. As depicted in figure 1, VEGF-
C, VEGF-D and Flt-4 
are thought be 
involved in tumor-
induced lymphangio-
genesis. However, as 
stated above, other 
factors may play a 
Figure 2. Schematic 
drawing of parasagital 
section of the human 
eye. The different 
layers of the bulbus 
oculi are depicted to 
show the localizations 
where primary uveal 
melanoma may arise 
(asteriks). 
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role in this process such as pre-existent blood and lymphatic vessels which 
may serve as a source of lymphatic endothelial cells. Evaluation of the 
lymphangiogenic proteins in a tumor type in which no lymphatic vessels are 
present (such as uveal melanoma) may therefore be useful in the identification 
of these additional factors. 
 
Microvascular or extracellular matrix patterns in uveal melanoma 
In the early nineties, Folberg et al. presented nine morphological types of 
microvessel architecture in uveal melanoma.81 These microvascular patterns 
were identified by fluorescein-conjugated Ulex europaeus I as a marker for 
endothelium and by periodic acid-Schiff (PAS) histochemistry that stains 
basement membranes and collagen.81,82 The patterns included: 1) the normal 
pattern (pre-existing blood vessels), 2) the silent pattern (lacking pre-existent 
tumor vessels), 3) the straight pattern (randomly oriented straight vessels that 
are not linked to one another), 4) the parallel pattern (straight vessels that are 
arranged to one another), 5) the parallel with cross-links pattern (vessels of 
parallel patterns that are also linked to each other), 6) the arcs patterns and 7) 
arcs with branching patterns (curves of vessels that form incomplete loops), 8) 
the loops pattern (vessel loops that are completely closed) and 9) the network 
pattern (composed of at least three back-to-back closed loops). By definition, if 
networks are present, loops are present.81 
In uveal melanoma, the PAS-positive patterns arranged in arcs, loops and 
networks proved to be related to rate of metastasis and, hence, prognosis.81,82 
Since then, similar patterns in human metastatic cutaneous melanoma, breast, 
ovarian and prostate carcinoma were found and these could be related to 
prognosis as well.83-87 These data indicate that the patterns play a biological 
role in tumor growth and metastasis. Their exact nature has become an 
extensive issue of debate in recent literature.81,82,88-92 It was suggested that 
they were, in fact, blood vessel like vascular channels.81,82 Re-assessment by 
an additional study questioned the true microvascular nature of the patterns 88 
as Foss et al. documented that the patterns consisted of extracellular matrix in 
which blood vessels were embedded. Furthermore, it was suggested that 
'vascular channels' were associated with the PAS-positive arcs, loops and 
network patterns.93 Vascular channels are blood-conducting channels lined by 
tumor cells (and not by endothelium) in close contact with the blood 
vasculature. In these channels along the PAS-positive patterns, melanoma cells 
mimic endothelial cells (i.e. vasculogenic mimicry 90,93). The finding of the 
possible existence of vasculogenic mimicry is of great significance for current 
insight in tumor biology and treatment: a tumor containing vascular channels 
would not be fully dependent on angiogenesis for growth and metastasis and it 
would be less sensitive to drugs aimed at interfering with endothelial cells. 
Besides a possible role in tumor perfusion, the PAS-positive patterns may 
also be involved in tumor infiltration by inflammatory cells, since recent studies 
reported the presence of macrophages along the arcs, loops and network 
patterns.94,95 In general, tumor-associated macrophages are present as a 
major component of the host leukocyte infiltrate and their presence is related 
to poor prognosis in several types of malignant tumors, including uveal 
melanoma.94,96-98 These data point at an important role of macrophages in 
tumor growth and metastasis. Chemotactic cytokines provide the directional 
stimulus for the movement of leukocytes and are thought to be important in 
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the recruitment of monocytes into tumors. Several cytokines have been 
identified in this recruitment, including monocyte chemotactic protein-1, 
macrophage colony stimulating factor and VEGF-A (for extensive review: see 
ref. 99). In addition, endothelial-monocyte activating protein-II (EMAP-II) and 
VEGF-C have macrophage-chemotactic properties. EMAP-II was originally 
described as a tumor-derived cytokine, isolated from MethA tumor 
supernatant.100,101 It is involved in embryonic development,102-104 inflammation 
105,106 and autoimmune disease.107 Tumor-associated macrophages may play a 
role in tumor progression and regression. For example, it is known that 
macrophages promote tumor angiogenesis.108 Furthermore, they may be 
involved in the genesis of the PAS-positive patterns. 
 
Outline of this thesis 
Despite the significant role of blood vessels, lymphatics and the arcs, loops and 
network PAS-positive patterns for tumor growth, progression and metastasis, 
especially the role of lymphatics, the presence of tumor-induced 
lymphangiogenesis and the nature of the PAS-positive patterns require further 
attention. Therefore, we decided to study the following issues: 
 
1. To investigate the anatomical relationship between the lymphatic 
vasculature and tumor cells, a reliable immunohistochemical detection of 
lymphatics is required. Therefore, in chapter 2 we further explored the 
differential blood and lymphatic staining by the previously described PAL-
E/CD31 double-staining protocol 9 in a panel of normal and malignant 
tissues. In addition, Flt-4 expression on blood vessels as a possible 
progression marker was analyzed in a series of human melanocytic skin 
lesions with increasing malignancy. 
2. For a better understanding of tumor-induced angiogenesis, identification of 
tumor derived factors that are involved in the induction of Flt-4 expression 
on blood vessels, would be useful. In chapter 3, we addressed the role of 
VEGF-A in this process using a xenograft mouse model of hematogenous 
human melanoma brain metastasis. 
3. In addition to VEGF-C and VEGF-D, other factors are involved in tumor-
induced lymphangiogenesis. In chapter 4, we determined the absence of 
lymphatics in primary uveal melanoma and studied the role of VEGF-A, 
VEGF-C, KDR and Flt-4 in this tumor type. 
4. Since the nature of the PAS-positive patterns is essentially unknown, we 
analyzed morphological and functional properties of these patterns in 
primary uveal and xenografted melanoma in chapters 5 and 6. 
5. In chapter 7, we further extended our study of the role of the PAS-positive 
arcs, loops and networks patterns by investigating the role of EMAP-II and 
VEGF-C in chemotaxis of monocytes and macrophages in primary uveal 
melanoma. 
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SUMMARY 
 
The anatomical relation between a malignant tumor and its vascular and 
lymphatic bed is an important factor influencing metastasis. Lack of specific 
markers for the lymphatic endothelium has long hampered a reliable detection 
of lymphatics. Here, we demonstrate that lymphatic endothelium can reliably 
be identified in a panel of different normal tissues and of benign and malignant 
tumors. Application of the previously described PAL-E/CD31 double staining 
protocol differentiates between blood capillaries and veins on one hand and 
lymphatic vessels on the other. Blood vessel marker CD34, absent from 
lymphatics, was used additionally to classify arteries. We found that the 
lymphatic Flt-4 receptor (also known as vascular endothelial growth factor 
receptor-3 (VEGFR-3)) was present on both lymphatic and blood vessels in 76 
of 113 malignant tumors (adenocarcinoma of kidney (n=3), colon (n=3) and 
liver (n=3), breast (n=9) and squamous cell carcinoma (n=5), primary (n=81) 
and metastatic (n=9) melanoma). No evident signs of tumor-induced 
lymphangiogenesis were observed. Evaluation of a series of 110 melanocytic 
skin lesions indicated that Flt-4 expression is confined to the lymphatic 
vasculature in benign lesions. However, its expression emerges on the blood 
neovasculature in malignant lesions as soon as metastatic potential develops. 
We conclude that induction of Flt-4 expression on tumor blood vessels may be 
a general phenomenon which would make Flt-4 a marker for tumor 
endothelium. In addition, we propose Flt-4 expression as a new microvascular 
progression marker in cutaneous melanoma. 
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INTRODUCTION 
 
The dependence of tumors on the presence of a vascular bed for outgrowth and 
metastasis has now been firmly established.1,2 Although tumor cell invasion of 
lymphatics worsens prognosis significantly,3,4 it is still unknown why several 
tumors have a tendency to spread via the lymphatic bed. Evaluation of the 
anatomical relation between tumor mass and lymphatic bed has not been 
studied in much detail due to the lack of specific lymphatic markers.5 Until 
recently, it was generally assumed that intratumorally no lymphatic vessels are 
present and that tumors are not able to induce formation of new lymphatic 
vasculature (lymphangiogenesis).6 This is confirmed in a number of cases of 
primary cutaneous melanoma lesions and in a murine sarcoma model.7,8 
However, the possibility that lymphangiogenesis may occur in human 
malignant tumors is suggested by several animal studies demonstrating that 
xenografted tumors induced lymphangiogenesis as a result of overexpression 
of vascular endothelial growth factor-C (VEGF-C) or –D.9-13  
More recently, several different specific lymphatic endothelial markers have 
been described which are not yet widely available however.14-17 Therefore, 
blood and lymphatic vessels have been differentiated often by exploiting histo-
morphological differences.18-20 In a previous study,7 we developed a staining 
protocol (using the pan-endothelial marker CD31 and the blood vessel 
endothelial marker PAL-E) that differentially highlights blood and lymphatic 
vasculature in normal skin and primary melanoma lesions. Arteries are not 
decorated by this staining protocol but this problem was overcome by 
supplementing the staining protocol with a monoclonal antibody (mAb) to the 
endothelial marker CD34.21 Staining for CD34 of the endothelia of arteries, 
venules and capillaries has been demonstrated in normal and tumor tissues.18-
20 The issue whether CD34 is expressed on lymphatic vessels is not completely 
settled since its absence 15,18 but also a variable, presumed lymphatic staining 
have been described.19,20,22 
Another, direct way of identification of lymphatics was more recently reported 
using the 9D9 mAb.23 9D9 specifically recognizes the Flt-4 receptor (also 
known as vascular endothelial growth factor receptor-3 (VEGFR-3)) that is 
expressed on lymphatic endothelium in normal adult tissues.24 However, the 
use of Flt-4 as a marker for lymphatic vessels in human disease is dubious 
since Flt-4 expression on blood vessels has been reported in different types of 
malignant tumors and granulation tissue.21,25-27 Flt-4 ligands are VEGF-C and -
D,28-30 of which VEGF-C induces both blood and lymphatic vessel 
development.9-12,31-33 So, the presence of Flt-4 on tumor vessels together with 
VEGF-C and/or -D might be indicative for both hem- and lymphangiogenesis in 
human cancer. 
Recent data suggest that Flt-4 expression on blood vessels may be a general 
phenomenon in human cancer.21,25,26 Furthermore, if this expression does not 
occur in normal tissues, it may have biological and clinical implications. 
Theoretically, it may be related to the rate of malignancy, and therapeutical 
interventions using Flt-4 as a target might selectively reduce tumor growth by 
inhibition of both hemangiogenesis and lymphangiogenesis with possibly little 
side effects. In human skin, proliferation of melanocytes can give rise to 
common acquired melanocytic nevus, atypical (dysplastic) nevus, melanoma in 
situ, primary melanoma and melanoma metastasis (referred to as "stages of 
  26
melanoma progression"). The probability of metastasis considerably rises once 
the stage of a thick (lesion thickness > 1.5 mm) primary melanoma lesion has 
been reached. In the present study, this series of melanocytic lesions was 
taken as a model to evaluate whether Flt-4 expression on tumor blood vessels 
may serve as a tumor progression marker. 
Thus, we evaluated blood and lymphatic vessel staining by the PAL-E/CD31 
staining protocol, and by the QBEnd/10 (anti-CD34) and 9D9 (anti-Flt-4) 23,24 
mAbs in a panel of different human normal and tumor tissues. The analysis 
focused on the following questions: 1) can blood and lymphatics be identified 
using serial sections stained by PAL-E/CD31 and CD34 in these tissues, 2) is 
Flt-4 expressed on blood vessels in the included tumor types, 3) are 
intratumoral lymphatics present in the various tumor types and can signs of 
lymphangiogenesis be observed, and 4) is Flt-4 expression on blood vessels a 
tumor progression marker? 
 
MATERIALS AND METHODS 
 
Patient Material 
Frozen specimens of 20 normal and 52 tumor human tissues (Table I) were 
obtained from the pathology archives of the University Hospital Nijmegen 
where they were stored at –1300C. Additional primary melanoma lesions 
(n=10) were kindly provided by Dr. U. Hofmann (Universitäts-Hautklinik, 
Würzburg, Germany). 68 paraffin-embedded primary cutaneous melanoma 
lesions (36 tumors with a Breslow diameter of < 0.75 mm; 17 tumors between 
0.76-1.50 mm; 7 tumors between 1.50-3.00 mm and 8 tumors of > 3.00 mm) 
and 3 paraffin-embedded squamous cell carcinomas of the larynx were 
obtained from our pathology archives. All specimens had been diagnosed by a 
pathologist. 
 
Table I. Tissues included in this study* 
normal tissues tumor tissues 
breast (n=3)  breast cancer (invasive intraductal carcinoma, n=8; invasive 
lobular carcinoma, n=1) 
colon (n=3) colon (adenocarcinoma, n=3) 
kidney (n=3) kidney (adenocarcinoma, n=3) 
liver (n=3) liver (hepatocellular carcinoma, n=3) 
preputial skin (n=5) larynx (squamous cell carcinoma, n=5) 
skin (n=3)  skin (common acquired melanocytic nevus, n=10) ** 
 skin (atypical (dysplastic) nevus, n=10) ** 
 skin (melanoma in situ, n=7) ** 
 skin (superficial spreading melanoma lesions, n=60) ** 
 skin (nodular melanoma lesions, n=11) ** 
 skin (acrolentiginous melanoma lesions, n=3) ** 
 skin (melanoma metastasis lesions, n=9) ** 
*  in total 20 normal and 133 tumor tissues were included 
** stages of melanoma progression 
 
Antibodies 
The mAbs used for immunohistochemistry were the endothelial markers CD34 
(QBEnd/10) (DAKO, Glostrup, Denmark) and Flt-4 (9D9) (Molecular/Cancer 
Biology Laboratory, Haartman Institute, University of Helsinki, Helsinki, 
Finland), the pan-endothelial marker CD31 (PECAM-1) (British Biotechnology, 
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ITK Diagnostics, Uithoorn, The Netherlands) and the blood vessel endothelial 
marker mAb PAL-E (our laboratory). Vascular staining by a batch of PAL-E 
hybridoma supernatant was optimized and evaluated in frozen skin sections. 
Polyclonal antibodies (PAbs) to Flt-4 (Santa Cruz, CA, USA) were purchased. 
 
Immunohistochemistry 
Except otherwise indicated, all incubation experiments were performed at room 
temperature. Four micron cryosections were air-dried and fixed in acetone at 
room temperature for 10 minutes. By haematoxylin and eosin (H&E) staining, 
representative sections of the included normal or tumor tissues (Table I) were 
identified. Areas in the normal tissue sections corresponding to tumor sites, 
were used as controls. Blocking of non-specific binding of biotin/avidin system 
reagents (Biotin/Avidin blocking kit, Vector Laboratories, Burlingame, CA, USA) 
was performed when necessary. After the first and all following incubation 
steps, the sections were rinsed with ample phosphate-buffered saline (PBS). 
Three successive sections of each specimen were incubated with 9D9, 
QBEnd/10 and PAL-E for 60 minutes, as previously described.7 Then the 
secondary biotinylated affinity-purified anti-mouse IgG (Vectastain, Vector 
Laboraties) was incubated for 30 minutes, followed by a 45-minute incubation 
for the PAL-E and CD34 stainings and 30 minutes for the 9D9 staining with 
peroxidase-labelled biotin avidin complex (Vectastain). Subsequently, the 9D9 
sections were incubated for 5 minutes with biotinylated tyramine, followed by a 
20-minute incubation with the ABC-peroxidase solution (CARD method 34). All 
three stainings were developed by a 10-minute incubation with a 0.4 mg/ml 
amino-9-ethyl-carbazole solution (Aldrich, Steinheim, Germany). In a part of 
the tumor tissues, a similar staining procedure was conducted with the PAbs to 
Flt-4. Sections prestained with PAL-E were incubated with the anti-CD31 
antibody 60 minutes. The secondary alkaline phosphate-labelled rabbit-anti-
mouse IgG was incubated for 30 minutes. The second staining was developed 
for 10 minutes with a mixture of 1 mg/ml Fast Blue, 0.2 mg/ml naphthol 
phosphate and 0.24 mg/ml levamisole (Sigma-Aldrich, Bornem, Belgium). 
Four micron paraffin-embedded serial sections were deparaffinized in xylene 
and rehydrated in an ethanol series. Antigen-retrieval was performed by boiling 
the sections for 10 minutes in sodium citrate buffer (pH=6.0) using a 
microwave oven. Endogenous peroxidase activity was blocked by treating the 
sections for 30 minutes with PBS containing 3% hydrogen peroxide. Then the 
sections were incubated with 20% normal horse serum (Vector Laboraties) for 
10 minutes. Two successive sections of each specimen were incubated with 
9D9 mAb and QBEnd/10 mAb overnight at 40C and further processed as 
described above. 
In control sections, primary antibodies were omitted. The following tissues 
were included as positive controls: normal skin, melanoma and breast 
carcinoma lesions in case of PECAM-1, PAL-E and 9D9 stainings 7,25,26,35 and 
hepatocellular carcinoma in case of QBEnd/10.36-38 The 9D9 and QBEnd/10 
stainings were counterstained for 45 seconds with Harris’ haematoxylin (Merck, 
Darmstadt, Germany) at room temperature. All sections were mounted in 
Imsol-mount medium (Klinipath B.V., Duiven, The Netherlands). 
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Determination of blood vessel density 
In case of the primary melanoma lesions, we selected the superficial spreading 
melanoma lesions to evaluate the microvascular density (MVD) as a parameter 
of the extent of hemangiogenesis which is a measure for tumor progression. 
The nodular and acrolentiginous melanoma lesions were excluded to avoid 
biasing data obtained. By visual examination of the PAL-E/CD31 and CD34 
immunostainings at 63x magnification, blood vessels in 10 nonoverlapping 
fields per tumor lesion were counted and averaged. Vascular counts included 
complete cross sections, partial cross sections and small groups of positive 
cells. 
 
RESULTS 
 
Evaluation of the PAL-E/CD31 and CD34 staining protocols in frozen 
sections 
In all normal and tumor tissues (Table I), both immunostainings decorated 
vascular structures, which could be identified on the basis of their architecture 
and characteristic staining pattern, as described earlier (Table II,7,18-20) (figure 
1a-d, appendix). 
As previously shown,7,21 the PAL-E/CD31-double staining differentially 
highlighted blood and lymphatic capillary beds in all normal (figure 1a) and 
tumor tissues (figure 1b). Because of PAL-E staining on arterial vessels was 
absent,39 PAL-E negative and CD31 positive (CD31+/PAL-E-) ones were 
classified as lymphatic or arterial vessels whereas PAL-E and CD31 positive 
(PAL-E+) ones were classified as blood vessels.7,21 Staining of infiltrating 
leukocytes by CD31 was prominent as well (figure 1b). 
Compared to the PAL-E/CD31 double staining, the anti-CD34 mAb stained 
PAL-E+ blood vessels and CD31+/PAL-E- vessels in all included tissues. Using 
the differences in morphological characteristics of arterial and lymphatic 
vessels, the CD34+ and CD31+/PAL-E- vessels could be classified as arteries. No 
staining of lymph vessels by the anti-CD34 mAb was observed in any of the 
normal tissues and tumor tissues (figure 1c,d, appendix). Also, stromal areas 
in sections of colon, colon carcinoma and (adnexal structures in) skin were 
positive using CD34 immunohistochemistry. 
 
Table II. Summary of the endothelial staining patterns in frozen sections 
  normal tissues:  tumor tissues  
antigen mAb blood vessel lymphatics blood vessel lymphatics 
CD31 PECAM-1 +* + +* + 
unknown PAL-E + - + - 
CD34 QBEnd/10 + - + - 
Flt-4 9D9 - + +** + 
+ = intensive staining (arrowhead, figure 1e), - = no staining (arrow, figure 1e) 
*  since PAL-E and anti-CD31 antibodies were used in a double staining protocol, it is 
not possible to identify CD31-staining of the capillary and venous blood vessels. 
Capillary and venous CD31 staining is overruled by the PAL-E staining 7 (figures 1-3) 
**  the occurrence of blood vessel staining in the various tumors by the anti-Flt-4 mAb is 
shown in more detail in Table III 
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Vascular Flt-4 expression in normal and tumor tissues on frozen 
sections 
Despite extensive testing, immunostaining by the anti-Flt-4 PAbs in our hands 
resulted in a high background staining of especially stromal areas and 
unreliable, irreproducible staining of the vasculature. Therefore, we excluded 
these PAbs from further analysis. 
Using serial PAL-E/CD31 and CD34 stainings, Flt-4 expression detected by 
the anti-Flt-4 mAb could be localized on lymphatic vessels in all normal tissues 
(figure 1e, Table II). No or very weak expression of Flt-4 on blood vessels was 
observed. However, we observed expression of Flt-4 on both blood and 
lymphatic vessels in 33 of the 42 investigated malignant tumors (Table II,III, 
figure 1b,f). In most malignant tumors, blood vessels surrounding nests of 
tumor cells were stained by the anti-Flt-4 mAb. In kidney and hepatocellular 
carcinoma, a more intense staining of the intratumoral blood vessels occurred 
compared to the other tumor types. In several malignant tumors within one 
section, both negative and positive Flt-4 staining of blood vessels was 
observed. The Flt-4 positive blood vessels were present in areas directly 
surrounding the tumor cells whereas Flt-4 negative ones were localized at 
further distance (figure 1f). 
 
Table III. Incidence of Flt-4 expression on tumor blood vessels 
tumor type  positive cases* 
breast (invasive intraductal and lobular carcinoma) 9/9 
colon (adenocarcinoma) 2/3 
larynx (squamous cell carcinoma) 4/5 
kidney (adenocarcinoma) 3/3 
liver (hepatocellular carcinoma) 3/3 
skin (common acquired melanocytic nevus) 0/10 
skin (atypical (dysplastic) nevus) 1/10 
skin (melanoma in situ) 0/7 
skin (superficial spreading melanoma lesions) 32/60 
skin (nodular melanoma lesions) 11/11 
skin (acrolentiginous melanoma lesions) 3/3 
skin (melanoma metastasis lesions) 9/9 
*  Positivity was defined as staining (as shown in figure 1 and 3 
(appendix)) by the mAb 9D9 (anti- Flt-4) of PAL-E+ or CD34+ vessels 
 
Lymphatics and lymphangiogenesis in the tumor tissues 
Presence of lymph vessels of kidney and liver carcinoma lesions were confined 
to the peritumoral areas. In common acquired melanocytic nevi, atypical 
(dysplastic) nevi, primary and metastatic melanoma, breast, colon and larynx 
carcinoma lesions, lymph vessels were also observed in the stroma between 
nests of melanocytes or tumor cells. These vessels may represent pre-existing 
lymphatics or may be newly formed (figure 1b). However, we were unable to 
observe evident signs of lymphangiogenesis, such as locally increased numbers 
of lymphatics or lymphatic sprouting. In addition, no major differences in 
localization or lymphatic density could be observed in the different stages of 
melanoma progression. 
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Figure 4. Bar diagram showing 
the distribution of vascular Flt-4 
expression in the melanoma 
progression series which 
includes common acquired 
melanocytic nevi (MN), 
dysplastic nevi (DN), melanoma 
in situ (MIS), superficial 
spreading melanoma (SSM), 
nodular melanoma (NM) and 
metastatic melanoma (MM). Flt-
4 blood vessel expression was 
classified as absent, locally and 
weakly present, locally present 
and ubiquitously present. For 
further details see text. Blood 
vessel Flt-4 expression was 
defined as staining (as shown in 
figure 2 and 3 (appendix)) by 
the mAb 9D9 (anti-Flt-4) of 
PAL-E+ or CD34+ vessels. 
Flt-4 expression during stages of melanoma progression 
The stages of melanoma progression are represented by the benign lesions 
common acquired melanocytic nevus, the premalignant lesions atypical 
(dysplastic) nevus and melanoma in situ, and the malignant lesions primary 
cutaneous melanoma (comprising superficial spreading, nodular and 
acrolentiginous melanoma) and melanoma metastasis (Table I). In these 
lesions, we analyzed vascular Flt-4 expression to assess its value as a 
progression marker. Sections of all 42 frozen melanoma lesions listed above, 
were evaluated. In addition, of the primary melanoma lesions, all 68 paraffin-
embedded tumors were used. Lymphatic staining by the Flt-4 mAb was 
comparable between frozen and paraffin-embedded sections facilitating 
comparison of expression of Flt-4 by blood vessel endothelial cells in all 
specimens.  
By comparison to a parallel PAL-E/CD31 double staining (frozen sections) or 
CD34 staining (paraffin-embedded sections), it became evident that Flt-4 
expression in benign melanocytic lesions was strictly confined to lymphatics, 
whereas in 55 out of 83 malignant melanoma lesions it was present on both 
lymphatic and blood vessels (level of significance: p<0.0001, two-sided 
Fisher’s exact test) (Table III, figure 2-3 (appendix), figure 4). In 2 benign 
lesions, Flt-4 was also found on dendritic Langerhans cells in the epidermis 
(figure 2a). In 2 superficial spreading melanoma lesions, extensive positivity of 
the epidermis, tumor cells and the epidermal area (i.e. blood and lymphatic 
endothelial cells, fibroblasts) was observed. Occasionally, dull Flt-4 staining of 
melanoma-associated macrophages was observed. 
In case of primary melanoma lesions, we analyzed our data with respect to 
tumor thickness according to Breslow which is the most prominent prognostic 
marker in cutaneous melanoma.40 As shown in Table III, none of the seven 
primary melanoma in situ lesions showed Flt-4 expression on dermal blood 
vessels whereas all 3 acrolentiginous melanoma (thickness between 0.7 and 
3.2 mm, median 0.9 mm) expressed Flt-4 on 
their blood vessels. In case of 60 superficial 
spreading melanoma lesions, 28 lesions 
expressing no Flt-4 (thickness between 0.15 
and 1.8 mm, median 0.60 mm) appeared to be 
thinner compared to 32 remaining lesions 
showing Flt-4 blood vessel expression 
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(thickness between 0.3 and 7 mm, median 1.2 mm) (p=0.0005, Mann-Whitney 
U test). In all 11 nodular melanoma (thickness between 2.1 and 11 mm, 
median 4.2 mm), Flt-4 was present on the blood vasculature. 
In 40 of the 46 Flt-4 positive primary melanoma lesions, expression was 
present on a subset of blood vessels in restricted areas (often located at the 
invasive front of the tumor) whereas in the remaining 6 primary and 8 
metastatic lesions Flt-4 expression was ubiquitous (figure 3a-d). No significant 
difference in thickness between the primary melanoma lesions with localized or 
ubiquitous Flt-4 expression was present. 
Using routine haematoxylin and eosin staining, all 60 superficial spreading 
melanomas were classified as horizontal (HGP) or vertical growth phase (VGP) 
according to Elder et al.41 and modified by Cook et al.42 A higher number of 
VGP melanomas contained blood vessels expressing Flt-4 (24 out of 35 tumors) 
compared to the number of melanomas in HGP (7 out of 25) (p=0.008) 
(Fisher's exact test). Next to growth phase classification (i.e. HGP and VGP), 
which relates to the pattern of tumor invasion, we related vascular Flt-4 
expression to the anatomical level of invasion, as defined by Clark et al.43 As 
shown in figure 5, vascular Flt-4 expression is absent in non-invasive 
melanoma (Clark I) and the majority of minimal invasive tumors (Clark II) 
whereas vascular Flt-4 becomes present in the majority of tumors filling up the 
papillary or invading the reticular dermis (Clark III-IV) (p<0.0001) (Chi-square 
test). 
Seven out of 17 most thin superficial spreading melanomas (thickness ≤ 0.5 
mm) contained Flt-4-positive blood vessels. 5 of these positive melanomas 
were classified as VGP and the remaining 2 as HGP which both showed clear 
signs of regression (figure 3e,f). The remaining 10 thin Flt-4 negative 
melanomas were all classified as HGP. In addition, in 4 of the positive tumors, 
evident signs of immunological regression were present. In total, 7 out of 9 
superficial spreading melanomas with evident signs of regression contained Flt-
4-positive blood vessels. 
The MVD in VGP lesions (mean density between 1.5-3.4 vessels per field, 
mean 2.1 vessels per field) was significantly increased compared with the HGP 
lesions (mean density between 0.85-2.4 vessels per field, mean 1.4 vessels per 
field) (Mann-Whitney U test, p=0.03), confirming earlier results 7 and indicating 
a process of hemangiogenesis. In tumors containing vascular Flt-4 expression, 
the MVD lesions (mean density between 1.6-3.4 vessels per field, mean 2.0 
vessels per field) was also significantly increased compared with tumors 
without Flt-4 expression 
lesions (mean density 
between 0.85-2.7 vessels per 
field, mean 1.4 vessels per 
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Figure 5. Bar diagram showing 
the distribution of vascular Flt-4 
expression in relation to the 
anatomical level of invasion 
according to Clark et al.43 Only 
one nodular melanoma lesion 
containing Flt-4 positive blood 
vessels invaded the sub-
cutaneous tissue (Clark V). 
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field) (Mann-Whitney U test, p=0.02). 
Data whether metastasis occurred were available in 57 (out of 74) primary 
superficial spreading, nodular and acrolentiginous melanoma lesions (follow up 
time: 4.1±2.2 years (mean±SD)). In this subset of 57 lesions, vascular Flt-4 
expression was not related to the rate of metastasis (p=0.22, Fisher's exact 
test), although in 6 out of 7 metastatic lesions Flt-4 was expressed on tumor 
blood vessels. 
 
DISCUSSION 
 
In the past, it has been difficult to study lymphatic vasculature because of a 
lack of specific endothelial markers.5 Here, we further extended the use of PAL-
E/CD31 double staining in different normal and tumor tissues. Our results 
confirmed earlier studies 7,39,44 on endothelial specificity of these markers. 
Identification of lymphatics by the PAL-E/CD31 double staining protocol 
depends on the lack of lymphatic staining by the PAL-E mAb. Because of the 
absence of PAL-E staining on arterial vessels, antigen is present on all blood 
vessels with exception of arteries,39,45 PAL-E negative vasculature could either 
be of lymphatic or arterial origin. Fortunately, these types of vasculature can 
easily be distinguished from each other by their morphological properties. The 
expression of CD31 by infiltrating cells may also hamper lymphatic detection in 
areas of extensive infiltration. So, with some limitations, the PAL-E/CD31 
double staining is a reliable technique to classify vessel types. In agreement 
with previous studies,15,18,20 CD34 was not detected on lymphatic channels in 
normal tissues. Although variable CD34 immunostaining of lymphatics was 
observed by others in a variety of vascular and lymphatic neoplasms,19,20,22 this 
may be explained by their use of conventional histological criteria for vessel 
classification.18-20 No direct comparison with a specific lymphatic staining was 
performed in these studies. We therefore suppose that these presumed 
lymphatics may have been, in fact, blood vessels. By combining the PAL-
E/CD31 and CD34 stainings, lymphatics and blood vessels can reliably be 
detected in both normal and tumor tissues. 
Flt-4 mRNA is detected on most endothelia in early embryogenesis, but later 
in development it becomes restricted almost exclusively to the lymphatic 
endothelium.24 Recently, an elevated number of Flt-4 positive blood vessels 
was found in different tumor types.21,25,26 By using the double staining protocol 
7 that differentially highlights the lymphatic and blood vasculature, we have 
now confirmed these earlier results 21,25,26 in a panel of different tumor types 
including breast carcinoma, melanoma, squamous cell carcinoma of the larynx 
and adenocarcinoma of colon, kidney and liver. These earlier and our present 
results show that induction of blood vessel Flt-4 expression may be a general 
phenomenon in malignant human solid tumors which makes it a potential 
marker for tumor blood vessel endothelium. The involvement of Flt-4 in tumor-
induced hemangiogenesis is supported by a murine model using transplanted 
tumors, showing that by blocking Flt-4 function this process is inhibited,46 and 
by our study showing that vascular Flt-4 expression is associated with an 
increase of the MVD. Furthermore, its ligands VEGF-C and VEGF-D are able to 
induce both hemangiogenesis and lymphangiogenesis.10-12,31-33 In this respect, 
it may be speculated that blood vessels expressing Flt-4 may be in an 
angiogenic state whereas blood vessels negative for Flt-4 are quiescent. This 
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hypothesis is supported by localisation of a subset of Flt-4 positive vessels at 
the invasive front of the tumor (this study) and by co-localisation of KDR (also 
known as VEGFR-2) (which may indicate endothelial activation 47) and Flt-4 in 
uveal melanoma.21 
Recent data provided by studies using transgenic mice which express soluble 
Flt-4,48 have suggested that lymphangiogenesis occurs during adult life, 
confirming earlier findings (for review see: ref. 49). These mice do not develop 
lymphatic vessels but show some regeneration of these vessels during adult 
life. This latter finding not only shows that lymphangiogenesis occurs, but also 
indicates that receptors other than Flt-4 may be involved. Recent studies 9-12 
have provided strong experimental evidence that tumors are capable of 
activating tumor lymphangiogenesis: overexpression of VEGF-C or –D by tumor 
cells in xenografts resulted in the development of an extensive lymphatic bed 
intra- and directly peritumorally. These studies indicate that VEGF-C mediated 
tumor-induced lymphangiogenesis may exist, which was recently confirmed in 
head and neck cancer patients.50 In our study, in a number of lesions, 
lymphatics were predominantly present between tumor cells in the stromal 
areas. The limited number of the samples per tumor type studied did not allow 
for a clear distinction between pre-existent or tumor-induced lymphatic 
neovasculature. A higher lymphatic density in areas directly surrounding the 
tumor could not be determined. However, it is remarkable that we did not 
observe evident differences in localization and lymphatic vessel density during 
melanoma progression. This observation might suggest that the lymphatic 
vasculature may not be involved in the progression of benign melanocytic 
lesions to malignant melanoma. In addition, data of this study seems to 
confirm our previous finding that lymphangiogenesis does not occur in primary 
cutaneous melanoma.7 However, in order to evaluate lymphangiogenesis in 
human cancer, comparison of lymphatic density to the normal tissue (in which 
the tumor arose) is absolutely necessary.7 This comparison requires the 
presence of both normal and tumor tissue in one biopsy, which was also often 
not the case in our series. 
Despite that our data strongly suggest that blood vessel Flt-4 expression is a 
melanoma progression marker, it remains questionable whether blood vessel 
Flt-4 expression is predictive of clinical and therapeutic outcome. Evident 
expression of Flt-4 by blood vessel endothelial cells was confined to the 
malignant lesions, i.e. those with dermal invasion and metastatic potential. In 
contrast, melanoma in situ which by definition does not invade the basal 
membrane and lacks metastatic potential, lacked Flt-4 expression. Moreover, in 
general, thin micro-invasive superficial spreading melanoma lesions (i.e. less 
than 0.60 mm) appeared to express no Flt-4 on their vessels whereas thicker 
superficial spreading and nodular melanomas did. The majority of thin 
superficial spreading melanoma lesions containing Flt-4-positive blood vessels 
showed signs of increased aggressiveness such as a vertical growth phase and 
regression.51 Finally, the localized Flt-4 expression in primary melanoma 
lesions compared to the ubiquitous expression in melanoma metastatic lesions, 
also supports the hypothesis that Flt-4 expression gradually increases as a 
tumor becomes more malignant. So, following this hypothesis, evaluation of 
Flt-4 expression in melanoma lesions may be an interesting candidate for 
further clinical evaluation. For example, similar as recently suggested for the 
presence of VEGF in cutaneous melanoma,52 detection of Flt-4 expression may 
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be helpful in those cases when differential diagnosis of benign and malignant 
lesions by conventional diagnostic methods (H&E staining), is difficult (which is 
often the case in the differential diagnosis of Spitz nevi and melanoma). 
Finally, the presence of blood vessel Flt-4 expression would have major 
therapeutic advances: by targeting Flt-4 expression, tumor vasculature may 
selectively be affected. 
Recently, an association between a negative clinical outcome and expression 
of P- and E-selectin by endothelium of intratumoral vessels in cutaneous 
melanoma has been reported.53 Together with our data, showing that primary 
and metastatic melanoma cells can cause Flt-4 expression on blood vessels in 
the skin and in distant tissues, these data point at an evident interaction of 
melanoma cells and their micro-environment as discussed previously.54 In this 
respect, the question arises which factor induces Flt-4 expression on blood 
vessels. In breast carcinoma, blood vessels expressing Flt-4 were located 
adjacent to islets of tumor cells by which VEGF-C was expressed.26 The fact 
that Flt-4 expression is restricted to the direct vicinity of tumor nests suggests 
that tumor-derived factors induce the appearance of Flt-4 in a paracrine way. 
Obviously, members of the VEGF-family are first target of investigation. So, 
thus far, most recent studies have assessed characteristics of melanoma cells 
themselves to predict clinical outcome. However, it is very likely that functional 
and morphological evaluation of the interaction of melanoma cells and 
surrounding stroma may yield data of substantial biological and clinical 
relevance as well. 
In conclusion, for lymphatic staining the PAL-E/CD31 double staining 
combined with CD34 immunohistochemistry is well-suited. The presence of Flt-
4 on tumor blood and lymphatic vessels is likely to play a role in mediating 
VEGF-C-induced hemangiogenesis and, perhaps, lymphangiogenesis. Our data 
suggest that induction of blood capillary and venous Flt-4 expression may be a 
general phenomenon in cutaneous melanoma and it may therefore be a marker 
for tumor endothelium. Finally, this induction may correlate with the degree of 
malignancy in human cutaneous melanoma. 
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SUMMARY 
 
In normal adults, Flt-4 (also known as vascular endothelial growth factor 
receptor-3 (VEGFR-3)) is restricted to the lymphatic vasculature. In malignant 
tumors, however, Flt-4 expression is induced on blood vessel endothelium. In a 
series of primary and metastatic cutaneous melanomas, we observed Flt-4 
expression on blood vessels in close apposition to VEGF-A expressing tumor 
cells. To determine the role of VEGF-A, a human cutaneous melanoma cell line 
with low endogenous VEGF-A expression was engineered to express high levels 
of VEGF-A165, or of a KDR (VEGFR-2) selective VEGF-A mutant. 
Immunohistochemical analysis of metastatic melanoma lesions in nude mouse 
brains showed that Flt-4 expression on blood vessel endothelium in these 
tumors is induced by VEGF-A165 via activation of KDR. 
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INTRODUCTION 
 
Flt-4 (also known as vascular endothelial growth factor receptor-3 (VEGFR-3)) 
is essential for development and maintenance of the lymphatic vasculature.1,2 
During mouse embryogenesis, Flt-4 expression starts at embryonic day 8 in 
developing vessels, and becomes largely restricted to the lymphatic 
endothelium from day 12.5 onward into adulthood.3 Overexpression of the Flt-4 
ligands VEGF-C or -D (reviewed in ref. 4) in the skin of transgenic mice 
resulted in hyperplasia of the lymphatic vasculature (probably caused by 
lymphangiogenesis), leaving the blood vasculature unaffected.1 Until now, the 
occurrence of lymphatic neovascularization in adult human tissue has only been 
reported in the context of wound healing.5 However, overexpression of VEGF-C 
or -D by transfected tumor cell lines induced lymphangiogenesis in different 
mouse models,6,7 opening up the possibility of lymphangiogenesis to occur in 
human cancer as well. In addition, VEGF-C was able to induce blood vessel 
angiogenesis (hemangiogenesis) in the cornea and malignant melanoma.6,8 The 
presence of both VEGF-C receptors KDR (VEGFR-2) and Flt-4 on tumor blood 
vessels and of VEGF-C in different types of malignant tumors also suggested 
their involvement in tumor hemangiogenesis.9,10 The role of KDR in tumor 
angiogenesis has been widely established (reviewed in ref. 4). In addition, a 
recent study 11 supported the additional involvement of Flt-4 in tumor 
hemangiogenesis by demonstrating that in xenografted tumors this process is 
inhibited by blocking Flt-4 function. Similar to VEGF-C, also VEGF-D may be 
involved in tumor-induced hemangiogenesis and lymphangiogenesis by binding 
and activating its receptors KDR and Flt-4,6,7 respectively. The mechanism of 
Flt-4 induction on tumor blood vessels is unknown. In breast carcinoma, blood 
vessels expressing Flt-4 were located adjacent to islets of tumor cells by which 
VEGF-C was expressed.12 The fact that Flt-4 expression is restricted to the 
direct vicinity of tumor nests suggests that tumor-derived factors induce the 
appearance of Flt-4 in a paracrine way. In a preliminary immunohistochemical 
study in primary cutaneous and metastatic melanoma, we observed co-
localization of VEGF-A in tumor cells and Flt-4 expression on adjacent blood 
vessels. Together, these findings suggest that VEGF-A and VEGF-C both may 
be involved in the induction of Flt-4 expression on blood vessels. In the present 
study, we focused on the role of VEGF-A in the induction of Flt-4 expression on 
tumor blood vessels, by analysing expression patterns in primary and 
metastatic cutaneous melanoma. In addition, we examined Flt-4 expression in 
a mouse model of hematogenous brain metastasis utilising a human cutaneous 
melanoma cell line that was engineered to express VEGF-A165. Finally, the 
effect of a KDR selective VEGF-A mutant was determined. 
 
MATERIALS AND METHODS 
 
Human melanoma lesions 
Frozen specimens of 8 primary and 3 cutaneous metastatic skin and 2 
metastatic lymph node lesions of cutaneous melanoma were obtained from the 
pathology archives of the University Medical Centre Nijmegen where they were 
stored at –1300C. All specimens had been diagnosed by a pathologist. 
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Cell lines 
The human melanoma cell line Mel57 with low endogenous VEGF-A expression 
was stably transfected with a plasmid pIRESneo (Clontech, Palo Alto, 
California) containing the coding sequence for VEGF-A165 (Mel57-VEGF-A165)
13 
or a KDR selective VEGF-A variant. Generation and selectivity of the specific 
KDR-sel-2 VEGF-A mutant used have been described recently.14,15 The 
transfected cells produced 300 ng recombinant protein/106 cells/24 hours while 
non-transfected cells produced less than 30 pg recombinant protein/106 
cells/24 hours. The obtained cell lines were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM, Life Technologies, Breda, The Netherlands). 
 
Xenografts 
Recently, we described a mouse model of brain parenchymal metastasis in 
which a modified internal carotid artery injection technique was used.16 In 
BALB/c nu/nu mice, 105 cells of Mel57 (n=6), Mel57- VEGF-A165 (n=6) or 
Mel57-KDR-sel-2 (n=2) were injected into the right internal carotid artery. Mice 
were sacrificed in case of severe cachexia or acute development of neurological 
symptoms. All brains containing xenografted tumors were harvested and snap-
frozen in liquid nitrogen. 
 
Immunohistochemistry 
Antibodies used for immunohistochemistry were polyclonal antibodies (PAbs) to 
mouse Flt-4 and human VEGF-A (Santa Cruz Biotechnology, Santa Cruz, USA), 
and monoclonal antibodies (mAbs) to human Flt-4 (9D9) (Molecular/Cancer 
Biology Laboratory, Haartman Institute, University of Helsinki, Finland), mouse 
CD31 (Mec 7.46) (Hycult Biotechnology, Uden, The Netherlands), human CD31 
(PECAM-1) (British Biotechnology, ITK Diagnostics, Uithoorn, The Netherlands) 
and PAL-E 17 (undiluted supernatant, our laboratory). Four micron cryosections 
were air-dried and fixed in acetone at room temperature for 10 minutes. Areas 
of interest were identified by routine H&E staining. Distribution of the binding 
of anti-VEGF-A, Flt-4 and CD31 antibodies was evaluated in serial sections 
using a standard three-step ABC method and development in 3-amino-9-ethyl-
carbazole solution (Aldrich, Steinheim, Germany). All sections were 
counterstained for 45 seconds with Harris’ haematoxylin (Merck, Darmstadt, 
Germany) at room temperature. A double staining protocol using the pan-
endothelial marker CD31 and the blood vessel marker PAL-E was performed as 
described recently.10,18 The PAL-E/CD31 double staining differentially 
highlighted blood and lymphatic vasculature in human tissue. Finally, all 
sections were mounted in Imsol-mount medium (Klinipath B.V., Duiven, The 
Netherlands). 
 
RESULTS 
 
Primary and metastatic human melanoma 
In all primary and metastatic lesions of cutaneous melanoma, the blood and 
lymphatic vasculature was differentially highlighted by the PAL-E/CD31 double 
staining as described previously (figure 1a, appendix).10,18 By comparison with 
a serial PAL-E/CD31 double stained section, Flt-4 expression could be 
attributed to blood vessels in 6 out of 8 primary and all of 5 metastatic 
cutaneous melanomas (figure 1a,b). Occasionally, Flt-4 was also present on 
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subsets of melanoma cells (not shown). In the two primary melanomas with 
Flt-4 negative blood vessels also no or faint VEGF-A staining was detected (not 
shown). In the remaining 6 primary and all metastatic melanomas, VEGF-A 
expression varied considerably, both between and within the tumor nests. In 
tumor areas where VEGF-A expression was high, Flt-4 staining co-localised with 
a marked VEGF-A staining on endothelial cells (figure 1c,d). Occasionally, 
stromal and inflammatory cells were positive for VEGF-A. In tumor areas with 
low VEGF-A expression, endothelial cells were negative or, at most, weakly 
positive for Flt-4 (figure 1e,f). 
 
Brain metastasis 
To further evaluate whether VEGF-A release is able to induce Flt-4 expression 
on tumor blood vessels, we compared Flt-4 stainings in xenografts derived 
from the Mel57 parental and the transfected Mel57-VEGF-A165 human 
melanoma cell line. The absence of lymphatics from brain prevented a possibly 
confusing background of Flt-4 positive lymphatic vessels. The blood vasculature 
was identified by the use of an anti-CD31 mAb (figure 2a). The morphological 
and functional properties of the brain parenchymal vasculature induced by 
metastatic growth of Mel57 and Mel57-VEGF-A165 tumors have recently been 
investigated by us.13 Untransfected Mel57 cells did not express VEGF-A and 
metastases formed by these cells appeared not to affect the cerebral 
vasculature. VEGF-A165 transfected cells, however, induced changes in the pre-
existent vessels comparable to the “mother vessel” phenotype.19 Flt-4 
expression on blood vessels was absent in control brains without tumor (not 
shown) and in parenchymal blood vessels in unaffected brain areas in tumor-
bearing mice. Serial section analysis showed that Flt-4 expression on tumor 
vessels in brain lesions of Mel57 was absent, both inside the metastatic lesions 
and peritumorally (figure 2b). In equally sized tumor islets in all Mel57-VEGF-
A165 brain xenografts, however, Flt-4 expression was clearly induced, as a 
marked staining of the intra- and peritumoral vessels was observed. This Flt-4 
expression on blood vessels gradually decreased with increasing distance from 
the tumor (figure 2c). Additional analysis of parental and VEGF-A165-transfected 
Mel57 xenografts located in liver or peritoneum confirmed the induction of Flt-4 
expression on blood vessels by VEGF-A165 (not shown). By mutating three 
amino-acids of the VEGF-A protein, the binding affinity of the resulting KDR-
sel-2 VEGF-A mutant for Flt-1 (VEGFR-1) was almost completely lost. However, 
this KDR-sel-2 mutant appeared to bind and activate KDR.14 Again, induction of 
Flt-4 expression on blood vessels by VEGF-A was observed in Mel57 lesions 
expressing this KDR-sel-2 variant (figure 2d). 
 
DISCUSSION 
 
In the present study, we demonstrated that Flt-4 expression on blood vessels 
is induced by VEGF-A165 in brain xenografts of human melanoma. Expression of 
a receptor-selective mutant showed that upregulation occurred via activation of 
KDR. The threshold levels of VEGF-A165 necessary for Flt-4 induction could not 
be determined, because we were not able to quantify the amounts of VEGF-
A165 released by the xenografted tumor cells in vivo. We did show in an earlier 
study, however, that these cells produce high levels of VEGF-A in vitro.13 As 
previously described,13 VEGF-A165 over-expression by xenografted tumor cells 
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resulted in evident changes in tumor and 
blood vessel morphology. Therefore, we 
conclude from our present results that VEGF-
A165 is released by the tumor cells, and that 
this factor is also responsible for the induction 
of Flt-4 expression on blood vessels in the 
brain metastasis model. Furthermore, 
signalling of VEGF-A via KDR is probably sufficient for this upregulation, since 
expression of the KDR-selective VEGF mutant led to a similar phenotype as 
seen after expression of wild type VEGF-A. 
VEGF-A co-localised with Flt-4 on blood vessel endothelial cells in most of the 
human cutaneous melanoma examined. Conversely, in tumors with low VEGF-A 
levels, and also in stromal areas, VEGF-A and Flt-4 staining on blood vessels 
was absent. These findings are fully in agreement with our data from the 
murine brain metastasis model and support the hypothesis that VEGF-A 
upregulates Flt-4 expression on tumor blood vessels in human disease. In our 
animal model, this effect is mediated by binding to KDR. In an earlier study in 
primary uveal melanoma, we showed that KDR and Flt-4 are expressed on 
tumoral blood vessels in absence of VEGF-A but in presence of VEGF-C.10 Since 
both VEGF-A and VEGF-C are ligands of KDR (for extensive review: see ref. 4) 
these data indicated that VEGF-C is also a possible mediator of Flt-4 induction 
in human cancer. Finally, the significance of VEGF-A binding to Flt-1 needs still 
to be evaluated. 
Tumor lesions are surrounded by a peri-tumoral zone in which many 
interactions exist between stromal, inflammatory and pre-existent cells of the 
tissue in which the tumor arised. It becomes more evident that especially this 
peritumoral tissue is essential for outgrowth of tumors, as discussed recently.20 
The observed decreasing Flt-4 expression on blood vessels with increasing 
distance of the metastatic brain lesion (figure 2c) nicely illustrates the range 
Figure 2. Immuno-histochemical 
analysis of the vasculature (using 
an anti-CD31 mAb, a) and Flt-4 
expression (b,c,d) in brain 
melanoma metastasis in nude 
mice. In a,c and d, tumor (T) and 
brain parenchyma (P) are 
indicated. Flt-4 expression was 
completely absent in the normal 
brain (not shown), whereas serial 
section analysis showed no 
presence of Flt-4 expression on 
blood vessels in metastasis 
formed by the parental cell line 
(b). In metastasis formed by 
VEGF-A165 transfected melano-ma 
cells (c), blood vessel Flt-4 
expression is clearly enhanced on 
both intra- and peritumoral 
vessels. Flt-4 expression on the 
vasculature decreases gradually 
with increasing distance form the 
tumor. In metastasis formed by 
KDR selective VEGF-A mutant 
transfected melanoma cells (d), 
Flt-4 expression is also present 
on the vascular endothelium. 
Counterstained with Harris' 
haematoxylin. Magnification a-c: 
100x, d: 250x. 
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over which tumor-induced factors may influence the surrounding tissue, 
thereby demarcating the extent of the peri-tumoral zone. 
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SUMMARY 
 
Because lymphatic vessels are absent from the normal eye and because uveal 
melanomas are presumed to spread by a hematogenous route in the absence 
of tumor exposure to conjunctival lymphatics, we investigated the presence of 
lymphatics in primary uveal melanomas. The presence of lymphatics in 2 
control eyes, 33 primary uveal, 10 primary cutaneous and 3 metastatic 
cutaneous melanomas was evaluated by using a double immunostaining 
protocol that differentially highlights blood and lymphatic vasculature. In 
addition, 14 uveal melanomas were immunostained for the lymphatic growth 
factor vascular endothelial growth factor-C (VEGF-C) (anti-VEGF-C polyclonal 
antibodies (PAbs)), its receptors Flt-4 (monoclonal antibody (mAb 9D9)) and 
KDR (anti-KDR mAb (Clone KDR-2)) and for the hemangiogenic factor VEGF-A 
(anti-VEGF PAbs). Lymphatics were detected in normal eyes or in uveal 
melanoma. As a consequence, signs of lymphangiogenesis were not present. 
There was coexpression of VEGF-C with Flt-4 and KDR in 6 out of the 14 
melanomas (43%). Staining for VEGF-A was completely negative in 25 uveal 
melanomas analyzed. The strictly hematogenous metastasis of primary uveal 
melanomas is explained by the absence of lymphatics in and around the tumor. 
The current data suggest that, in the presence of endothelial Flt-4, VEGF-C 
expression is not sufficient to induce lymphangiogenesis from preexisting blood 
vessels in human cancer. 
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INTRODUCTION 
 
Primary uveal melanoma is the most common malignant intraocular tumor. It 
has a marked metastatic preference for the liver.1 Once metastasis occurs, 
prognosis becomes very poor.1 Microvessel density was identified as an 
important prognostic factor for many types of tumors.2 However, in the case of 
uveal and cutaneous melanoma, there are conflicting reports on the presence 
of an association between microvascular density and prognosis.3-7 In uveal 
melanoma, blood vessel architecture 3,8 9 and both architecture and density 4 
have been related to prognosis. 
Dissemination of primary intraocular and posterior uveal melanoma occurs 
exclusively by a hematogenous route. Anterior uveal melanomas may also 
metastasize to local cervical lymph nodes after invasion of conjunctival 
lymphatics.10,11 The restricted hematogenous metastasis is generally explained 
by the intraocular absence of lymphatics and the extrapolated assumption that, 
hence, this vessel type is therefore absent in uveal melanoma as well. 
However, this hypothesis has never been confirmed. In skin, lymphatic vessels 
are abundant, which explains the phenomenon of locoregional metastasis that 
is frequently observed in cutaneous melanoma. It is therefore possible that the 
mere presence of pre-existent lymphatics in skin contributes to the difference 
in metastatic pattern between uveal and cutaneous melanoma. Furthermore, 
the presence of lymphatics in cutaneous melanoma might obscure the relation 
between blood vessel density and prognosis that was established in uveal 
melanoma.3,4 However, induction of lymphatic vessel formation 
(lymphangiogenesis) may play a role. 
Angiogenesis is necessary for tumor growth.12 In this process, the role of 
vascular endothelial growth factor (VEGF-A) has been firmly established. 
Another VEGF family member, VEGF-C, has been identified as a lymphatic 
endothelial growth factor.13 VEGF-C expression has been observed in tumor 
cells,14 which theoretically opens the possibility that tumors, besides 
hemangiogenesis,15 also induce lymphangiogenesis.16 During embryogenesis, 
lymphatics arise from venous endothelial cells, but whether veins can be the 
source of lymphatic neovascularization during adult life, should this occur, is 
unknown. Because VEGF-C exerts part of its function via the tyrosine kinase 
receptor Flt-4,17 and because this receptor is upregulated in blood vessels of 
certain tumor types,18,19 analysis of Flt-4 expression in uveal melanoma may be 
relevant as well. Should lymphatics in uveal melanomas be absent, VEGF-C 
expression in this type of tumor might influence hemangiogenesis, as reported 
in animal studies.20,21 
To elucidate the nature of the vasculature in uveal melanoma and its role in 
mediating growth and metastasis, knowledge of the presence of a lymphatic 
vasculature becomes very relevant. In the present study, we have evaluated 
the presence of lymphatics in primary uveal melanoma and in primary and 
cutaneous metastatic lesions of cutaneous melanoma by using a double-
immunostaining protocol (using the blood vessel endothelial marker PAL-E and 
the panendothelial marker CD31) that differentially highlights blood and 
lymphatic vasculature.22 In addition, we studied the expression of VEGF-A, 
VEGF-C and the receptors KDR and Flt-4, the latter of which is believed to be 
specific for VEGF-C. 
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MATERIALS AND METHODS 
 
Patient material 
Frozen specimens of 33 primary uveal melanomas, 10 primary cutaneous 
melanomas, 3 cutaneous metastatic lesions of cutaneous melanoma, 2 
uninvolved eyes, 1 invasive ductal breast carcinoma, 1 hemangioma and 1 
normal preputial skin (Table I) were obtained from the pathology archives of 
the University Hospital Nijmegen where they were stored at -1300C. Presence 
or absence of disease in all specimens had been determined by a pathologist. 
All primary melanomas and the uninvolved eyes were obtained by surgery. The 
uveal melanomas varied from 5 to 28 mm in diameter (median 17 mm) and 
included 31 choroidal and 2 ciliary melanoma lesions. Uveal melanoma lesions 
were divided in two parts along the maximal diameter. One part was formalin-
fixed and the other part was snap-frozen. By using hematoxylin and eosin 
staining on paraffin sections, the uveal melanomas were classified as 11 
spindle cell type and 22 epithelioid and mixed type. Azan staining without 
counterstaining on unbleached paraffin sections showed that 15 uveal 
melanomas contained the arcs, loops and networks matrix patterns (figure 1, 
i.e. PAS-positive patterns as described recently 8,23). 
 
Table I. Antibodies and positive controls used for immunohistochemistry 
Antigen Ab Type of endothelium Tissue 
CD34 QBEnd/10 blood vessel preputial skin, 
cutaneous melanoma 
? PAL-E venous blood vessel and 
capillaries, not cerebral and retinal 
vessel* 
preputial skin 25 
 
CD31 PECAM-1 blood and lymphatic vessel preputial skin, 
cutaneous melanoma 
22 
alpha-
smooth 
muscle 
actin 
α-SM1 - preputial skin 
KDR Clone KDR-
2 
blood vessel hemangioma 42 
Flt-4 9D9 lymphatic in normal tissues 
lymphatic and blood in tumor 
tissues 
preputial skin, 
cutaneous melanoma 
22 
VEGF-A VEGF-A Abs - invasive ductal breast 
carcinoma 43 
VEGF-C VEGF-C Abs - invasive ductal breast 
carcinoma 18 
* venous vessels that form a blood-brain barrier 30 or blood-retinal barrier 28 
 
Antibodies 
Monoclonal antibodies used for immunohistochemistry (Table I) included anti-
CD34 (QBEnd/10) (DAKO, Glostrup, Denmark), the blood vessel endothelial 
marker mAb PAL-E (undiluted supernatant, our laboratory), the pan-endothelial 
marker CD31 (PECAM-1) (British Biotechnology, ITK Diagnostics, Uithoorn, The 
Netherlands), anti-alpha-smooth muscle actin (α-SM1) (Sigma Chemical Co., 
St. Louis, USA), anti-KDR (Clone KDR-2) (Sigma, Saint Louis, Missouri, USA) 
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and anti-Flt-4 (9D9) (Molecular/Cancer Biology 
Laboratory, University of Helsinki, Finland). For 
VEGF-A and VEGF-C stainings, polyclonal 
antibodies (Santa Cruz, California, USA) were used. 
 
Immunohistochemistry 
Four-micrometer cryosections were air-dried and fixed in acetone at room 
temperature for 10 minutes. After incubation steps, sections were rinsed with 
ample phosphate-buffered saline (PBS). For the primary melanomas, each 
analysis included six successive sections of each specimen incubated with 
QBEnd/10 (diluted: 1:100), PAL-E (undiluted supernatant), anti-KDR (diluted 
1:400), 9D9 (diluted: 1:1000) and the polyclonal antibodies to VEGF-A (diluted 
1:20) and VEGF-C (diluted: 1:20) for 60 minutes at room temperature. Then, 
secondary 1:200 diluted biotinylated affinity-purified anti-mouse IgG 
(Vectastain, Vector Laboraties) (CD34, PAL-E, KDR and Flt-4) or affinity-
purified anti-rabbit IgG (VEGF-A and VEGF-C) was incubated for 30 minutes, 
followed by a 45-minute incubation (CD34, PAL-E and VEGF-A) or 30-minute 
incubation (Flt-4, KDR, VEGF-C) with peroxidase-labeled biotin-avidin complex 
(Vectastain). Subsequently, the KDR, Flt-4 and VEGF-C sections were 
incubated for 10 minutes with biotinylated tyramine (dilution 1:200), followed 
by a 20-minute incubation with ABC-peroxidase solution (catalysed reporter 
deposition method 24). All stainings were developed by a 10-minute incubation 
with 0.4 mg/ml 3-amino-9-ethyl-carbazole solution (Aldrich, Steinheim, 
Germany). For double staining, sections prestained with PAL-E were incubated 
with anti-CD31 antibody (diluted: 1:2000) for 60 minutes. The secondary 1:40 
diluted rabbit-anti-mouse alkaline phosphate-labeled antibody was incubated 
for 30 minutes. The second staining was developed for 10 minutes with a 
mixture of 1 mg/ml Fast Blue, 0.2 mg/ml naphthol phosphate and 0.24 mg/ml 
levamisole (Sigma-Aldrich, Bornem, Belgium). In control sections, primary 
antibodies were omitted. Positive controls for all antibodies were included 
(Table I). The QBEnd/10, KDR, VEGF-A, VEGF-C and 9D9 stainings were 
counterstained for 45 seconds with Harris’ haematoxylin (Merck, Darmstadt, 
Germany) at room temperature. All sections were mounted in Imsol-mount 
medium (Klinipath B.V., Duiven, The Netherlands). 
To validate our PAL-E/CD31 double staining protocol, we additionally stained 
serial sections of preputial skin by anti-CD34 mAb and by mouse anti-human 
alpha-smooth-muscle actin mAb (diluted 1:15,000). Furthermore, Masson 
trichrome histochemistry was performed as well, on an adjacent section. 
Figure 1. Evaluation of 
matrix patterns in a paraffin-
embedded primary uveal 
melanoma stained by azan 
histochemistry. Extracellular 
matrix and nuclei of tumor 
cells were highlighted. Loops 
and network patterns were 
clearly visualized. The area 
indicated in a (magnification: 
100x) is shown enlarged in b 
(magnification: 400x) 
demonstrating the clear 
decoration of the matrix 
patterns. 
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By including positive controls, stainings of the normal and tumor tissues were 
validated. To exclude exogenous peroxidase activity or non-specific 
background, all serial stainings were incubated in a mixture of 1 ml 30% H2O2 
in 200 ml acetone during fixation for 5 minutes and blocked by incubation with 
20% normal horse (PAL-E, CD34, KDR, Flt-4, α-SM1) or 20% normal goat 
serum (VEGF-A and VEGF-C). 
 
RESULTS 
 
Vascular staining in human skin 
To validate vascular staining protocols, preputial skin was used because of its 
richness in lymphatics. As described previously,22 the PAL-E/CD31-double 
staining design was based on the reactivity of anti-CD31 mAb with both 
lymphatic and blood vessel endothelial cells, in combination with the reactivity 
of PAL-E with blood vessel endothelium alone. The blood vessel endothelial 
staining produced initially by anti-CD31 is overruled by staining by PAL-E. 
Thus, the vasculature was differentially highlighted in preputial skin sections 
(figure 2a, appendix). We found strong PAL-E positivity of blood capillaries and 
venules, but no staining of arterial vessels. The CD31 antibody staining, that 
was not masked by PAL-E, decorated both fine, thin-walled capillaries and 
arterial vessels. PAL-E and CD31 positive (PAL-E+) vessels were classified as 
blood vessels and PAL-E negative and CD31 positive (CD31+/PAL-E-) ones were 
classified as lymphatic (or arterial) vessels.22,25,26 The blood vessel specificity of 
the differential staining was confirmed by the presence of smooth muscle cells 
(figure 2a,b). Masson trichrome histochemistry, highlighting elastic fibers in 
blood vessel walls, confirmed this specificity (figure 2d). Because arteries and 
lymphatics are both negative for PAL-E, it is not always possible to differentiate 
these vessel types. As we have recently demonstrated,27 an anti-CD34 mAb 
stained the PAL-E+ blood vasculature and CD31+/PAL-E- arteries, whereas the 
CD31+/PAL-E- lymphatic vessels were negative for CD34 (figure 2a,c). Using 
this combination of stainings all vessels could be classified. 
 
Vascular staining in normal eyes 
Frozen specimens of the ocular wall of 2 normal eyes were evaluated. In the 
choroid layer, PAL-E+ blood capillaries and venules were observed (figure 3a, 
appendix). As demonstrated previously,28 no PAL-E positivity of the vasculature 
in the retinal layer containing the blood-retinal barrier 29 was observed. Since 
all CD31+/PAL-E- vessels were stained by the anti-CD34 mAb (figure 3b), these 
were identified as arterial vessels. No CD31+/PAL-E- lymphatics were observed 
in the choroid layer. 
 
Vascular staining in cutaneous and uveal melanomas 
In all primary uveal (n=33), cutaneous melanomas (n=10) and cutaneous 
metastatic lesions of cutaneous melanomas (n=3), PAL-E+ blood capillaries and 
venules were observed, whereas CD31+/PAL-E- arteries were present in only 3 
uveal melanoma lesions. In the primary and metastatic cutaneous melanomas, 
CD31+/PAL-E-  lymphatics were observed in the pre-existent skin directly 
surrounding the tumor (figure 4a, appendix) and delicate lymphatics between 
tumor fields as described in more detail previously 22. In uveal melanomas, all 
PAL-E+ blood capillaries and venules and CD31+/PAL-E- arteries were also 
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stained by the anti-CD34 mAb. In none of the uveal melanomas, CD31+/PAL-E- 
lymphatics were observed. A representative example is shown in figure 4b and 
c. Vascular staining by the PAL-E mAb was superior to staining by the anti-
CD34 mAb (figure 4c,d). No evident staining of uveal melanoma cells was 
observed by any of the endothelial markers. 
 
VEGF-A, VEGF-C, KDR and Flt-4 staining in uveal melanomas 
Staining for VEGF-A was completely negative in series of 25 uveal melanomas. 
In total, 14 uveal melanomas were evaluated for VEGF-C, KDR and Flt-4 
expression. Table II summarizes all staining results. 8 tumors were positive for 
expression of VEGF-C (figure 5a) and 6 tumors were negative. In the positive 
tumors, distinct areas of positive cytoplasmatic staining for VEGF-C were 
observed in the tumor cells directly surrounding Flt-4 positive blood vessels 
(figure 5a,b). VEGF-C expression colocalized with blood vessel endothelial Flt-4 
expression in 7 tumors and in 6 of those with expression of endothelial Flt-4 
and KDR (figure 5), whereas in only one VEGF-C positive tumor, neither Flt-4, 
nor KDR expression could be detected. (melanoma 2, Table II). In 9 tumors, 
endothelial Flt-4 expression was observed, and in 2 of those, no evident VEGF-
C staining could be detected (melanoma 1 and 4, Table II). In 1 of these 2 
latter tumors KDR was co-expressed (melanoma 1, Table II).  In one tumor 
sample, two separate nodules were present, in one of which both VEGF-C, KDR 
and Flt-4 expression was observed, whereas in the other nodule these stainings 
were negative (melanoma 13, Table II). 
 
DISCUSSION 
 
To address the hypothesis whether the absence of lymphatic spread in primary 
uveal melanoma can be explained by the absence of lymphatic vasculature, we 
evaluated the presence of lymphatics and the expression of VEGF-C and Flt-4 
in this type of tumor. Our staining approach made it possible to differentiate 
between lymphatic and blood vasculature, confirming our recent analysis in a 
variety of normal tissues and carcinoma types 22 and was validated in the 
present study by additional alpha-smooth-muscle immunostaining and Masson 
trichrome histochemistry. However, it is known that PAL-E is present on 
capillary and venous endothelium throughout the body 25 with the exception of 
vessels in areas in the brain with an intact blood-brain barrier.30 In the eye, a 
similar barrier (i.e., blood-retinal), and endothelial PAL-E antigen expression is 
absent as well.28 In areas in both brain and the eye where such a barrier is not 
present, the PAL-E antigen is expressed on the endothelium.28,31 Therefore, it 
was not possible to evaluate blood and lymphatic staining by the PAL-E/CD31 
double staining protocol in normal eyes alone. Because anti-CD34 mAb detects 
all types of vessel endothelium with exception of the lymphatic vasculature.27,32 
blue (CD31+/PAL-E-) vessels could be classified as blood or lymphatic vessels 
by comparison with CD34 expression. In uveal melanomas, all vessels were 
stained by PAL-E or CD34, confirming earlier results.28,31 So, in conclusion, in 
this way, we were able to classify both types of vessels in preputial skin, 
normal eye and uveal melanoma sections. 
In our specimens, the extent of melanin pigmentation did not interfere with 
the detection of the vascular patterns, making bleaching unnecessary. Azan 
histochemistry resulted in deep blue staining of extracellular matrix and red 
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staining of the cell nuclei whereas PAS-histochemistry is less powerful in 
extracellular matrix component detection. Indeed, for this approach, bleaching 
of melanoma sections and the use of a green filter during microscopy are 
required for reliable evaluation. However, in case of the presence of strongly 
pigmented melanophages along the matrix patterns (as seen in figure 4), 
bleaching may still be necessary differentiating between melanophages and the 
Azan-positive blue matrix patterns. The use of Azan histochemistry in 
identifying matrix patterns was confirmed by immunofluorescence and electron 
microscopy (data not shown). 
 
Table II Overview of the expression of VEGF-C, Flt-4, KDR and the 
presence loops and networks pattern in 14 uveal melanoma 
melanoma VEGF-C Flt-4 KDR loops and 
networks 
1 -* + + - 
2 +† - - - 
3 - - - - 
4 - + - - 
5 - - - - 
6 - - - + 
7 + ++ + - 
8 ++‡ ++ + - 
9 + + - - 
10 + ++ ++ + 
11 ++ ++ ++ - 
12 + ++ + - 
13 + + + + 
14 - - - + 
mean: 57% 64% 50%  
95% CI§: 28%-83% 35%-88% 23%-77%  
* -: expression or loops and networks absent 
† + moderate expression or presence of loops and networks 
‡ ++ strong expression (as depicted in figure 5) 
§ CI: confidence interval 
 
Electron microscopy has suggested that endothelium-free channels are lined by 
basement membrane.33 Although PAL-E detects the epidermal basal membrane 
22,34 this is a specific pattern and staining of basal membranes of endothelium-
free channels in the fibrovascular patterns is not likely to occur. However, at 
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low magnification, the PAL-E/CD31 double 
staining may have given the impression that 
next to blood vessels, also certain parts of 
fibrovascular patterns were identified. 
Evaluation at higher magnifications (figure 4c 
and d) demonstrated, however, that this 
impression was caused by the presence of 
numerous melanin-laden macrophages spread 
along the vasculature. Furthermore, vascular 
detection by PAL-E mAb was superior to anti-
CD34 mAb in all uveal melanomas, and in 
those melanoma lesions that did not contain 
arcs, loops and network patterns. In 
conclusion, the PAL-E/CD31 double staining 
protocol could not be used to evaluate the 
existence of endothelium-free channels. 
Knowledge of the absence of lymphatics 
contributes to the evaluation of the existence 
and nature of the non-endothelialized blood 
conducting channels.33 Although these are still 
controversial in uveal melanoma, the absence 
of lymphatics rules out the possibility that 
these channels were, in fact, lymphatic 
channels. 
The present study demonstrates that 
lymphatics are absent from both the normal 
eye and uveal melanoma. This is in line with 
the lack of lymphogenous metastasis of 
intraocular and posterior uveal melanoma 
leaving only the hematogenous route open for 
dissemination. Although prognosis is related to 
microvascular density in uveal melanoma,3,4 
this correlation is absent in cutaneous melanoma.35,36 In addition to blood 
vessels, lymphatics are involved in indirect metastasis to the blood stream. So, 
the absence of lymphatics in uveal melanoma and presence of lymphatics in 
cutaneous melanoma makes it plausible that lymphatics also play a role in 
determining the rate of distant metastasis and prognosis. In this respect, it is 
an interesting question whether lymphatic vessel density, or rather a 
combination, with blood vessel density is related to prognosis and metastatic 
spread in cutaneous melanomas. However, since we were not able to evaluate 
microvascular density in relation to prognosis to our series, we can not confirm 
this hypothesis. 
Although blood vessel angiogenesis is an established phenomenon, it is 
unknown whether lymphangiogenesis occurs in human cancer. Because we can 
Figure 5. Immunohistochemical analysis of VEGF-C 
(a), Flt-4 (b) and KDR (c) expression in uveal 
melanoma. VEGF-C expression is located in part of 
the tumor cells surrounding the Flt-4 and KDR 
positive blood vasculature. Counterstained with 
Harris' haematoxylin. Magnification: 200x. 
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not be absolutely sure that immature lymphatic vessels express lymphatic 
markers like CD31 or Flt-4, we can not rule out the occurrence of 
lymphangiogenesis in uveal melanoma. However, it is likely that life-span of 
larger tumors would allow maturation of lymphatic vessels after 
lymphangiogenesis. These mature vessels would readily be detected by our 
staining protocol. Furthermore, Flt-4 expression is present on sprouting 
lymphatic vessels during wound healing in the adult whereas lymphatic vessels 
remain PAL-E negative during development.37 In our series, we did not observe 
such Flt-4+ and PAL-E- vessels. Thus, our study strongly suggests that 
lymphangiogenesis does not occur in this type of tumor although we can not 
rule out this completely. 
VEGF-C has been identified as a lymphatic endothelial growth factor during 
embryogenesis 13,38. In the present study, although VEGF-C was expressed and 
Flt-4+ positive blood vessels are present concurrently as a source of endothelial 
cells (for review ref. 39), lymphangiogenesis did not occur in uveal melanomas. 
VEGF-C is, however, also able to induce hemangiogenesis.20,21 In addition, its 
receptors KDR and Flt-4 are involved in angiogenesis (for review see ref. 40). 
Therefore, the clear relation between the expression of VEGF-C, KDR and Flt-4 
suggests that the presence of VEGF-C and its receptors in uveal melanoma 
may contribute to hemangiogenesis. KDR is early involved in angiogenesis 
during embryogenesis and its expression becomes upregulated on tumor 
endothelium under hypoxia (for review see ref. 40) These data suggest that in 
tumor areas with local KDR expression, endothelium is in a state of 
angiogenesis whereas in areas lacking KDR, no new vessels can be formed. 
Therefore the coexpression of KDR and VEGF-C supports the role of VEGF-C as 
a hemangiogenic growth factor. 
Many different types of tumors express VEGF-A, an important regulator of 
angiogenesis, indicating that tumor cells in addition to endothelial cells 
contribute to the tumor blood vasculature. Therefore, it was surprising that 
VEGF-A was absent from all uveal melanoma lesions, as demonstrated 
previously.41 Because of the absence of VEGF-A, it appears that 
hemangiogenesis in uveal melanoma may instead be driven by VEGF-C. In this 
respect, the presence of VEGF-B and VEGF-D needs to be further evaluated. 
In conclusion, although the lymphatic endothelial growth factor VEGF-C and 
its receptor Flt-4 are expressed, neither lymphatics, nor signs of 
lymphangiogenesis are present in normal eye and primary uveal melanomas, 
indicating that the concerted action of these players is not sufficient for 
lymphangiogenesis to occur in the adult in this type of tumor. Furthermore, 
hemangiogenesis in uveal melanoma is not associated with expression of 
VEGF-A, but may be driven by other angiogenic factors like VEGF-C. 
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SUMMARY 
 
Recently, it was reported that tumor cells themselves generate channels and 
networks in three-dimensional culture and can be found lining channels (some 
containing red blood cells (RBCs)) in vivo, and they express endothelial or 
vascular genes in aggressive uveal melanoma. The implications of these data 
for current insights in the involvement of angiogenesis in tumor growth, 
metastasis and therapeutic intervention are considerable. Therefore, we 
evaluated this issue in our material. 30 human uveal melanomas and 20 
xenografts of human cutaneous melanoma were analysed by Azan 
histochemistry and immunostaining of endothelial markers. Additionally, in 
xenografted tumors a tracer study using confocal microscopy and (immuno)-
electron microscopy was performed. Lumina or spaces without endothelial 
lining containing RBCs were not detected in any lesion. Functional evaluation of 
the vasculature in xenografts demonstrated rapid tracer appearance both in- 
and outside blood vessels. Outside blood vessels it spread along matrix 
networks of arcs and back-to-back loops. Confocal microscopy showed that this 
extracellular matrix was deposited as stromal sheets around nests of tumor 
cells. Laminin immunostaining revealed that between sheets surrounding 
adjacent nests, spaces were present. These spaces were, however, filled with 
collagen and different types of cells, including cells stained for macrophage 
markers. Although no evident endothelium-free and RBC-containing channels 
were present in the tissues examined, fluid conducting spaces exist in the form 
of stromal sheets between nests of tumor cells. In this stromal network, blood 
vessels are embedded. We postulate that this extracellular matrix tissue 
represents a "fluid conducting meshwork". 
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INTRODUCTION 
 
Malignant tumor growth, survival and metastasis is facilitated by several 
different factors including angiogenesis.1 The role of the vasculature in 
mediating metastatic spread has been supported by studies demonstrating that 
microvessel density is a negative prognostic factor in several types of 
tumors,2,3 although in other types of tumors this could not be confirmed.4-8 
Concerning both uveal and cutaneous melanoma, the relation between 
microvascular density and clinical outcome is controversial.9-17 In uveal 
melanoma, also certain patterns of extracellular matrix deposition (i.e. arcs 
and back-to-back loop networks) were related to rate of metastasis and, 
hence, prognosis.9,10 Initially, these patterns, identified by conventional 
periodic acid-Schiff (PAS) staining, were believed to represent blood vessels. 
Foss et al.18 re-evaluated this issue and concluded that, instead, they consisted 
of connective tissue in which blood vessels were present at certain locations 
only, the so-called fibrovascular tissue. However, it was questioned whether 
the patterns described by Foss et al. were identical to the patterns studied by 
Folberg et al.19 
Recently, Maniotis et al.20 suggested that melanoma cells themselves could 
form a new type of vessel: blood-conducting channels lined by tumor cells, that 
were present in the PAS-positive back-to-back loop networks in both 
aggressive uveal and cutaneous melanoma. They could also be detected 
angiographically, indicating that channels and the normal blood vasculature 
were interconnected. This newly described phenomenon was termed 
'vasculogenic mimicry'. A recent report 21 demonstrated the presence of 
"mosaic" blood vessels in which endothelial cells and tumor cells alternatingly 
form the luminal surface. 
These data have great implications: the existence of blood conducting 
channels lined by tumor cells or blood vessel walls consisting out of mosaics of 
tumor and endothelial cells challenges the current concept stating that a tumor 
is fully dependent on angiogenesis for growth and metastasis.2 In addition, 
tumors with vascular channels or mosaic blood vessels would be less sensitive 
to anti-angiogenic or anti-endothelial drugs. 
Thus, elucidation of the nature of the extracellular matrix patterns is 
appropriate. Therefore, we set out to evaluate this issue in primary uveal 
melanoma. Since previous studies 22,23 showed that arc-like patterns of matrix 
deposition are also present in xenografts derived from human cutaneous 
melanoma cell lines, we re-examined this tissue as well. 
 
MATERIALS AND METHODS 
 
Primary uveal melanoma 
Formaldehyde-fixed paraffin-embedded tissues from 30 human primary uveal 
melanoma cases were obtained from our archive. Uveal melanomas varied 
from 0.5 to 2.5 cm in diameter (median 1.7 cm) and included 28 choroidal and 
2 ciliary melanoma lesions. Using H&E staining on paraffin sections, uveal 
melanomas were classified as 10 spindle cell type, 5 epithelioid and 15 mixed 
type. No information on clinical outcome was available. 
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Xenografts in nude mice 
Human melanoma cell lines 1F6 (non-aggressive), Mel 57 (aggressive) 24 and 
Mel57, stably transfected with VEGF (Mel57-VEGF) (constructed by dr. W.P. 
Leenders, our laboratory) were cultured as previously described.25 For 
induction of tumor growth, 2.5 x 106 cells were injected s.c. into BALB/c nu/nu 
mice. A number of 5 (1F6, Mel57-VEGF) or 10 (Mel57) animals were included. 
Subcutaneous xenografts developed in 17 mice. In the remaining 3 mice (1 
injected with Mel57 and 2 mice with Mel57-VEGF cells) extensive 
intraperitoneal outgrowth occurred. Subcutaneous tumor volumes were 
estimated by multiplying length, width and height. When the tumors reached 
sizes between 100 and 700 mm3, mice were injected i.v. with 100 µl of a 3% 
(w/v) solution of fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) 
(12 mol FITC/mol BSA, Sigma, Brunschwig, Amsterdam, The Netherlands). 
Tumors were excised 60 minutes after injection and divided in three equal 
parts: one part was formalin-fixed, the second part was divided in two 
fragments that were fixed by either glutaraldehyde or periodate-lysine-2% 
paraformaldehyde. The last part was snap-frozen in liquid nitrogen. 
 
(Immuno)histochemistry 
Markers are listed in Table I: CD31 (JC/70A), CD34 (QBEnd/10), H and Y 
antigens (BNH9), thrombomodulin (anti-thrombomodulin) (all from DAKO, 
Glostrup, Denmark), CD31 (Mec 7.46) (Hycult Biotechnology, Uden, The 
Netherlands), 9F1 (Dr. A. Hamann, Hamburg, Germany) and ASD-13 (Dr. 
K.J.M. Assmann, our laboratory). UEA-1 (DAKO, Glostrup, Denmark), 
polyclonal antibodies to FVIIIrA (vWF) (CLB, Amsterdam, The Netherlands) and 
laminin (E2 EHS) (Dr. J. van den Born, Department of Nephrology, UMC 
Nijmegen) were used. Macrophages were detected by FA/11 mAb 26 (Dr. M.J. 
Smith, Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, 
England). 
 
Table I. Endothelial markers used for immunohistochemistry 
Antibody Antigen Type of 
antibody 
Tissue 
examined 
JC70A 45,46 CD31 mAb* uveal melanoma 
QBEnd/10 46,47 CD34 mAb uveal melanoma 
anti-vWF 18 vWF (FVIIIrA) PAbs† uveal melanoma 
xenografts 
BNH9 46 H and Y antigens mAb uveal melanoma 
anti-Thrombomodulin 48 Thrombomodulin mAb uveal melanoma 
UEA-1 ‡ 18 - PAbs uveal melanoma 
MEC 7.46 49 CD31 mAb xenografts 
9F1 24 unknown mAb xenografts 
ASD-13 50 unknown mAb xenografts 
* mAb: monoclonal antibody 
† PAbs: polyclonal antibodies 
‡ lectin stained by using peroxidase-linked rabbit anti-UEA-1 PAbs  
 
Serial paraffin-embedded 4 µm sections were stained by H&E, PAS and Azan 
histochemistry and by immunohistochemistry using polyclonal antibodies to 
laminin and markers shown in Table I. The distribution of endothelial (Mec 
7.46), matrix (laminin) and macrophage (FA/11) markers was evaluated using 
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a standard three-step ABC method and development in 3-amino-9-ethyl-
carbazole solution (Aldrich, Steinheim, Germany). Sections were 
counterstained for 45 seconds with Harris' haematoxylin (Merck, Darmstadt, 
Germany) at room temperature and mounted in Imsol-mount medium 
(Klinipath B.V., Duiven, The Netherlands). 
 
(Immuno) fluorescence and confocal microscopy 
Serial 4 µm cryosections of xenograft tissue were fixed in acetone for 10 
minutes. Subsequently, binding of Mec 7.46 mAb or anti-laminin antibodies 
was detected by secondary tetramethylrhodamine isothiocyanate (TRITC)-
labelled antibodies (Alexa Fluor 568, Molecular Probes, Leiden, The 
Netherlands) and mounted in Vecta Shield (Vector Laboratories, Inc. 
Burlingame, USA). FITC-labelled BSA was visualised in these sections as well. 
For confocal microscopy 20 µm cryosections of Mel 57 and Mel 57-VEGF 
xenografts (n=3) were fixed in acetone for 10 minutes and stained by a 
secondary TRITC-labelled anti-rat antibody to detect Mec 7.46 binding and a 
secondary Cy 5-labelled anti-rabbit antibody (Amersham, Pharmacia Biotech 
UK Limited, Buckinghamshire, U.K.) to detect laminin. 
 
(Immuno)electron microscopy 
The endothelial marker 9F1 (Table I) and laminin were visualised in Mel 57 and 
Mel 57-VEGF xenografts (n=2) both by light and immuno-electron microscopy 
as described previously.27,28 9F1 mbinding was detected using DAB and anti-
laminin polyclonal antibody binding using ultra small gold particles. 
 
RESULTS 
 
Evaluation of extracellular matrix patterns in uveal melanoma and 
xenografts 
Vessel detection was compared in sections of uveal melanoma lesions. The 
anti-CD34 mAb consistently stained the vasculature (identified by 
morphological characteristics) in all areas of the tumor and was superior to 
endothelial detection by other antibodies (data not shown). For paraffin-
embedded xenograft tissue, endothelial staining by ASD-13 was superior to 
anti-vWF, 9F1 and Mec 7.46 antibodies (not shown). Mec 7.46, 9F1 and ASD-
13 mAbs immunostaining of frozen sections of various normal mouse tissues 
and xenografted tumors demonstrated the specificity of these mAbs for 
endothelial cells (not shown). Further evaluation of the vasculature on paraffin 
sections was therefore performed using the anti-CD34 mAb for uveal 
melanoma and ASD-13 mAb for xenografts. None of the used antibodies 
stained melanoma cells. In addition, Mel57 cells grown in vitro on microscopic 
slides did not express endothelial markers (not shown). 
Azan staining highlighted extracellular matrix in all 30 uveal melanomas and 
20 xenografts corresponding to the earlier described PAS-positive 
patterns,9,10,18 which was confirmed by PAS staining of serial sections (figure 
1). Erythrocytes intensely stained red (figure 2a,c (appendix)). 
In 14 out of 30 uveal melanomas (47%) arcs, loops and network patterns 
were present confirming earlier results.9,10 In all 30 melanomas, erythrocytes 
were localized in circumscript lumina in the extracellular matrix which were 
invariably identified as blood vessels by endothelial CD34 staining and 
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morphological characteris-
tics in parallel sections 
(figure 2a,b). Certain parts 
of the arced patterns were 
also detected by the anti-
CD34 mAb, but these were 
not associated with closed 
loops, lumina or 
erythrocytes. Occasionally, 
erythrocytes were observed 
outside vessels in areas 
with hemorrhage and/or 
necrosis. Otherwise, neither evident circumscript lumina lacking endothelial 
CD34 staining nor erythrocytes outside the blood vasculature could be 
localized. 
All xenografts (including liver and peritoneal metastasis) of human melanoma 
cell lines Mel57 and Mel57-VEGF contained similar arcs, loops and network 
patterns 10,18 as observed in the 14 uveal melanomas (see above) (figure 1). 
Occasionally, loops surrounded smaller groups of tumor cells and were more 
abundantly present than in uveal melanoma. 
Xenografts of the less malignant 1F6 cell line contained an organised 
structure of extracellular matrix arranged in parallel patterns between groups 
of tumor cells.10,18 As in uveal melanoma, erythrocytes were exclusively 
present in lumina surrounded by ASD-13 positive blood vessel endothelium 
(figure 2c,d). Especially in the Mel57-VEGF xenografts, necrosis and 
hemorrhage were observed in the tumor center. Note that necrosis in human 
uveal melanoma was hardly observed. Other evident morphological differences 
with Mel57 wild type xenografts were not observed. 
 
Tumor perfusion in xenografts 
To study tumor perfusion, we injected FITC-BSA as a tracer i.v. into nude mice 
carrying melanoma xenografts. The distribution of endothelium and laminin 
was identical to what was observed by endothelial immunostaining and PAS 
and Azan histochemistry (figure 1, 2a-f and 3c,d). Dots of laminin were also 
observed inside tumor cell nests. In addition, laminin was also present in PAS 
and Azan-positive patterns in the primary uveal melanoma (figure 3a,b). In 
more detail, the amount of laminin related positively with the diameter of the 
depositions. Based on these findings, we were able to compare the distribution 
of tracer in relation to the extracellular matrix patterns using fluorescence and 
The tracer was located exclusively within the vascular lumina in the 1F6 
Figure 1. Evaluation of 
extracellular matrix patterns 
by PAS (a,c) and Azan 
histochemistry (b,d) in a 
human primary uveal 
melanoma (a,b) and 
xenografts of cutaneous 
melanoma (c,d) in serial 
paraffin-embedded sections. 
Bar = 0.1 mm. 
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xenografts (not shown). 
However, in Mel57 and Mel57-
VEGF xenografts, tracer was 
present both in and outside 
blood vessels in different tumor 
areas. Considerable amounts of 
tracer were found in the 
extracellular matrix present 
between tumor cell nests (arcs, 
loops and network patterns 10,18) as shown by laminin staining (figure 2e-i). In 
xenografts of Mel57-VEGF, fluorescence intensity was slightly increased 
compared to xenografts of Mel57, and tracer also penetrated a larger area 
around the blood vasculature. In the extracellular matrix, laminin deposition 
enclosed tumor cell nodules (figure 2f). Often, some space was present 
between layers of laminin bordering tumor cells (figure 2h-i). Additional 
evaluation of 20 µm cryosections by confocal microscopy also failed to produce 
evidence for a network of open channels in these laminin-containing structures. 
Instead, regular patterns of matrix deposition were observed, similar as shown 
in figure 1f. So, these results indicated that laminin was distributed as septa 
surrounding nodules of tumor cells and that, where two laminin-enveloped 
tumor nests lie adjacent, extra space between the laminin layers may be 
present. 
 
(Immuno)electron microscopic examination of extracellular matrix 
patterns in xenografts 
Despite the presence of tracer in the extracellular matrix patterns outside blood 
vessels, we did not observe lumina containing erythrocytes and lacking 
endothelial staining at such sites. The nature of the spaces between the sheets 
of laminin was unclear. Therefore, 4 xenograft lesions (2 Mel57, 2 Mel57-VEGF) 
were processed for electron microscopy and evaluated. In agreement with our 
light and immunofluorescence microscopy findings, connective tissue 
containing large amounts of collagen, often surrounded by laminin depositions, 
was located between (groups of) tumor cells (figure 4b-e) in which at certain 
locations, lumina containing erythrocytes were present (figure 4f-g). Although 
it is known that tumor cells, pericytes or stromal cells cannot always be clearly 
differentiated from endothelial cells lining lumina in tumors by (immuno) 
electron microscopy,29 additional immuno-electron microscopy using 9F1 mAb 
(figure 4f) indicated that lumina containing erythrocytes were lined by 
endothelial cells. These lumen lining cells were morphologically different from 
Figure 3. Evaluation of 
extracellular matrix patterns by 
PAS (a), laminin (b,d) and Azan 
(c) (immuno) histochemistry in 
human primary uveal melanoma 
(a,b) and xenografts of cutaneous 
melanoma (c,d) in serial sections. 
Melanin-laden macrophages 
(melanophages) (white arrow) are 
located along the PAS and laminin 
positive extracellular matrix 
patterns. Bar = 0.1 mm. 
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neighbouring tumor cells and had 
endothelial characteristics such as Weibel-
Palade bodies and tight junctions (figure 
4g-h). Lumina were always surrounded by 
rims of (likely endothelial) cytoplasm, 
which were separated from tumor cells by 
a basal membrane and often also by 
extracellular matrix (figure 4g). On the 
basis of these observations, these lumina 
were classified as putative pre-existent or 
extracellular matrix-associated new blood 
vessels. Only in case of hemorrhage or 
necrosis, erythrocytes were seen outside 
these lumina. No other true lumina 
besides the described lumina could be 
detected in the connective tissue present 
between the (nests of) tumor cells. No 
evident fenestrae between endothelial 
cells or transendothelial holes were 
observed. 
Different cell types besides tumor cells 
were associated with the extracellular 
matrix patterns. Morphological analysis 
suggested the presence of macrophages 
(figure 4b), and endothelial cells (figure 
4f). The presence of macrophages could 
be confirmed by additional 
immunostaining. Macrophages were 
mostly located between the laminin 
positive sheets surrounding tumor cell 
nests (figure 5) and present in areas of 
necrosis. In addition, melanin-laden macrophages were also associated with 
laminin-positive sheets in uveal melanoma (figure 3a,b) confirming earlier 
observations.30 
Figure 5. Immunohistochemical evaluation of 
the presence of macrophages in cryosections 
of a Mel57-VEGF xenograft. Macrophages, 
detected by FA/11 immunostaining, were 
abundantly present and closely associated 
with the extracellular matrix sheets (a, bar = 
0.1 mm). Magnification of the boxed area (a) 
shows that macrophages (b) were located 
between the laminin positive sheets 
surrounding tumor cell nests (c) (b,c, bar = 
50 µm). A blood vessel lumen is indicated by 
the asterisk (c) as could be detected by anti-
mouse CD31 immunohistochemistry (not 
shown). All sections were counterstained with 
Harris' haematoxylin. 
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DISCUSSION 
 
Maniotis et al.20 observed endothelial characteristics of tumor cells lining 
channels which is supported by the recent report by Bittner et al.31 showing 
that mRNA transcripts of CD34 and other endothelial markers are expressed in 
melanoma cells. In this respect, the question arises whether the CD34-positive 
structures are blood vessels, mosaic vessels (i.e. lined by endothelial and 
tumor cells 21), channels lined by tumor cells, extracellular matrix or a 
combination of these (for review see ref. 32). Although there are limitations in 
identifying endothelial cells in histological sections 32 and we did not double-
stain melanoma cells for melanoma and endothelial markers, no evident 
positivity of any included endothelial marker (Table I) was observed on 
melanoma cells using light microscopy. Therefore, the identity of non-luminal 
CD34 positive cells is uncertain, but they may represent vascular channels 
lined by tumor cells expressing CD34.20,31 So, by using of CD34 as a marker for 
endothelial cells in primary uveal melanoma, we were not able to confirm or 
rule out the existence of vascular mimicry 20 in primary uveal melanoma. 
Except in the less malignant 1F6 xenografts, i.v. injected tracer could be 
found outside the blood vasculature in arcs, loops and network matrix 10,18 in 
similar patterns as observed after angiography by Maniotis et al.20 and 
others.22 These findings indicate that besides blood vessels, spaces accessible 
to fluids must be present in the extracellular matrix whenever these specific 
matrix patterns are formed. Azan staining and electron microscopy, however, 
failed to detect endothelium-free channels or open spaces, whereas laminin 
and macrophage staining indicated the existence of a compartment in which 
tracer and macrophages were both present. Additional evaluation of laminin 
deposition in sectional scanning by confocal microscopy demonstrated the 
presence of regular matrix patterns, deposited closely around nests of tumor 
cells like curved sheets. Laminin is just one of the components of the 
extracellular matrix. The 'spaces' visible in laminin-immunostainings contain 
other extracellular matrix components such as collagen (which is clearly shown 
in figure 4). The conduction of the i.v. administrated tracer is therefore 
explained by spaces in the extracellular matrix (through the network of 
collagen, laminin and other components) which are not visible in electron 
microscopy and are not observed in this study to contain blood cells such as 
erythrocytes. Our observations indicate that extracellular matrix is deposited as 
curved sheets around nests or nodules of tumor cells. In these structures, 
blood vessels are embedded. The extracellular matrix pattern is present 
between spheres of tumor cells, probably deposited as envelopes, resulting in 
the arcs, loops and network patterns, detected in 2D-analysis. If two spheres 
of tumor cells lie apposed, either one layer of matrix may be formed or two 
layers can be deposited separately. Between these two different septa, matrix 
material is localised consisting of different components (including laminin and 
collagen 33) in which (limited) flow may occur (as demonstrated by the 
appearance of the tracer), and where different types of cells (including 
macrophages) are present. On the basis of these considerations, we postulate 
that, in fact, the extracellular matrix arcs, loops and network patterns 
represent a meshwork. 
The presence of the tracer outside the vasculature in the extracellular matrix 
pattern indicates a close relationship with blood vessels. This relationship is 
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confirmed by the enhanced leakage of tracer in the extracellular matrix in 
xenografts of the VEGF-transfected cell line, which is due to vascular 
hyperpermeability.22 Tracer distribution may simply be explained by two 
hypotheses. On one hand, it is possible that spaces in the extracellular matrix 
generated by tumor cells 34 connect to blood vessels and are organized as 
channels, which was suggested previously.20,35 In that case, non-migratory 
blood cells like erythrocytes would be localized in this tissue outside the 
vasculature, which we did not observe in the xenografted melanoma. On the 
other hand, interstitial spaces present in the extracellular matrix tissue (i.e. 
meshwork) may allow limited flow of fluid by (enhanced) leakage or 
permeability of the endothelium out of the blood vessels into the surrounding 
tissue. Considering our results, the latter hypothesis is the more likely, at least 
in the animal model, and the extracellular matrix arcs, loops and network 
patterns may thus represent a fluid-conducting meshwork. 
In general, fluid movement across vessel walls is governed by differences 
between blood pressure and local interstitial fluid pressure (IFP). Although IFP 
is elevated and close to microvascular pressure in different types of solid 
tumors including melanoma,36-39 our and other studies 20,22 indicate that fluid 
can leave the blood stream and form an exudate (without non-migratory blood 
cells) that moves across the microvascular arterial wall into the extracellular 
matrix meshwork tissue. The fluid movement is induced by the local higher 
arterial pressure compared to the IFP. The exudate may be conducted by the 
meshwork towards the venous microvasculature, where pressure is likely to be 
lower than the elevated IFP. This difference in pressure would allow re-entry of 
the interstitial fluid into veins. Alternatively, interstitial fluid may leak into 
surrounding pre-existent tissue (which has an IFP of approximately 0 mm Hg 
37,39) or vitreous body (oozing out) in case of uveal melanoma. High IFP is 
maintained by the absence of lymphatics 40 and by a limited drainage capacity 
of the fibrous vascular network. Comparison of the kinetics and composition of 
the fluid stream and composition of the extracellular matrix to that in normal 
Figure 4. (Immuno)electron microscopy analysis of Mel57 (b-f) and Mel57-VEGF (g,h) 
xenograft lesions. In a, a low-powered overview is shown (toluidin-blue-stained 1 
micron section of Mel57 xenograft tissue). A network is defined as the presence of at 
least 3 loops.10 In b, tumor cells (T) are separated by a layer of matrix (M). The central 
part of b is shown in detail in c. Matrix consisting mainly of collagen fibers is present 
whereas no evident lumina are visible. Immuno-electron microscopy shows the 
deposition of laminin in basal membranes of blood vessels (d, arrowhead, lumen 
indicated by L). These layers continued into the extracellular matrix sheets (d, arrow), 
surrounding bundles of collagen (e, C) (indicated box in d is magnified in e). Different 
types of stromal cells (SC), including macrophages (MP, b) were associated with these 
layers. The nature of other stromal cells (b, SC) was identified by 9F1 immuno-electron 
microscopy (arrow) (f). 9F1 immunostaining demonstrated that lumina present in the 
extracellular matrix patterns represent blood vessels lined by endothelium, occasionally 
containing erythrocytes (E). Neither evident lumina, nor erythrocytes were found in the 
extracellular matrix besides blood vessels. Further support for the endothelial nature of 
the lumen-lining cells is provided in figure g and h: the lumen is lined by a rim of 
cytoplasm (C, g) which is separated from the tumor cells (T, g) by a basal membrane 
(B, g) and often matrix depositions (M, g) were present between the tumor and 
endothelial cells. The right part of the lumen wall (boxed area) is shown in more detail 
in h. Typical endothelial characteristics (i.e. tight junctions (arrows), Weibel-Palade 
bodies (arrowhead) and a basal membrane (white arrowhead) are present. Bar in a: 
0.1 mm; in b-h: 1 µm. 
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tissues could yield insight in the role of this phenomenon in tumor biology. The 
subcutaneous space normally is essentially avascular, however, and cannot be 
taken as a standard tissue. Nevertheless, our previous data indicated that 
tracer distribution into subcutaneous tumor tissue is relatively slow, requiring 
up to 45 minutes to accomplish.22 
The extracellular matrix also harboured different types of cells, including 
macrophages which were located between sheets of extracellular matrix 
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surrounding nests of tumor cells. This observation supports the idea that 
migratory cells leave tumor vessels and invade by adhering to matrix 
components present in stromal sheets, thereby migrating into the spaces 
between them. This hypothetical mechanism is of significant importance since 
tumor-associated inflammatory cells play an evident role in tumor survival. For 
example, macrophages are associated both with angiogenesis and a poor 
prognosis in different tumor types including melanoma.30,41-43 If macrophages 
are able to invade the tumor site by using the extracellular matrix, it is also 
possible that tumor cells can enter the blood stream via the same route. 
Furthermore, by formation of extracellular matrix networks, uveal melanoma 
could acquire an alternative system to drain excess tissue fluids, as a 
substitute for a lymphatic system which is absent in this type of tumor.40 Also, 
the presence of the tracer in the extracellular matrix patterns indicates that 
nutritional components of the blood can reach tumor cells located at large 
distance of blood vessels. Indeed, the arcs, loops and network patterns are 
abundantly present in those areas in which blood vessel density is low.20 Most 
data of the present study were obtained in an animal xenograft model. In this 
model, however, matrix patterns are formed that have evident morphological 
similarities with the matrix patterns present in primary  uveal melanoma. 
Therefore, these considerations may support and explain why uveal and 
cutaneous melanoma containing the arcs, loops and network extracellular 
matrix patterns are associated with a poor prognosis.9,10 
The close parallels such as Azan- and PAS-positivity, and the association of 
laminin and macrophages with these patterns highly suggest the presence of a 
fluid-conducting meshwork in primary uveal melanoma. In this respect, the 
existence of vascular mimicry 20,35 is of significant importance. Although we did 
not observe convincing evidence of the presence of vascular channels in the 
xenografted melanoma on one hand and we can not rule out their presence in 
uveal melanoma on the other hand, it is well possible that these blood-
conducting channels and a fluid-conducting meshwork are both present in 
primary uveal melanoma. Furthermore, since the raised doubt about the nature 
of the PAS-positive patterns 9,10,18,19 and the existence of vascular 
mimicry,20,35,44 the present study may further point at the true identity of the 
patterns. Additional study, however, is required to elucidate the exact nature of 
extracellular matrix patterns in uveal melanoma. 
In conclusion, we propose that both in aggressive uveal and cutaneous 
melanoma, extravascular spaces are present besides the normal blood 
vasculature. These spaces are located between bordering curved septa of 
extracellular matrix, surrounding nests or spheres of tumor cells representing a 
fluid-conducting meshwork and contain different types of cells, including 
macrophages. There are strong indications that the arcs and loops forming the 
extracellular matrix are involved in inflammatory cell invasion, nutrition of 
tumor cells, regulation of local tissue fluid flow and, possibly, metastasis. 
Indeed, a fluid-conducting meshwork may represent an alternative to a 
lymphatic system in uveal melanoma. 
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ABSTRACT 
 
In uveal melanoma, frequently a network of extracellular matrix and capillaries 
forms as 'fibrovascular septa'. Follow-up data indicate that these septa 
negatively influence prognosis, but the pathomechanism behind this effect is 
unknown. We recently proposed that these structures represent a fluid-
conducting meshwork which is different from the earlier described vascular 
channels. Evaluation of the septa in human melanoma xenografts showed that 
intravenously injected tracer molecules crossed the vessel wall and spread 
along the extracellular matrix patterns dependent on size. Murine host cells 
were found restricted to the matrix compartment. Our data suggest that this 
matrix meshwork accommodates transport of plasma-derived molecules, e.g. 
nutrients, to the tumor, thus enhancing growth and progression, and facilitates 
infiltration by host-derived cells. 
Chapter 6 
 81
INTRODUCTION 
 
In both primary uveal and cutaneous melanoma, nine different patterns of 
extracellular matrix (ECM) deposition have been identified by conventional 
periodic acid-Schiff (PAS) staining.1-4 Analysis of prognostic relevance indicated 
that the PAS-positive arcs, loops and network patterns are associated with 
tumor progression and subsequent poor survival.1-5 A few years ago, it was 
suggested that these patterns contained or represented blood-conducting 
channels lined by tumor cells instead of endothelial cells (vasculogenic 
mimicry).6 Since then, nature of the PAS-positive patterns and the existence of 
vasculogenic mimicry have become subjects of extensive debate.6-10 
Recent studies reported the presence of laminin, collagen I and VI in uveal 
melanoma,9,11 and different types of cells including endothelial cells and 
macrophages along the PAS-positive arcs, loops and network patterns.9,12,13 
Macrophages in malignant tumors, including uveal melanoma, have been 
associated with adverse prognosis,12-16 although their function is unknown. 
Heparan sulfate proteoglycans (HSPGs) and other structural proteins which are 
key components of the ECM, may also be of significant importance for tumor 
growth and metastasis, but their exact role is unclear as well. 
In a recent study,9 we re-assessed the nature of the PAS-positive patterns in 
primary uveal and xenografted melanoma. We were not able to confirm the 
presence of blood-conducting channels, but our findings are in line with data of 
Foss et al.17 showing that the patterns constitute fibrovascular septa. 
Furthermore, we suggested that a fluid stream might be present in these ECM 
depositions apart from the blood vasculature. This "fluid-conducting meshwork" 
(figure 1a) was found in areas with a relatively low vascular density but without 
evident necrosis,7 indicating that it might play a role in tumor cell nutrition. 
Obtaining knowledge of the functional properties of this presumed fluid-stream 
is essential to understand the mechanisms of tumor outgrowth and metastasis, 
and may be helpful in designing more efficient diagnostic and therapeutic 
intervention. 
To elucidate the properties of the ECM arcs, loops and network patterns, we 
have now analyzed their ability to transport tracer molecules, details of their 
composition and the presence of associated cell types in xenografted cutaneous 
and primary uveal melanoma. 
 
Figure 1. Schematic drawing of a hypothetical mechanism of fibrovascular tissue 
perfusion in tumors. In a, blood flow is conducted by the artery, via the capillary 
network (CN) towards the venous vessel (large arrows). Exudate-like fluid moves 
across an arterial microvessel wall (small arrows) into the extracellular matrix (ECM) in 
tumor areas where arterial pressure exceeds interstitial fluid pressure. ECM patterns 
conduct the exudate-like fluid towards the venous microvasculature (small arrows) 
where blood pressure is lower than the elevated interstitial fluid pressure,26 causing re-
entry into the blood stream. Also, leakage into peri-tumoral tissue (in which the 
interstitial fluid pressure is approximately 0 mm Hg 39) or the vitreous body in case of 
uveal melanoma (i.e. oozing out) may occur. The boxed area (a) is magnified in b, 
showing leakage of the exudate-like fluid containing small and large sized molecules 
from the blood vasculature into the ECM compartment. Deep infiltration of large sized 
molecules is limited. Only small sized molecules are able to penetrate fully into the ECM 
patterns and also in small amounts between the tumor cells lining these patterns (T, 
tumor; C, capillary; F, fibrovascular septa). 
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MATERIALS AND METHODS 
 
Uveal melanoma 
Frozen specimens of 6 uveal melanoma lesions were obtained from the 
pathology archives of the University Medical Center Nijmegen where they were 
stored at –1300C. Tissues were obtained according to guidelines of Dutch 
legislation. All specimens had been diagnosed by a pathologist and were 
stained by Azan histochemistry for visualization of the extracellular matrix 
patterns.9,18 Three melanomas contained the arcs, loops and network patterns 
and were selected for further immunohistochemical study. 
 
Xenografts in nude mice 
The human cutaneous melanoma cell line Mel57 19 was cultured as previously 
described.20 For the induction of tumor growth, 2.5 x 106 cells were injected 
s.c. into BALB/c nu/nu mice (n=83). Subcutaneous xenografts developed in all 
mice as a result of the tumor cell injection. Subcutaneous tumor volumes were 
estimated by multiplying length, width and height. When the tumors reached 
sizes between 100 and 700 mm3, mice (n=80) were injected i.v. with 100 µl of 
tracer solution (see below). Tumors were excised at 2, 10, 15, 30, 45 minutes 
or 1, 3 or 24 hours after injection and snap-frozen in liquid nitrogen. In 
xenografts, tumors were divided in two parts: one part was snap-frozen in 
liquid nitrogen and the other part was formalin-fixed. Two animals were 
included per tracer type and time point. 
 
Tracers 
Tracers with a broad range of molecular size were chosen. A 3% (w/v) solution 
of bovine serum albumin (BSA) labeled with fluorescein isothiocyanate (FITC-
BSA, molecular weight approximately 68 kDa) (12 mol FITC/mol BSA), with 
sulfo-rhodamine 101 acid chloride (Texas Red-BSA) (3 mol Texas Red/mol 
BSA) or with biotin (8-16 mol biotin/mol BSA) was injected i.v. In addition, 6% 
(w/v) of FITC-labeled bovine insulin (FITC-I) (1 mol FITC/mol insulin, 
molecular weight approximately 5.8 kDa) and 1%, 2%, 3% and 6% (w/v) 
solutions of FITC-labeled dextrans (FITC-D) (0.003-0.02 mol FITC /mol 
glucose) with average molecular weights of 20,000 (FITC-D20), 40,000 (FITC-
D40), 70,000 (FITC-D70) and 2,000,000 (FITC-D2000) were also tested. We 
selected these tracers since they were representative for small nutrient 
molecules (i.e. FITC-I, FITC-D20 and 40), indicative for endothelial 
permeability changes (i.e. FITC-D70, labeled BSA), or assumed to be purely 
intravascular molecules (i.e. FITC2.000). All tracers were obtained from Sigma, 
Brunschwig, Amsterdam, The Netherlands. 
To determine the optimal conditions for studying tumor perfusion, we first 
injected nude mice carrying melanoma xenografts i.v. with 3% labeled BSA, 
6% FITC-I or 1, 2 ,3, 6% FITC-D70 and evaluated tracer distribution in the 
tumor tissue after 2 (in case of FITC-I), 30 and 60 minutes (in case of labeled 
BSA and FITC-D70). The distribution of FITC-BSA and FITC-I could readily be 
detected in all xenografts as shown previously for FITC-BSA (figure 2b 
(appendix)).9,21 After perfusion with Texas Red-BSA, fluorescence was hardly 
detectable (not shown). Histochemical visualization of biotin-BSA was 
unsuccessful as well because of high background (not shown). With 6% FITC-
D70 there was reproducible visualization of tracer distribution on fresh 
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cryosections (not shown). Therefore, 3% FITC-BSA, 6% FITC-I and 6% FITC-D 
solutions were selected for further study. 
 
Table I. Primary antibodies used for immunohistochemistry.* 
primary 
antibody 
marker  
specificity  
source of antibody 
Mec 7.46  CD31 Hycult Biotechnology, Uden, The Netherlands 
anti-laminin ** laminin Dr. J. van den Born, Department of 
Nephrology, UMC Nijmegen, The Netherlands 
3G10 pan-HSPG 29 
JM403 heparan sulfate side 
chains 
30 
10H4 syndecan-2 31,32 
2E9 syndecan-1,-3 32,33 
1C7 syndecan-3 32,33 
S1 glypican-1 34,35 
JM72 agrin 36 
1948 perlecan Chemicon International Inc, Temecula, CA, 
USA 
anti-all hu XVIII 
(QH48.18) ** 
both collagen XVIII 
variants 37 
38 
ASO2 fibroblast Dianova, Hamburg, Germany 
L26 CD20 DAKO, Glostrup, Denmark 
anti-leu-4 CD3 Becton Dickinson, San Jose, CA, USA 
anti-collagen I ** collagen I Monosan, Uden, The Netherlands 
anti-collagen III 
** 
collagen III Monosan 
anti-collagen IV collagen IV Sigma, Brunschwig, Amsterdam, The 
Netherlands 
anti-collagen V** collagen V Monosan 
HHF35 α-smooth muscle 
actin (pericytes) 
Dako 
* all antibodies were applied in uveal melanoma except for Mec 7.46 which was applied 
in xenografted melanoma. 
** polyclonal antibodies 
 
(Immuno) fluorescence 
4 µm cryosections of xenografts containing labeled BSA were fixed in acetone 
for 10 minutes. Binding of anti-CD31 monoclonal antibody (MAb) Mec 7.46 
(Table I) was detected by secondary tetramethylrhodamine isothiocyanate 
(TRITC)-labeled antibodies (Alexa Fluor 568, Molecular Probes, Leiden, The 
Netherlands). In the same section, binding of anti-laminin polyclonal antibodies 
(Table I) was detected by a secondary Cy 5-labelled anti-rabbit antibody 
(Amersham, Pharmacia Biotech UK Limited, Buckinghamshire, U.K.) Nuclear 
counterstaining was performed by incubating the sections for 1 minute in 4',6-
diamidino-2-phenylindole solution (Dapi, 0,2 mg/ml) (Sigma) and mounted in 
Vecta Shield (Vector Laboratories Inc., Burlingame, USA). In case of xenograft 
perfusion with FITC-I and FITC-D, tracer distribution was directly visualized in 
an unfixed 4 µm cryosection. Images were digitally stored. Subsequently, 
sections were fixed and double-stained. Distribution of CD31 and laminin were 
also visualized and digitally stored. To evaluate tracer distribution, digital 
images before and after double staining were matched. 
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In situ hybridization 
Three xenografted tumors were used for DNA in situ hybridization analysis. 4 
µm paraffin-embedded sections were deparaffinized, rehydrated, and immersed 
in 3% H2O2 in phosphate-buffered saline for 30 minutes. Subsequently, 
sections were incubated for 10 minutes in 1M sodium thiocyanate at 80°C and 
protein digestion was performed for 15 minutes in pepsin dissolved in 
distillated water (400 U/ml, pH 2.0). Sections were dehydrated and air-dried 
before hybridization. Total DNA was isolated from human whole blood and 
murine kidney and liver tissue by using the Puregene DNA isolation Kit (Gentra, 
Minneapolis, USA). Human DNA was labeled with biotine-16-dUTP using a nick 
translation mix (Roche Diagnostics GmbH, Mannheim, Germany) and murine 
DNA with digoxigenin-11-dUTP (Roche Diagnostics GmbH). Both probes (each 
probe: 3.3 ng/µl) were mixed in hybridization buffer (62.5% formamid, 10% 
dextran sulphate, 2x SSC-tween, pH 7.0) and denaturated at 72.5°C for 5 
minutes. Sections were hybridized overnight at 42°C. Subsequently, sections 
were washed at 45°C for 15 min with a solution of 50% formamid and 2x SSC 
(pH 7.0) and in PN buffer (10 mM/L Na2HPO4, 10 mM Na2H2PO4, 0.5% 
Nonidet P-40 detergent) for 10 minutes at room temperature. Biotin-labeled 
human DNA was detected with mouse anti-biotin polyclonal antibodies (PAbs) 
(diluted 1:100) (Dako, Glostrup, Denmark), alkaline phosphatase-conjungated 
biotin-avidin complex (Vectorstain, Vector Laboraties), and visualized by 
incubation with a mixture of 1 mg/ml Fast Blue, 0.2 mg/ml naphthol phosphate 
and 0.24 mg/ml levamisole (Sigma) for 10 minutes. Digoxigenin-labeled mouse 
DNA was detected using mouse anti-digoxigenin PAbs (dilution 1:50) (Roche 
Diagnostics GmbH), EnVision system HRP (Dako), and developed by a 10-
minute incubation with a 0.4 mg/ml amino-9-ethyl-carbazole solution. Sections 
were mounted using Imsol mounting medium. 
 
Immunohistochemistry 
Antibodies used for immunohistochemistry are listed in Table I. The distribution 
of all included markers and biotin-BSA was evaluated using a standard three-
step ABC method (Vectastain, Vector Laboratories) and development in 3-
amino-9-ethyl-carbazole (Aldrich, Steinheim, Germany). Strongly pigmented 
sections were selectively bleached when necessary. For staining with the 3G10 
MAb antibody, directed against heparitinase-digested HSPGs, sections were 
pretreated with 50 mU heparitinase (heparinase III, EC 4.2.2.8; Sigma). All 
sections were counterstained for 45 seconds with Harris’ haematoxylin (Merck, 
Darmstadt, Germany) at room temperature and mounted in Imsol-mount 
medium (Klinipath B.V, Duiven, The Netherlands). 
 
RESULTS 
 
Tracer studies 
Tracer localization was determined by comparing its distribution with laminin 
(ECM patterns) and CD31 (microvasculature) immunofluorescence as described 
previously.9 We found that tracer ability to enter the ECM was dependant on 
molecular size: FITC-BSA spread along matrix patterns outside the blood 
vasculature in approximately 45 minutes (not shown). FITC-I entered the 
patterns within 2 minutes (figure 2a-c, appendix). FITC-D70 infiltrated the 
patterns after a time interval similar to that observed with FITC-BSA (figure 
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2j), whereas FITC-D20 and FITC-D40 appeared already after 10 minutes 
(figure 2d-f, j). In particular with FITC-I and FITC-D20, a diffuse staining 
pattern was seen, indicating that this tracer was able to penetrate into the 
tumor nests as well. The large molecular size marker FITC-D2,000 
extravasated perivascularly and was observed occasionally close to large 
vessels (figure 2g-h). Remarkably, at 24 hours after injection FITC-BSA was 
still present in the patterns whereas FITC-D of any size had completely 
disappeared. When we incubated a 3% FITC-BSA solution for one hour on a 4 
µm unfixed cryosection of three xenografts, it appeared that FITC-BSA was 
able to bind to the ECM patterns directly and, to a lesser extent, to the tumor 
cells as well (not shown). 
 
In situ hybridization of xenografted tumors 
In situ hybridization analysis of both human total DNA and mouse total DNA 
showed the localization of human tumor cells and associated murine stromal 
cells in melanoma xenografts. Apart from intravascular white blood cells and 
endothelial cells, host cells were present predominantly along the ECM patterns 
whereas infiltration between tumor cells was rare (figure 3 (appendix)). 
 
Table II. Immunohistochemical analysis of uveal melanoma* 
extracellular 
matrix 
component 
arcs, loops 
and network 
patterns 
micro 
vasculature 
tumor 
cells 
pan-HSPG + + + 
heparan sulfate 
side chains 
 
+ 
 
+ 
 
- 
syndecan-2 - - -/± 
syndecan-1,-3 - - + 
syndecan-3 - + - 
glypican-1 -/± - ± 
agrin + + - 
perlecan + + - 
collagen XVIII + + - 
collagen I + + - 
collagen III - ± - 
collagen IV + + - 
collagen V + + - 
* Intensity of staining was scored as negative (-, figure 4a), weak (±,  
figure 4i) or strong (+, figure 4b). 
 
Morphological analysis of the extracellular matrix patterns in uveal 
melanoma 
To investigate the composition of the ECM patterns and to study effects of the 
presence of such patterns on the localization of infiltrating immune cells in 
uveal melanoma, immunohistochemical analysis was performed using a panel 
of well-characterized antibodies. The results are listed in Table II. Except 
collagen III, all tested subtypes of collagen were present in the ECM patterns in 
primary uveal melanoma (figure 4a-d). Basement membrane-associated HSPGs 
agrin (figure 4e) and perlecan (figure 4f were found in the extracellular matrix 
patterns and surrounding the vasculature whereas expression of the cell 
membrane-associated HSPGs syndecan-1,-3 (figure 4g), syndecan-2 (figure 
4h) and glypican-1 (figure 4i) was weak and mainly restricted to tumor cells. 
  86
Occasionally, syndecan-1,-3 and syndecan-2 were 
expressed by pattern-associated cells, probably 
macrophages, as shown previously 22 (figure 4g-h). 
Extensive staining of the ECM patterns by a fibroblast marker (Table I) was 
observed. However, no individual cells could be identified in these patterns (not 
shown) which suggests that a truly reliable marker for fibroblasts may not be 
available yet. α-Smooth muscle actin-positive pericytes were mostly confined 
to larger vessels (figure 4j). 
Infiltrate analysis showed that few B-lymphocytes were present around major 
vessels at sites of dense infiltration (figure 4k). T-lymphocytes were also 
present in the perivascular infiltrates but could occasionally be found along the 
patterns in uveal melanoma (figure 4l). 
 
DISCUSSION 
 
Theoretically, there are a number of possible explanations for the effects of the 
ECM arcs, loops and network patterns on tumor progression in uveal 
melanoma: 1) the matrix deposits facilitate angiogenesis, 2) they facilitate 
access of plasma-derived molecules to the tumor cells, 3) they facilitate 
infiltration of tumor tissue by macrophages, that, in turn, enhance 
angiogenesis,23 4) they facilitate escape of tumor cells from the primary tumor 
lesion and 5) matrix deposition is merely a secondary effect of tumor 
Figure 4. Immuno-
istochemical analysis of 
the expression of 
collagen III (a), collagen 
IV (b), collagen V (c), 
collagen XVIII (d), agrin 
(e), perlecan (f), 
syndecan-1,-3 (g), 
syndecan-2 (h) and 
glypican-1 (i) and the 
presence of pericytes 
(anti-α-SM1 mAb, j), B-
lymphocytes (anti-CD20 
mAb, k) and T-
lymphocytes (anti-CD3 
mAb, l) in primary uveal 
melanoma. Blood vessel 
lumina are indicated by 
asterisks (a,d,f,g) and 
syndecan-positive 
stromal cells (possibly 
macrophages) by arrows 
(g,h). In k, B-cells are 
neighbouring a large 
blood vessel. In l, T-cells 
are occasionally 
associated with the 
extracellular matrix arcs, 
loops and network 
patterns (arrow). 
Counterstained with 
Harris' haematoxylin. 
Magnification a-f, i, k, l: 
200x, g-h, j: 400x. 
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progression. In line with the second explanation, we recently described that the 
ECM arcs, loops and network patterns present in uveal and cutaneous 
melanoma and in melanoma xenografts, may represent a fluid-conducting 
meshwork, functionally analogous to but anatomically different from the 
previously described vascular channels.6,9 Functional evaluation of this 
meshwork by fluorochrome-labeled insulin, BSA and dextrans of different size 
indicated that there is a rapid entrance into the patterns of particles with a 
Stokes' radius of 4.4 nm of less (based on the molecular weight of FITC-D40 
using the method of Granath et al.24) within 2-10 minutes, whereas infiltration 
of larger particles (Stokes' radius more than 5.8 nm (FITC-D70)) took 
approximately 30 to 45 minutes. In addition, some leakage of small molecular 
sized FITC-I and FITC-D20 out of the ECM patterns between the tumor cells 
lining these patterns occurred (figure 1b). The exact nature of this transport is 
unclear: fluid may be transported by an actual current, by diffusion and 
convection,25 or through vascular channels. We did, however, not observe 
these channels in our animal model.9 In addition, it is expected that the 
intravascular tracer FITC-D2,000 should have been outside the vasculature in 
larger amounts than that we observed, if vascular channels had been present. 
Our data are therefore in line with either a process of diffusion and 
convection,25 or with a stream of molecules of limited size, comparable to 
pressure-driven filtration (figure 1). Entrance of fluid derived from the blood 
into the patterns is determined by the permeability of the endothelium and the 
compactness of the extracellular matrix. Leakage of FITC-D2,000 was mainly 
restricted to the perivascular space, indicating that entrance of particles with a 
Stokes' radius of at least 27.9 nm, is mainly determined by extracellular matrix 
composition. 
Our tracer data imply that nutrients can relatively rapidly be transported via 
the arcs, loops and network patterns towards tumor cells located at some 
distance from the blood vasculature. Hence, in primary uveal melanoma the 
role of the fluid-conducting meshwork may be essential for survival of tumor 
cells and explains why necrosis is absent in areas that contain arcs, loops and 
network patterns but have low numbers of blood vessels.7 Although tumor 
vessels are leaky to macromolecules in many experimental and human solid 
tumors, extravasation of these molecules is often poor. This may be explained 
by the high interstitial fluid pressure in the center of a tumor.26 This 
phenomenon is of significant importance for the design and application of 
therapeutic agents. However, in case of tumors containing the arcs, loops and 
network patterns, these patterns may provide a gateway for the delivery of 
therapeutic agents into the tumor lesion. So, although the patterns may be 
involved in tumor cell nutrition and progression on one hand, their presence 
may contribute to efficient therapy using agents directed against tumor and 
tumor-associated cells on the other hand. In this respect, a possible effect on 
immunotherapy is supported by a previous study showing that intravenous 
injection of specific monoclonal antibodies and FITC-D in melanoma-bearing 
mice resulted in similar distribution patterns.27 
In this and a previous study,9 we have shown that the matrix-associated cells 
were mainly macrophages, endothelial cells and stromal cells in both uveal and 
xenografted melanoma. In addition, it appeared that murine cells were hardly 
present inside the tumor cells nests in melanoma xenografts, indicating that 
infiltration of hosts cells is limited to the ECM patterns. So, these data indicate 
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that the extracellular matrix patterns may serve as a gateway for host cells 
entering the tumor, and perhaps, also for tumor cells to escape from the 
tumor, explaining thereby the higher degree of malignancy. Furthermore, the 
presence of non-tumor cells along the matrix patterns raises the question 
whether ECM patterns are assembled by stromal cells, by melanoma cells or by 
both. In any case, they seem to be induced primarily by the presence of the 
tumor cells, and are therefore fundamentally different from a pre-existent 
stroma in which a tumor lesion invades. It may be hypothesized that 
melanoma cells deposit ECM around small nests of tumor cells, that then the 
deposited matrix becomes infiltrated by different types of cells, including 
endothelial cells, fibroblasts and macrophages, and finally, that these latter 
cells contribute to further remodeling, maturation and expansion of the 
patterns. As suggested previously,11,28 tumors containing extracellular matrix 
arcs, loops and network patterns may thus be comparable to a battlefield: the 
neoplastic cells being the commanding officers and the stroma (fibroblasts, 
macrophages) the executing soldiers. 
In conclusion, our data suggest that the ECM arcs, loops and network 
patterns accommodate the transport of plasma-derived molecules (oxygen and 
nutrients) into the tumor lesion, thereby enhancing tumor growth and 
progression and facilitating infiltration of tumor tissue by host-derived cells. 
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SUMMARY 
 
Primary uveal melanoma may contain arcs, loops and networks of periodic 
acid-Schiff (PAS)-positive patterns along which numerous macrophages are 
present. Their recruitment into tumor tissue is mediated by chemotactic 
cytokines, for which endothelial growth factor C (VEGF-C) and endothelial-
monocyte activating polypeptide II (EMAP-II) are candidates. In this study, the 
extent of VEGF-C and EMAP-II immunoreaction was related to macrophage 
infiltration. Serial sections of 25 primary uveal melanoma lesions were 
analyzed by immunohistochemistry. Our analysis showed no correlation of 
VEGF-C immunoreaction and localization of macrophages. However, 
accumulation of macrophages occurred at sites of EMAP-II expression, 
especially in areas containing nests of tumor cells, surrounded with arcs, loops 
and network patterns. In tumors with a strong EMAP-II immunoreaction, the 
adhesion molecule intracellular adhesion molecule-1 (ICAM-1) was strongly 
expressed on endothelial cells. EMAP-II-positive endothelial cells did not 
express vascular endothelial growth factor receptor-2. However, extensive 
release of von Willebrand Factor was observed. Signs of apoptosis were found 
neither in tumor cells nor endothelial cells. In uveal melanoma, macrophages 
accumulate at sites of EMAP-II expression. Based on the results, it may be 
hypothesized that this process of chemotaxis is facilitated by EMAP-II-
dependent expression of ICAM-1 on vascular endothelial cells and 
concomitantly leads to localised vascular damage as indicated by von 
Willebrand Factor release. 
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INTRODUCTION 
 
In both primary uveal and cutaneous melanoma, nine different patterns of 
extracellular matrix deposition have been identified by conventional periodic 
acid-Schiff (PAS)-staining.1-3 These different patterns appeared to be of 
prognostic significance: especially the presence of PAS-positive arcs, loops and 
network patterns was associated with poor survival.1-4 
In a recent study,5 we suggested that these fibrovascular septa constitute a 
fluid-conducting meshwork and contain endothelial cells, stromal cells and 
macrophages along the arcs, loops and network patterns. Other reports 6,7 also 
noted the abundant presence of macrophages in uveal melanoma. In spite of 
this abundance,5-7 their role in uveal melanoma is largely unknown. 
Macrophages may be involved in angiogenesis (reviewed in ref. 8), which is 
supported by a recent study that showed that the number of macrophages was 
related to microvascular density.6 High numbers of macrophages located in the 
tumor have also been related to poor prognosis in primary uveal melanoma 6,7 
and in other tumor types.9-11 Furthermore, their strict colocalization with the 
arcs, loops and network patterns 5,6 suggests either a role in the development 
of these patterns or, alternatively, the use of these patterns to invade the 
tumor lesion. 
It is unknown how invasion of macrophages in uveal melanoma is mediated. 
As recently reported, in xenografted melanoma macrophages were recruited by 
vascular endothelial growth factor C (VEGF-C),12 which is also expressed in 
uveal melanoma.13 Besides VEGF-C, endothelial-monocyte activating 
polypeptide II (EMAP-II) may also be involved in the process of macrophage 
invasion because of its ability to attract monocytes and granulocytes.14,15 
EMAP-II mRNA was detected in normal and in tumor tissues.16-21 EMAP-II was 
originally described as a tumor-derived cytokine, isolated from MethA tumor 
supernatant.14,15 It is involved in embryonic development,16,22,23 inflammation 
21,24 and autoimmune disease.25 
The possible effects of EMAP-II on tumor growth are complex.26 On one hand, 
EMAP-II release by hypoxic or apoptotic tumor cells may be involved in 
macrophage influx and subsequent macrophage-mediated angiogenesis in 
hypoxic or apoptotic areas.14,15,17 Indeed, hypoxic prostate adenocarcinoma 
cells release EMAP-II.20 Infiltration of blood-stream monocytes in tumor tissue 
is mediated via endothelial adhesion proteins ICAM-1 and VCAM-1 and, to 
lesser extent, P- and E-selectin (for extensive review see: ref 27). If EMAP-II 
expression mediates recruitment of monocytes and resident macrophages to 
malignant tumors, this would require concomitant expression of endothelial 
adhesion proteins. It was already described previously that P- and E-selectin 
are upregulated on endothelial cells under the influence of recombinant EMAP-
II in vitro.14 On the other hand, EMAP-II-mediated influx of macrophages may 
enhance the immune response against a tumor and thereby counteract tumor 
growth. Furthermore, EMAP-II may also inhibit tumor growth by targeting the 
tumor vascular bed via induction of endothelial cell apoptosis 18 by binding to α-
ATP synthase 28 and priming the tumor vasculature for (local) destruction by 
TNF-α.19,29,30 These previously proposed mechanisms were based on 
circumstantial evidence, however, and are therefore speculative. Most data in 
recent literature were obtained by studying the effects of applied, recombinant 
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EMAP-II. So, the effects of endogenous EMAP-II, produced in the tumor 
interstitium, are unclear. 
In order to elucidate the role of endogenous, tumor-derived EMAP-II in 
primary uveal melanoma, we evaluated both the occurrence and localization of 
EMAP-II, ICAM-1 and VCAM-1 and determined the presence of macrophages by 
immunohistochemistry. In addition, levels of apoptosis, endothelial activation 
(as indicated by expression of KDR (also known as vascular endothelial growth 
factor receptor-2 (VEGFR-2 31)) and signs of endothelial damage (as 
characterized by von Willebrand Factor (vWF)-release 32) were studied. Finally, 
we investigated VEGF-C expression in relation to the presence and localization 
of macrophages. 
 
MATERIALS AND METHODS 
 
Patient material 
Tissues were obtained according to guidelines of the Dutch legislation and our 
work adhered to the tenets of the Declaration of Helsinki. Frozen specimens 
from 25 uveal melanomas were obtained from the pathology archives of the 
University Medical Centre Nijmegen where they were stored at –1300C. 
Presence of disease in all specimens had been determined by a pathologist. All 
primary melanomas were obtained by surgery and data of the clinical outcome 
was obtained of 16 patients with a follow-up time from 1 to 13 years (median 
4.5 years). The uveal melanomas varied from 7 to 28 mm in diameter (median 
22 mm) and included 23 choroidal and 2 ciliary melanoma lesions. Uveal 
melanoma lesions were divided in two parts along the maximal diameter. One 
part was formalin-fixed and the other part was snap-frozen. Using H&E staining 
on paraffin sections, 5 uveal melanomas were classified as 5 spindle cell type 
and 20 epithelioid or mixed type. Azan and PAS histochemistry without 
counterstaining on unbleached paraffin sections showed that 10 (44%) uveal 
melanomas contained loops and networks matrix patterns (figure 1a).1,2,5,13,33 
It appeared that in lesions previously classified as 'arcs, loops and network 
patterns’,1,2 the presence of arcs (with and without branching) is minimal. In 
addition, the arcs, loops and network patterns. are focally present in a tumor. 
Therefore, it is possible that sampling errors occurred leading to evaluation of a 
section containing as no network patterns whereas they were present in other 
parts of the tumor. Taken together, these considerations may explain the 
relatively low incidence of arcs, loops and network patterns in our specimen. In 
our previous experience,5,13 the extent of melanin pigmentation did not 
significantly hamper the detection of extracellular matrix by PAS and Azan 
histochemistry. The use of PAS and Azan histochemistry in identifying matrix 
patterns was recently confirmed by immunofluorescence and electron 
microscopy.5 
 
Antibodies 
Antibodies used for immunohistochemistry are listed in Table I. Anti-CD34 
(QBEnd/10), anti-CD68 (Kp1 and PG-M1) and anti-vWF were from DAKO, 
Glostrup, Denmark. Anti-ICAM-1 (PN-E12.1) was raised in our laboratory 34 and 
anti-VCAM-1 was from Immunotech S.A., Marseilles, France Anti-KDR (Clone 
KDR-2) was from Sigma, Saint Louis, Missouri, USA. Goat polyclonal antibodies 
to VEGF-C were purchased from Santa Cruz Biotechnology, Santa Cruz, CA. 
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Rabbit polyclonal antibodies EMAP-II (SA 2846) were obtained from Dr. M. 
Clauss, Max Planck Institute, Bad Nauheim, Germany. The rabbit was boosted 
once against a purified recombinant peptide containing 20 amino acids located 
at the amino terminal site of the mature human EMAP-II form. Control 
experiments demonstrated the specificity of the antibodies to both mouse and 
human EMAP-II and its precursor p43 as previously shown.17,35 
 
 Table I. Primary antibodies used: antigens and type of  
 cells stained 
Antigen Ab type of cell 
CD34 QBEnd/10 endothelial 
EMAP-II anti-EMAP-II * tumor, endothelial 
CD68 Kp1 macrophages 
CD68 PG-M1 macrophages 
VEGF-C Anti-VEGF-C * macrophages 
ICAM-1 PN-E12.1 endothelial 
VCAM anti-VCAM-1 endothelial 
vWF anti-vWF * endothelial 
KDR  anti-KDR  endothelial 
  * polyclonal antibodies 
 
Immunohistochemistry 
Four micron cryosections were air-dried and fixed in acetone at room 
temperature for 10 minutes. Only strongly pigmented sections were bleached 
by incubating the sections in 3.0% (v/v) hydrogen peroxide and 1.0% (w/v) 
disodium hydrogen phosphate for 18 hours at room temperature. Cryosections 
were incubated with 3% hydrogen peroxide for 30 minutes and subsequently 
with 20% normal goat (EMAP-II and vWF stainings) or horse serum (other 
stainings) for 10 minutes. Successive sections of each specimen were 
incubated with QBEnd/10 (diluted: 1:100), anti-EMAP-II (diluted: 1:80) 
polyclonal antibodies, Kp1 (diluted: 1:100), PG-M1 (diluted 1:50), PN-E12.1 
(undiluted supernatant), anti-VCAM-1 (diluted: 1:40), anti-vWF (diluted: 
1:300), anti-VEGF-C (diluted 1:20) for 60 minutes at room temperature. Anti-
KDR (diluted 1:400) was incubated overnight at 4oC. After the first and all 
following incubation steps, sections were rinsed with ample phosphate-buffered 
saline (PBS). Then secondary, 1:200 diluted biotinylated affinity-purified anti-
rabbit IgG (for the EMAP-II and vWF stainings), anti-goat (for VEGF-C staining) 
or anti-mouse IgG (all other stainings) (Vectastain, Vector Laboraties) was 
incubated for 30 minutes, followed by a 30 minute (KDR and VEGF-C stainings) 
or 45-minute (all other stainings) incubation with peroxidase-labelled biotin 
avidin complex (Vectastain). Subsequently, the sections stained with KDR and 
VEGF-C antibodies were incubated for 10 minutes with biotinylated tyramine 
(dilution 1:200), followed by a 20-minute incubation with ABC-peroxidase 
solution (catalysed reporter deposition method 36). All stainings were developed 
by a 10-minute incubation with a 0.4 mg/ml 3-amino-9-ethyl-carbazole 
solution (Aldrich, Steinheim, Germany). 
Four micron paraffin-embedded serial sections were deparaffinized in xylene 
and rehydrated in an ethanol series. Antigen retrieval was performed by boiling 
sections for 10 minutes in sodium citrate buffer (pH=6.0) using a microwave 
oven. Endogenous peroxidase activity was blocked by treating the sections for 
30 minutes with PBS containing 3% hydrogen peroxide. Then, sections were 
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incubated with 20% normal horse serum (Vector Laboraties) for 10 minutes. Of 
each specimen, the sections directly adjacent to the section stained by Azan 
histochemistry were incubated with QBEnd/10 mAb (diluted: 1:50) and further 
processed as described above. 
In control sections, primary antibodies were omitted. All stainings were 
counterstained for 45 seconds with Harris’ haematoxylin (Merck, Darmstadt, 
Germany) at room temperature and were mounted in Imsol-mount medium 
(Klinipath B.V., Duiven, The Netherlands). 
 
Determination of macrophage density 
In a subset of tumors expressing EMAP-II, the density of macrophages in areas 
with low or without immunoreaction and in areas with strong immunoreaction 
was assessed by visual examination of EMAP-II and CD68 immunostainings 
using an ocular with counting grid at 163x magnification. In a tumor containing 
areas with both low and with strong EMAP-II immunoreaction, numbers of 
macrophages were counted in 10 non-overlapping fields for either level of 
immunoreaction. Statistical analysis was performed by a paired t-test. 
 
Detection of apoptosis 
Apoptotic cells were detected in four micron cryosections using the ApopTag Kit 
S7100 from Introgen Therapeutics, Houston, Texas, USA, according to the 
manufacturer’s guidelines. 
 
RESULTS 
 
Vascular staining 
In all 25 uveal melanomas, the vasculature was identified by anti-CD34 mAb 
staining on frozen sections (Table I) and morphological properties as described 
previously.5,13,37 Often, the endothelial layer was discontinuous, compatible 
Figure 1. PAS-histochemistry (a) and immunohistochemical analysis of CD34 (b) and 
EMAP-II expression (c,d) and presence of macrophages (i.e. CD68-positive cells) (e,f 
(KP1), g (MG-P1)) and laminin (h) in (serial) sections of primary uveal melanoma. PAS-
histochemistry without bleaching decorates loops and network patterns containing 
melanophages (arrowhead, a). The vasculature was identified by an anti-CD34 mAb 
(b), often the endothelial lining appeared to be discontinues (arrowhead) and damaged 
(arrow). In areas with strongest EMAP-II immunoreaction (c), abundant CD68 staining 
is present associated with the vasculature (CD34 staining of the boxed area is depicted 
in b), indicating the accumulation of macrophages (e). Single asterisks indicate these 
corresponding areas (c,e). EMAP-II positivity of tumor cells in area without 
accumulation of macrophages can be explained by the detection of its precursor p43 
which is retained intracellularly.17,35 EMAP-II positivity of tumor cells in area without 
accumulation of macrophages is explained by the detection of the EMAP-II 34,000 form 
which is retained intracellulary.17,35 Inflammatory infiltrating cells (other than 
macrophages) are negative for EMAP-II (c **). Especially in melanoma containing loops 
and network patterns (arrow, d), EMAP-II immunoreaction was high (d). Next to 
macrophages (arrow, f), tumor cells were occasionally positive for CD68 stained by the 
KP1 mAb (*, f). In a serial section macrophages are stained for CD68 by MP-G1 mAb 
(g) showed that they are closely related to the extracellular matrix structures 
containing laminin (g,h). By using CD68 mAb Kp1 and MG-P1, we confirmed earlier 
data of Mäkitie et al.6 Stainings in b-h were counterstained with Harris’ haematoxylin. 
Magnification a,b,d,f: 100x. c,e: 40x, g,h: 400x 
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with endothelial damage (figure 1b). Although blood vessel density varied 
among different lesions, no evident increase of blood vessel density in distinct 
areas within a tumor lesion was observed. Azan and PAS histochemistry (figure 
1a) and CD34-immunohistochemistry of serial paraffin-embedded sections 
indicated that the blood vasculature was closely associated with loops and 
network patterns as described previously.5 
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Co-localization of EMAP-II expression and macrophages 
EMAP-II expression was detected in 23 out of 25 (92%) uveal melanomas as a 
cytoplasmic staining of tumor cells (figure 1c,d). In 15 tumors, EMAP-II 
expression was localized in circumscript areas. Especially tumor cells directly 
surrounding blood vessels were strongly positive for EMAP-II. In 8 melanomas, 
all tumor cells were intensely positive for EMAP-II (referred to as ubiquitous 
immunoreaction). By comparison to parallel endothelial CD34 staining in serial 
sections, EMAP-II was also present on blood vascular endothelium in 3 tumors 
in the areas with local expression of EMAP-II, whereas in 6 tumors with 
ubiquitous EMAP-II staining of tumor cells, endothelial cells were also 
ubiquitously positive. Especially in areas of loops and network patterns, all 
tumor cells showed strong EMAP-II immunoreaction (figure 1d). Strong 
endothelial EMAP-II immunoreaction was also observed in areas with necrosis 
(not shown). Finally, background staining patterns that could interfere with 
EMAP-II expression analysis were not observed when using other polyclonal 
antibodies (e.g. anti-vWF polyclonal antibodies). 
In all 25 melanomas, macrophages could be detected by CD68 staining and 
by morphological characteristics (compare serial sections in figures 1e and f). 
When using Kp1 antibody, tumor cells were also weakly positive for CD68 in 8 
melanoma lesions (figure 1f), whereas incubation with the PG-M1 mAb did not 
result in CD68 staining of melanoma cells (figure 1h). These data confirm 
earlier results.6,38 Both macrophages and melanophages were strongly 
associated with the extracellular loops and network patterns which contain 
laminin (figure 1g,h).5 
In the 15 tumors with local differences in EMAP-II staining intensity, 
macrophages were consistently more abundant in areas with higher EMAP-II 
levels, especially around blood vessels (compare serial sections in figures 1c 
and e). Counting of the numbers of macrophages in 4 of these tumors 
demonstrated a significant difference (p<0.0001) between those in tumor 
areas with negative to low EMAP-II immunoreaction (72±49 (mean±SD) 
macrophages/mm2) and those in areas with strong EMAP-II immunoreaction 
(457±129 macrophages/mm2). Macrophages were detected around both EMAP-
II negative (n=12) and positive (n=3) blood vessel endothelium. In 8 
melanomas with ubiquitous EMAP-II immunoreaction, macrophages were 
equally distributed over the tumor tissue. In these tumors, macrophages were 
present around EMAP-II negative and positive (n=7) vessels as well. In areas 
containing loops and network extracellular matrix patterns, nests of tumor cells 
were intensively positive for EMAP-II immunostaining. In addition, EMAP-II 
immunoreaction was lower in areas containing no loops and network patterns 
compared to areas with these patterns within one lesion. 
 
ICAM-1 and VCAM-1 immunostaining 
Co-expression of ICAM-1 and EMAP-II was found on tumor cells in all 23 EMAP-
II positive cases (figure 2a,b). Conversely, in areas with no or low tumoral 
EMAP-II immunoreaction, ICAM-1 could not be detected on tumor cells. In only 
3 out of 15 tumors with local EMAP-II expression, ICAM-1 expression was 
observed on EMAP-II positive endothelium whereas this was the case in 6 out 
of 8 tumors (figure 2a,b) with generalised immunoreaction. ICAM-1 was often 
expressed on a subset of endothelial cells (figure 2c,d). In this group of 
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tumors, EMAP-II negative endothelium did not express ICAM-1 (central vessel 
in figure 2a,b). 
In only 4 melanomas, delicate VCAM-1 staining could be detected on both 
EMAP-II positive and negative blood vascular endothelium (not shown). VCAM-
1 expression on tumor cells was never observed. 
 
KDR and vWF immunostainings 
We analyzed 16 EMAP-II-positive uveal melanomas for the presence of KDR 
and vWF as markers of endothelial activation and damage, respectively. In 14 
melanomas, comparison to parallel EMAP-II staining demonstrated that EMAP-
II positive endothelial cells lacked expression of KDR (figure 3a,b). However, 
strong staining of vWF in endothelial cells and underlying tissue indicated a 
release of vWF by this endothelium (figure 3a,c). Conversely, EMAP-II negative 
endothelial cells did express KDR in 5 melanomas (figure 3d,e) whereas no 
evident damage could be detected in these cells by vWF staining (not shown). 
In only 2 tumors a weak co-localization of EMAP-II positivity, KDR and absence 
of vWF-release was observed. Note that patterns similar to patterns that of 
EMAP-II staining were not observed when using other polyclonal antibodies 
(e.g. anti-vWF polyclonal antibodies). 
 
Detection of apoptosis 
Apoptosis was detectable in only 3 out of 15 uveal melanomas. In none of the 
tumors, apoptotic endothelial cells could be found. In one tumor, an evidently 
necrotic area, positive for EMAP-II, showed staining whereas in the remaining 
tumor cells apoptosis was absent. In the other 2 tumors, apoptosis was 
confined to a few tumor cells dispersed over the entire tumor area (not 
shown). 
Figure 2. Immuno-
histochemical analysis in 
serial sections of EMAP-II 
(a) and ICAM-1 (b) 
expression in primary 
uveal melanoma (magni-
fication: 100x). Intense 
ubiquitous EMAP-II 
staining and ICAM-1 
expression are observed 
at both tumor and 
endothelial cells (a,b). 
Insets in b are shown 
enlarged in c and d 
(magnification: 250x). 
Part of the EMAP-II 
positive endothelial cells 
express ICAM-1 (arrow 
c,d) whereas the central 
EMAP-II negative vessel 
expressed no ICAM-1 
(a,b). All stainings were 
counterstained with 
Harris’ haematoxylin. 
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Absence of co-localization of VEGF-C expression 
and macrophages 
Finally, we analyzed 12 melanomas for VEGF-C expression. In 6 melanoma, 
VEGF-C was expressed in restricted areas. No evident co-localization of 
accumulation or absence of macrophages and VEGF-C expression was observed 
in any lesion (data not shown). 
 
Correlation with clinical outcome: 
In only one patient, liver metastasis was found 2 years after enucleation. This 
tumor contained PAS-positive loops and network patterns, ubiquitous EMAP-II 
immunoreaction of both tumor and endothelial cells and macrophages, was 
equally distributed over the lesion. In addition, ICAM-1 was expressed by the 
tumor and a subset of endothelial cells. No VCAM-1 expression or apoptosis 
were observed. EMAP-II positive endothelial cells lacked expression of KDR but 
strongly stained for vWF. VEGF-C expression was not evaluated. 
 
DISCUSSION 
 
Recently, we described that the arcs, loops and network extracellular matrix 
patterns may represent a fluid-conducting meshwork in xenografted and 
primary uveal melanoma.5 Our findings indicated that these structures closely 
parallel the previously described vascular channels.39 Although it has been 
demonstrated that melanoma cells may express non-melanocytic markers like 
endothelial cell-associated CD34 and macrophage-associated CD68,39,40 we 
could not confirm the presence of blood-conducting channels lined by tumor 
cells. Instead, septa consisting of extracellular matrix components that could 
be visualized by PAS and Azan histochemistry, surrounded tumor cell nests. 
Remarkably, many macrophages (i.e. CD68 positive cells) were found 
associated with this meshwork in melanoma xenografts. We now have studied 
the presence and localization of macrophages in uveal melanoma, focusing on 
Figure 3. Immuno-
histochemical analysis in 
serial sections of EMAP-
II (a,d), KDR (b,e) and 
vWF (c) expression in 
primary uveal 
melanoma. Although 
endothelial EMAP-II 
immuno-reaction is 
delicate (a), KDR is not 
expressed (b) whereas 
endothelial damage is 
shown by leakage of 
vWF towards surroun-
ding tumor tissue 
(arrows, c). In the 
absence of endothelial 
EMAP-II expression (d), 
KDR is expressed (e). All 
stainings were 
counterstained with 
Harris’ haematoxylin. 
Magnification: 250x 
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the mechanisms underlying infiltration by this cell type. Our results also show 
that in uveal melanoma, macrophages are abundantly present and co-localize 
with the extracellular matrix patterns containing laminin.5,41 
In uveal melanoma containing loops and network extracellular matrix PAS-
positive patterns, the monocyte chemoattractant protein EMAP-II was 
abundantly present in the cytoplasm of tumor cells, which was accompanied by 
local macrophage accumulation. Additional analysis in uveal melanomas lacking 
these patterns showed that different levels of local EMAP-II staining within one 
tumor were present and that macrophages were preferentially located at areas 
with highest EMAP-II immunoreaction. These data supported the hypothesis 
that tumor cells recruit local resident tissue macrophages and peripheral 
monocytes by release of EMAP-II. This hypothesis was corroborated by several 
previous studies on the expression of EMAP-II in tumor cells and the ability of 
EMAP-II to attract macrophages.14,15 Indeed, infiltration of the tumor may be 
facilitated by the loops and network patterns by serving as a gateway. 
However, secondary changes including extensive retinal detachments, 
glaucoma, rubeosis and intraocular hemorrhage may contribute to the influx of 
macrophages as well since the majority of the lesions analyzed were large. 
Since VEGF-C expression did not co-localize with absence or accumulation of 
macrophages, our data suggest that VEGF-C does not play a substantial role in 
macrophage invasion in uveal melanoma. 
EMAP-II is normally retained intracellulary and can be released and partially 
processed by several triggers, including apoptosis and hypoxia.17,20 Since 
apoptotic cells were hardly present in the tumor lesions, this does not seem to 
be a decisive factor in EMAP-II expression in uveal melanoma. Hypoxic tumor 
cells may express hypoxia inducible factor -1 (HIF-1) 8,42 and release vascular 
endothelial growth factor-A (VEGF-A). In this respect, it is noteworthy that we 
observed no release of VEGF-A in these primary uveal melanoma lesions.13 
However, to the best of our knowledge, expression of HIF-1 in uveal melanoma 
has never been reported thus far. 
Purified recombinant mature EMAP-II protein is able to activate endothelial 
cells and enhance the expression of adhesion molecules P- and E-selectin.14 
These adhesion molecules mediate invasion of different types of leukocytes into 
the underlying tissue (for review see ref. 27). Macrophage infiltration is 
primarily mediated by ICAM-1 and VCAM-1 adhesion molecules, however. 
Remarkably, one of our first observations was that EMAP-II and ICAM-1 are co-
expressed on tumor cells. This indicates that either both these molecules are 
upregulated by the same stimulus, or that EMAP-II expression induces ICAM-1 
expression by an autocrine mechanism. Moreover, ICAM-1 was predominantly 
expressed on the vascular endothelium in those tumors that showed intense 
ubiquitous staining for EMAP-II. In tumors with focal EMAP-II immunoreaction, 
the endothelium was often negative for both EMAP-II and ICAM-1, suggesting 
that a certain threshold level of EMAP-II binding to endothelial cells is 
necessary for ICAM-1 induction. Functional experiments in cell cultures are 
necessary to confirm these findings. Since only 4 tumors expressed VCAM on 
their vessels, it is unlikely that this adhesion molecule is induced by EMAP-II 
expression and contributes to infiltration of monocytes.27 
In order to further elucidate the role of endogenously produced EMAP-II in 
primary uveal melanoma, we evaluated additional parameters that have been 
associated with EMAP-II expression in the literature, i.e. the induction of 
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apoptosis and of angiogenesis. As stated earlier, EMAP-II is involved in 
macrophage influx in several types of carcinomas. This has been related to 
tumor progression 9,10 and may partly be explained by macrophage-induced 
neovascularization 43 (for review see ref. 44). We hypothesized that in primary 
uveal melanoma, hypoxic tumor cells secrete EMAP-II contributing to 
recruitment and infiltration of monocytes into the tumor tissue. Our results 
suggest that this sequence of events is not followed by angiogenesis: EMAP-II 
positive endothelium did not express KDR as a sign of endothelial activation 
like occurring during angiogenesis. Rather, our data suggest extensive release 
or leakage of vWF out of the EMAP-positive endothelial cells into surrounding 
tumor tissue, indicating endothelial cell damage. These findings imply that 
EMAP-II, instead of triggering angiogenesis, rather induces endothelial cell 
death in vivo. In uveal melanoma therefore, EMAP-II appears to have an 
adverse effect on the neovasculature, supporting the results obtained by 
administering exogenous EMAP-II in previous studies.14,18,45 It was 
demonstrated that EMAP-II did induce endothelial apoptosis 18 after release by 
apoptotic (tumor) cells. However, in our study no evident apoptosis of EMAP-II 
positive endothelial or tumor cells was observed. The involvement of apoptosis, 
either as a trigger of EMAP-II induction or as a result of its formation, remains 
therefore questionable, at least in uveal melanoma. Our data support earlier 
results indicating that processing and release of EMAP-II is not restricted to 
apoptotic cells but may also occur in cells that ultimately die by ischemia and 
subsequent necrosis. 
The question arises whether local administration of EMAP-II will induce 
extensive vascular damage which may lead to necrosis of the tumor. Previous 
data of our laboratory indicated that the PAS-positive loops and network 
patterns may be involved in tumor cell nutrition (chapter 6). So, by inhibiting 
angiogenesis via EMAP-II administration, uveal melanoma may (partly) escape 
this intervention by formation of loops and network patterns. Local 
administration of EMAP-II may also lead to extensive influx of macrophages 
which may trigger an immune response or, alternatively, result in release of 
growth factors necessary for tumor growth and subsequent metastasis. Thus, 
the effects of EMAP-II expression are complex, the possible effects of 
intervention with EMAP-II expression in uveal melanoma or other tumor types 
are yet unpredictable and, therefore, require extensive additional research. 
Data of clinical outcome of 16 patients could be obtained with only in one 
patient proven metastatic disease. This could be explained by the relatively 
short follow-up time in the primary uveal melanoma patients, since this tumor 
is notorious of metastatic disease after years. Therefore, our study does not 
allow to draw any conclusion on the role EMAP-II of expression in determining 
prognosis. 
In summary, our data are in line with the following sequence of events: 
tumor cells promote adhesion and invasion of macrophages via the release of 
EMAP-II. This process is mediated by EMAP-II-induced expression of ICAM-1 on 
endothelial cells. Infiltrating macrophages follow the PAS-positive extracellular 
matrix patterns. Binding of substantial amounts of EMAP-II to vascular 
endothelial cells may lead to endothelial damage, resulting in vWF release. 
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Malignant solid tumors consist of a mixture of neoplastic and non-neoplastic 
(host) cells. In this respect, a solid tumor can be regarded as a functional 
tissue in which architecture and function are maintained by a dynamic interplay 
between tumor cells and a microenvironment consisting of extracellular matrix 
containing fibroblasts, blood and lymphatic vasculature and infiltrating and 
resident immune cells (i.e. tumor stroma).1 Indeed, evidence is accumulating 
that many stromal components are able to activate cellular processes as 
growth, death, adhesion, migration, invasion, gene expression and 
differentiation.2-5 Therefore, the involvement of tumor stroma appears not to 
be restricted to deposition of structural components only, but also includes 
release of cytokines, chemokines and growth factors by tumor and host cells 
and regulation of their final effects. The importance of understanding the role 
of extracellular matrix (ECM) and interaction of tumor and host cells has been 
further emphasized by studies showing that deposition of extracellular matrix 
and its interactions are of essential importance for primary tumor growth and 
rate of metastasis (reviewed in refs. 6-8), which is the major cause of death in 
cancer patients. In this thesis, we have studied the role of the ECM 
compartment with respect to tumor growth, progression and metastasis. In 
more detail, in chapter 2, 3 and 4, we studied the lymphatic and blood 
vasculature and the key players in the process of lymph- and 
hemangiogenesis. In chapter 5, 6 and 7, we studied ECM deposition patterns 
present in cutaneous and uveal melanoma which have been associated with 
poor prognosis.9-12 
 
ECM: lymphatic and blood vasculature 
The significance of the ECM for tumor metastasis may be explained by the 
close relationship of tumor cells with the lymphatic and blood vasculature in 
this compartment. The exact anatomical relation between tumor cells and the 
lymphatic bed is unclear since reliable lymphatic endothelial markers are 
lacking.13 Recently, however, a few promising lymphatic markers have been 
identified 14-16 and, in addition, gene array profiling data identified several new 
genes with specific expression in lymphatic endothelial cells.17 These latter data 
would facilitate the possible identification of new additional markers. To be able 
to study the role of the lymphatic vasculature in tumor growth and metastasis 
in our material, we further explored differential staining of the blood and 
lymphatic vasculature by a previously described double staining protocol using 
the blood endothelial marker PAL-E and pan-endothelial marker CD31 (chapter 
2, 3 and 4).18 We showed that the lymphatic vasculature could reliable be 
detected in different types of normal tissues and malignant tumors, being 
confined to the peritumoral stroma (kidney and liver carcinoma lesions) and in 
the stroma between tumor cell nests (melanoma, breast, colon and larynx 
carcinoma lesions) (chapter 2-3). These data are in line with previous 
studies.18-22 
Metastasis to regional lymph nodes may be mediated by pre-existent or, 
perhaps, newly formed lymphatics (i.e. via tumor-induced lymphangiogenesis). 
Tumor-induced lymphangiogenesis has been reported in xenografted tumors 
which overexpressed the lymphatic growth factors VEGF-C and D (vascular 
endothelial growth factor-C, -D 23-26).25,27-31 In addition, few studies suggested 
the existence of tumor-induced lymphangiogenesis in human cancer.20,22 
Furthermore, its existence is supported by the relationship between expression 
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of VEGF-C and lymph node metastasis in different human tumor types.32-38 
However, we (chapter 2, 3 and 4) and others 18,19,39 did not observe evident 
signs of lymphangiogenesis in a panel of different tumor types. As explained in 
chapter 1 (figure 1, page 14), tumor-induced lymphangiogenesis should 
involve binding and activation of Flt-4, present on the lymphatic endothelium 40 
by VEGF-C and VEGF-D.23-25,25-31,41 However, VEGF-C and Flt-4 are both 
expressed in uveal melanoma lesions, a tumor type lacking lymphatics and 
consequently lymphangiogenesis (chapter 4). Therefore, these data indicate 
that the concerted action of VEGF-C and Flt-4 is not sufficient for 
lymphangiogenesis to occur in, at least, uveal melanoma. Indeed, tumor-
induced lymphangiogenesis, if it exists, may rather be a sporadic than a 
general phenomenon in human cancer.42 Furthermore, it remains to be 
determined whether these new lymphatics are functional.43 
In normal adult tissues, Flt-4 expression is restricted to the lymphatic 
endothelium.23,40 However, Flt-4 is also expressed on intra- and periumoral 
blood vessels in different types of malignant tumor lesions (chapter 2, 3 and 
4).21,44 which may be explained by tumor cell release of VEGF-A (a major 
angiogenic growth factor) (chapter 3). In addition, other factors, like VEGF-C, 
may also be involved (chapter 4). Next to lymphangiogenesis, Flt-4 and its 
ligand VEGF-C have been involved in tumor-induced angiogenesis.45-47 
Therefore, if induction of Flt-4 expression on tumor blood vessels would be a 
general phenomenon, Flt-4 would be a marker for tumor endothelium and, 
hence, it may serve as a therapeutic target. By targeting Flt-4, blood vessels in 
the tumor area would selectively be targeted and the formation of tumor-
associated lymphatics may be inhibited leading ultimately to reduction of both 
tumor growth and metastasis.43,48,49 Our data (chapter 2) also suggested that 
Flt-4 expression on blood vessels gradually increases as a tumor becomes more 
malignant in case melanocytic skin lesions. Indeed, besides providing a 
possible therapeutic target, immunohistochemical analysis of Flt-4 expression 
may provide additional support in determining clinical outcome. 
 
ECM formation in uveal melanoma 
Although it is known that the ECM contains blood vessels, the exact nature and 
function of the depositions in uveal melanoma have not been elucidated 
yet.11,12,50-54 Relevant research started in the early nineties when Folberg et al. 
proposed nine distinct morphological types of microvessel architecture in uveal 
melanoma.11 These microvascular patterns were identified in tissue sections by 
fluorescein-conjugated Ulex europaeus I and by periodic acid-Schiff (PAS) 
histochemistry that stains basement membrane and collagen.11,12 In addition, 
we showed that these PAS-positive patterns could also be detected by Azan 
and laminin (immuno)histochemistry in primary uveal and xenografted 
melanoma (chapter 4 and 5) The PAS-positive patterns, arranged in arcs, loops 
and networks, proved to be related to rate of metastasis and, hence, 
prognosis.11,12 Since then, similar patterns in human metastatic cutaneous 
melanoma, breast, ovarian and prostate carcinoma could be related to 
prognosis.9,10,55-57 
Re-assessment by an additional study questioned the true microvascular 
nature of the patterns 50 as Foss et al. showed that the patterns consisted of 
extracellular matrix in which blood vessels were embedded, the so-called 
“fibrovascular tissue”. These results were supported by data presented in 
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chapter 5 and 6, suggesting that PAS-positive structures surrounding tumor 
cell nests represented fibrovascular septa. These may act as a matrix network 
that provides a medium for diffusion of soluble factors (i.e. a fluid-conducting 
meshwork). Finally, Maniotis et al.51 suggested that vascular channels were 
closely associated with the PAS-positive arcs, loops and network patterns. 
Vascular channels were defined as blood-conducting channels lined by tumor 
cells (and therefore not by endothelium) in close contact with the blood 
vasculature. In these channels along the PAS-positive patterns, melanoma cells 
mimic endothelial cells (i.e. vasculogenic mimicry 51,52). Since the first report of 
the possible existence of vascular mimicry, a number of proteins involved in 
the formation of the PAS-positive arcs, loops and network patterns and in 
vasculogenic mimicry have been identified.58-61 In addition to the possible 
phenomenon of melanoma cells mimicking endothelial cells, it was suggested 
that these tumor cells may also express cell-fate determination molecules 
which are normally expressed during embryonic vasculogenesis, and may 
participate in neovascularization in ischemic muscle.62,63 Besides channels lined 
by tumor cells, also "mosaic" vessels in which endothelial cells and tumor cells 
alternatingly form the luminal surface, may be present in tumors.64 
The existence of vasculogenic mimicry was seriously questioned since several 
authors, including us, did not observe conductance of blood along the PAS-
positive structures outside the blood vasculature.53,54 In more detail, by 
applying Azan histochemistry resulting in a sharp contrast of red-stained 
erythrocytes and blue-stained matrix components, combined with 
immunohistochemical analysis using a panel of established endothelial 
markers, no evident presence of endothelium-free blood-conducting structures 
were observed (chapter 5) although it was found that melanoma cells may 
express endothelial markers as well.65 So, reliable identification of blood-
conducting structures was questioned (for review see ref. 54), thereby 
hampering a definitive elucidation whether vasculogenic mimicry is present or 
absent in malignant tumors. 
 
ECM patterns: morphological and functional properties 
As stated above, Foss et al. proposed that the PAS-positive arcs, loops and 
network patterns constitute fibrovascular tissue,50 which was confirmed by us 
using electron microscopy (chapter 5). In addition, our observations suggested 
that extracellular matrix is deposited as curved sheets around nests or nodules 
of tumor cells. In these structures, blood vessels are embedded and, at least in 
uveal melanoma, lymphatics are absent (chapter 4). The extracellular matrix 
pattern is present between spheres of tumor cells and is probably deposited as 
envelopes. In 2D-analysis, this matrix deposition is detected as arcs, loops and 
network patterns. Intravenous injection of fluorescein isothiocyanate-labeled 
bovine serum albumin in nude mice bearing subcutaneous xenografted 
melanoma containing the arcs, loops and network patterns showed that this 
tracer was able to leave the blood stream and enter the arcs, loops and 
network patterns (chapter 5).66 This observation suggested that exudate-like 
fluid is transported (conducted) by diffusion and/or by a fluid stream via 
extracellular spaces located in the patterns. Therefore, we proposed in chapter 
5 and 6 that the arcs, loops and network patterns represent a "fluid-conducting 
meshwork". In this respect, it is noteworthy that the original reporters of the 
existence of vasculogenic mimicry, Maniotis et al.,51 suggested recently the 
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presence of plasma within laminin-positive looped patterns from contiguous 
leaky vessels in melanoma.67 Indeed, in our opinion, the term "channel" as 
description of fluid-conducting extracellular spaces may be incorrect since the 
concept of blood conducting channel formation by tumor cells postulated by 
Maniotis et al.51 is questionable. 
In primary uveal melanoma containing arcs, loops and network patterns, 
microvascular density is often so low that necrosis is to be expected.52 
However, necrotic foci are absent in these areas.52 Previously, it was suggested 
that this phenomenon could be explained by the presence of vascular 
channels.51,52 However, our data suggest that vascular channels (if they exist) 
may not be the only contributor involved since exudate-like fluid is transported 
along the extracellular matrix patterns as well (chapter 5 and 6). Indeed, small 
molecules like most nutrients are able to reach tumor cells located at some 
distance from the blood vasculature within 2 minutes (chapter 6). In addition, 
besides nutrition of tumor cells, uveal melanoma could also acquire an 
alternative system to drain excess tissue fluids by formation of extracellular 
matrix networks, as a substitute for a lymphatic system which is absent in this 
type of tumor (chapter 4). 
 
ECM matrix patterns: tumor and associated host cells 
The arcs, loops and network extracellular matrix patterns harbor different types 
of cells, including endothelial cells, pericytes, fibroblasts and inflammatory cells 
including macrophages (chapter 5, 6 and 7).68 Although it is unknown how the 
patterns are formed, the presence of fibroblasts suggested their involvement. 
Matrix may be deposited by stromal cells, melanoma cells or both. In any case, 
they seem to be induced primarily by the presence of the tumor cells, and are 
therefore fundamentally different from a pre-existent stroma in which a tumor 
lesion invades. 
The abundant presence of macrophages along the arcs, loops and network 
patterns in uveal melanoma (chapter 5 and 7) 68,69 supports the idea that 
migratory cells leave tumor vessels and invade by adhering to matrix 
components present in stromal sheets, thereby migrating actively into the 
spaces between them or drilling their way by proteolytic enzymes expressed at 
their migratory front. Otherwise, it is possible that the extracellular matrix 
patterns may also serve as a gateway for tumor cells to escape from the 
tumor, explaining thereby the higher degree of malignancy.9-12,55-57 The exact 
function of macrophages in tumor growth and metastasis is essentially 
unknown, although macrophages have been associated with a poor prognosis 
in different tumor types (for review see refs. 70) including uveal 
melanoma.69,71-74 Indeed, the number of macrophages is related to 
microvascular density (for review see ref. 75), indicating that they induce 
neovascularization 76 which is essential for tumor growth and metastasis.77 In 
addition, their strict colocalization with the arcs, loops and network patterns 
(chapter 5 and 7) 68,69 suggests also a role in the development of these 
patterns. It is largely unknown how invasion of macrophages into the arcs, 
loops and network patterns is mediated, although expression of chemokines 
like monocyte chemotactic protein-1 78 and endothelial-monocyte activating 
polypeptide-II (chapter 7) 79,80 by melanoma cells has been identified. EMAP-II 
expression was closely associated with macrophages distributed along the arcs, 
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loops and network patterns, suggesting that EMAP-II may act as chemotactic 
factors for the tumor-infiltrating cells. 
In conclusion, in this thesis, we provided evidence suggesting that the ECM 
compartment of solid tumors is of essential importance for tumor growth and 
metastasis. Indeed, we showed that it represents the tumor compartment in 
which tumor cells interact with the blood and lymphatic vasculature. 
Furthermore, the formation of the arcs, loops and network ECM patterns may 
1) accommodate transport of plasma-derived molecules (nutrients) into the 
tumor lesion and waste products away from the tumor tissue, 2) serve as an 
alternative lymphatic system regulating interstitial pressure, 3) mediate 
infiltration of tumor tissue by host-derived cells and 4) provide a gateway for 
tumor cells to leave the tumor. 
 
REFERENCES 
 
1.   Radisky D, Hagios C, Bissell MJ. Tumors are unique organs defined by abnormal 
signaling and context. Semin. Cancer Biol. 2001; 11:87-95. 
2.   Ingber DE, Folkman J. Mechanochemical switching between growth and 
differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role 
of extracellular matrix. J. Cell Biol. 1989; 109:317-330. 
3.   Juliano RL, Haskill S. Signal transduction from the extracellular matrix. J. Cell 
Biol. 1993; 120:577-585. 
4.   Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control 
element in atherosclerosis and restenosis. J. Clin. Invest 1996; 98:2436-2439. 
5.   Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of 
extracellular matrix during tumor onset and progression. J. Cell Physiol 2002; 
192:259-267. 
6.   Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on 
the malignant phenotype. Mol. Med. Today 2000; 6:324-329. 
7.   Rintoul RC, Sethi T. The role of extracellular matrix in small-cell lung cancer. 
Lancet Oncol 2001; 2:437-442. 
8.   Ruiter DJ, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions - 
Structural and functional aspects. Lancet Oncol. 2002; 3:35-43. 
9.   Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK, 
Folberg R. Prognostic significance of periodic acid-Schiff-positive patterns in 
primary cutaneous melanoma. Clin. Cancer Res. 2001; 7:473-477. 
10.   Thies A, Mangold U, Moll I, Schumacher U. PAS-positive loops and networks as a 
prognostic indicator in cutaneous malignant melanoma. J. Pathol. 2001; 195:537-
542. 
11.   Folberg R, Pe'er J, Gruman LM, Woolson RF, Jeng G, Montague PR, Moninger TO, 
Yi H, Moore KC. The morphologic characteristics of tumor blood vessels as a 
marker of tumor progression in primary human uveal melanoma. Hum. Pathol. 
1992; 23:1298-1305. 
12.   Folberg R, Rummelt V, Parys van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, 
Gruman LM. The prognostic value of tumor blood vessel morphology in primary 
uveal melanoma. Ophthalmology 1993; 100:1389-1398. 
13.   Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic 
endothelium: in search of the holy grail? Microsc. Res Tech. 2001; 55:61-69. 
14.   Breiteneder GS, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner 
G, Kerjaschki D. Podoplanin, novel 43-kd membrane protein of glomerular 
epithelial cells, is down-regulated in puromycin nephrosis. Am. J. Pathol. 1997; 
151:1141-1152. 
Summary 
 115
15.   Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-
1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for 
hyaluronan. J. Cell Biol. 1999; 144:789-801. 
16.   Wigle JT, Oliver G. Prox1 function is required for the development of the murine 
lymphatic system. Cell 1999; 98:769-778. 
17.   Hirakawa S, Hong YK, Harvey N, Schacht V, Matsuda K, Libermann T, Detmar M. 
Identification of vascular lineage-specific genes by transcriptional profiling of 
isolated blood vascular and lymphatic endothelial cells. Am. J. Pathol. 2003; 
162:575-586. 
18.   de Waal RM, van Altena MC, Erhard H, Weidle UH, Nooijen PT, Ruiter DJ. Lack of 
lymphangiogenesis in human primary cutaneous melanoma. Consequences for the 
mechanism of lymphatic dissemination. Am. J. Pathol. 1997; 150:1951-1957. 
19.   Carreira CM, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain 
RK. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood 
sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 
2001; 61:8079-8084. 
20.   Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris 
AL, Jackson DG. Intratumoral lymphangiogenesis and lymph node metastasis in 
head and neck cancer. Cancer Res 2002; 62:1315-1320. 
21.   Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, 
Weich H, de Waal RM, Alitalo K. VEGFR-3 and its ligand VEGF-C are associated 
with angiogenesis in breast cancer. Am. J. Pathol. 1999; 145:1381-1390. 
22.   Schoppmann SF, Birner P, Studer P, Breiteneder-Geleff S. Lymphatic microvessel 
density and lymphovascular invasion assessed by anti-podoplanin immunostaining 
in human breast cancer. Anticancer Res. 2001; 21:2351-2355. 
23.   Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. 
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role 
in lymphatic vascular development. Development 1996; 122:3829-3837. 
24.   Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, Alitalo K, 
Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and 
lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 
1997; 188:96-109. 
25.   Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, 
Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. Signalling via vascular 
endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in 
transgenic mice. EMBO J 2001; 20:1223-1231. 
26.   Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. 
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases 
VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA. 
1998; 95:548-553. 
27.   Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, 
Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis 
and intralymphatic tumor growth. Cancer Res. 2001; 61:1786-1790. 
28.   Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, 
Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. 
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes 
tumour metastasis. EMBO J. 2001; 20:672-682. 
29.   Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, 
Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C 
promotes breast cancer metastasis. Nat. Med. 2001; 7:192-198. 
30.   Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M. 
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage 
recruitment by vascular endothelial growth factor-C in melanoma . Am. J Pathol. 
2001; 159:893-903. 
  116
31.   Papoutsi M, Sleeman JP, Wilting J. Interaction of rat tumor cells with blood 
vessels and lymphatics of the avian chorioallantoic membrane. Microsc. Res. Tech. 
2001; 55:100-107. 
32.   Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, Taniguchi K, 
Miwa K, Ohoyama S, Sugiyma K, Sasaki T. Role of vascular endothelial growth 
factor C expression in the development of lymph node metastasis in gastric 
cancer. Clin. Cancer Res. 1999; 5:1823-1829. 
33.   Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y, 
Pass HI. VEGF and VEGF type C play an important role in angiogenesis and 
lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 
1999; 81:54-61. 
34.   Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, 
Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human 
thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 
1999; 155:1967-1976. 
35.   Tsurusaki T, Kanda S, Sakai H, Kanetake H, Saito Y, Alitalo K, Koji T. Vascular 
endothelial growth factor-C expression in human prostatic carcinoma and its 
relationship to lymph node metastasis. Br. J. Cancer 1999; 80:309-313. 
36.   O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial 
growth factor family members in head and neck squamous cell carcinoma 
correlates with lymph node metastasis. Cancer 2001; 92:556-568. 
37.   Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, 
Watanabe G. The expression of vascular endothelial growth factor C and its 
receptors in non-small cell lung cancer. Br. J. Cancer 2001; 85:255-260. 
38.   Nakashima T, Kondoh S, Kitoh H, Ozawa H, Okita S, Harada T, Shiraishi K, 
Ryozawa S, Okita K. Vascular endothelial growth factor-C expression in human 
gallbladder cancer and its relationship to lymph node metastasis. Int. J. Mol. Med. 
2003; 11:33-39. 
39.   Birner P, Schindl M, Obermair A, Breitenecker G, Kowalski H, Oberhuber G. 
Lymphatic microvessel density as a novel prognostic factor in early-stage invasive 
cervical cancer. Int. J. Cancer 2001; 95:29-33. 
40.   Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh V, Fang G-H, Dumont D, 
Breitman M, Alitalo K. Expression of the fms-like tyrosine kinase 4 gene becomes 
restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. 
USA. 1995; 92:3566-3570. 
41.   He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. 
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking 
vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 2002; 
94:819-825. 
42.   Cassella M, Skobe M. Lymphatic vessel activation in cancer. Ann. N. Y. Acad. Sci. 
2002; 979:120-130. 
43.   Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, 
Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the 
absence of functional intratumor lymphatics. Science 2002; 296:1883-1886. 
44.   Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of 
vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 
1999; 86:2406-2412. 
45.   Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, 
Principe N, Kearney M, Hu J-S, Isner JM. Vascular endothelial growth factor-C 
(VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. 
Pathol. 1998; 153:381-394. 
46.   Cao Y, Linden P, Fernebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, 
Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. 
Natl. Acad. Sci. USA. 1998; 95:14389-14394. 
47.   Hofman P, van Blijswijk BC, Gaillard PJ, Vrensen GF, Schlingemann RO. 
Endothelial Cell Hypertrophy Induced by Vascular Endothelial Growth Factor in the 
Summary 
 117
Retina: New Insights Into the Pathogenesis of Capillary Nonperfusion. Arch. 
Ophthalmol. 2001; 119:861-866. 
48.   Jain RK, Padera TP. Prevention and treatment of lymphatic metastasis by 
antilymphangiogenic therapy. J. Natl. Cancer Inst. 2002; 94:785-787. 
49.   Kubo H, Fuijwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, Awane M, Sakai Y, 
Takabayashi A, Alitalo K, Yamaoka Y, Nishikawa SI. Involvement of vascular 
endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell 
lining during tumor angiogenesis. Blood 2000; 96:546-553. 
50.   Foss AJ, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. 
Reassessment of the PAS patterns in uveal melanoma. Br. J. Ophthalmol. 1997; 
81:240-246. 
51.   Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, Trent JM, 
Meltzer PS, Hendrix MJC. Vascular channel formation by human melanoma cells in 
vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 1999; 155:739-752. 
52.   Folberg R, Hendrix MJC, Maniotis AJ. Vasculogenic mimicry and tumor 
angiogenesis. Am. J. Pathol. 2000; 156:361-381. 
53.   McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how 
novel and how significant? Am. J. Pathol. 2000; 156:383-388. 
54.   McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not 
absent. Cancer Metastasis Rev. 2000; 19:109-120. 
55.   Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi 
F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, Wakasugi H. Absence of 
endothelial cells, central necrosis, and fibrosis are associated with aggressive 
inflammatory breast cancer. Cancer Res. 2001; 61:445-451. 
56.   Hendrix MJ, Seftor EA, Kirschmann DA, Seftor RE. Molecular biology of breast 
cancer metastasis. Molecular expression of vascular markers by aggressive breast 
cancer cells. Breast Cancer Res 2000; 2:417-422. 
57.   Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB, Lubaroff 
DM, Hendrix MJ. Prostatic tumor cell plasticity involves cooperative interactions of 
distinct phenotypic subpopulations: Role in vasculogenic mimicry. Prostate 2002; 
50:189-201. 
58.   Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, 
Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin 
in aggressive human melanoma cells: Role in vasculogenic mimicry. Proc. Natl. 
Acad. Sci. USA 2001; 98:8018-8023. 
59.   Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch 
MS, Hendrix MJ. Molecular regulation of tumor cell vasculogenic mimicry by 
tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 
2001; 61:3250-3255. 
60.   Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-
Stevenson WG, Quaranta V, Hendrix MJ. Cooperative interactions of laminin 5 
gamma2 chain, matrix metalloproteinase-2, and membrane type-1-
matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by 
aggressive melanoma. Cancer Res 2001; 61:6322-6327. 
61.   Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE, 
Hendrix MJ. Molecular Determinants of Ovarian Cancer Plasticity. Am. J. Pathol. 
2001; 158:1279-1288. 
62.   Hendrix MJ, Seftor RE, Seftor EA, Gruman LM, Lee LM, Nickoloff BJ, Miele L, 
Sheriff DD, Schatteman GC. Transendothelial function of human metastatic 
melanoma cells: role of the microenvironment in cell-fate determination. Cancer 
Res. 2002; 62:665-668. 
63.   Sood AK, Fletcher MS, Hendrix MJ. The embryonic-like properties of aggressive 
human tumor cells. J. Soc.. Gynecol. Investig. 2002; 9:2-9. 
64.   Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood 
vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc 
Natl Acad Sci USA 2000; 97:14608-14613. 
  118
65.   Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon 
R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, 
Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, 
Beaudry C, Berens M, Alberts D, Sondak V. Molecular classification of cutaneous 
malignant melanoma by gene expression profiling. Nature 2000; 406:536-540. 
66.   Pötgens AJ, van Altena, MC, Lubsen NH, Ruiter DJ., de Waal RM. Analysis of the 
tumor vasculature and metastatic behavior of xenografts of human melanoma cell 
lines transfected with vascular permeabilily factor. Am. J. Pathol. 1996; 148:1203-
1217.  
67.   Maniotis AJ, Chen X, Garcia C, DeChristopher PJ, Wu D, Pe'er J, Folberg R. 
Control of melanoma morphogenesis, endothelial survival, and perfusion by 
extracellular matrix. Lab Invest 2002; 82:1031-1043. 
68.   Makitie T, Tarkkanen A, Kivela T. Comparative immunohistochemical oestrogen 
receptor analysis in primary and metastatic uveal melanoma. Graefes Arch. Clin. 
Exp. Ophthalmol. 1998; 236:415-419. 
69.   Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages 
(cd68(+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. 
Vis. Sci. 2001; 42:1414-1421. 
70.   Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in 
tumour progression: implications for new anticancer therapies. J. Pathol. 2002; 
196:254-265. 
71.   Takanami I, Takeuchi K, Kodaira S. Tumor-associated macrophage infiltration in 
pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. 
Oncology 1999; 57:138-142. 
72.   Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, 
Kuwano M. Macrophage infiltration correlates with tumor stage and angiogenesis 
in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. 
Int. J. Cancer 2000; 85:182-188. 
73.   Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of 
macrophage infiltration with angiogenesis and prognosis in invasive breast 
carcinoma. Cancer Res. 1996; 56:4625-4629. 
74.   Ono M, Torisu H, Fukushi J, Nishie A, Kuwano M. Biological implications of 
macrophage infiltration in human tumor angiogenesis. Cancer Chemother. 
Pharmacol. 1999; 43 Suppl. 
75.   Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and 
angiogenesis. J. Leukoc. Biol. 1994; 55:410-422. 
76.   Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial 
proliferation in vitro by tumor-associated macrophages. Lab. Invest. 1984; 
51:635-642. 
77.   Folkman J. What is the evidence that tumors are angiogenesis dependent? J. 
Natl. Cancer Inst. 1990; 82:4-6.  
78.   Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, Chayama K. 
Vascular endothelial growth factor-C expression predicts lymph node metastasis of 
human gastric carcinomas invading the submucosa. Eur. J. Cancer 2002; 38:1413-
1419. 
79.   Kao J, Houck K, Fan Y, Haehnel I, Libutti SK, Kayton ML, Grikscheit T, Chabot J, 
Nowygrod R, Greenberg S, Kuang W-J, Leung DW, Hayward R, Kisiel W, Heath M, 
Brett J, Stern D. Characterization of a novel tumor-derived cytokine. Endothelial-
monocyte activating polypeptide II. J. Biol. Chem. 1994; 269:25106-25119. 
80.   Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familletti PC, Wang 
F, Pan YC, Stern D, Clauss M. Endothelial monocyte-activating polypeptide II. A 
novel tumor-derived polypeptide that activates host-response mechanisms. J. Biol. 
Chem. 1992; 267:20239-20247. 
 
Samenvatting 
 119
Samenvatting 
 
Het melanoom is een kwaadaardige tumor die uitgaat van pigmentvormende 
cellen (melanocyten) die zich voornamelijk in de huid en het oog bevinden. Het 
huidmelanoom is een van de meest voorkomende kwaadaardige tumoren bij 
jonge volwassen (in Nederland ca 2000 nieuwe gevallen per jaar). Het 
oogmelanoom is de meest frequente oogtumor. Deze laatst genoemde tumor 
wordt per jaar bij iets meer dan 100 mensen in Nederland vastgesteld. Beide 
tumortypen hebben sterk de neiging tot uitzaaien (metastasering), waarbij het 
oogmelanoom een sterke voorkeur heeft voor de lever. Eenmaal 
gemetastaseerd, is de prognose van beide typen melanomen slecht. 
Behalve cellen wordt in zowel huid- als oogmelanomen vaak tussencelstof 
(oftewel extracellulaire matrix (ECM)) aangetroffen. Eigenschappen van deze 
ECM blijken essentieel te zijn voor het optreden van metastasering. In de ECM 
bevinden zich ook andere celtypen, zoals ontstekingscellen, cellen die ECM 
produceren (fibroblasten), bloed- en lymfevaten. Tumoren zijn sterk 
afhankelijk van deze bloedvaten om te kunnen uitgroeien: zonder bloedvaten 
kunnen tumoren niet groter worden dan circa 2 mm. Om te kunnen groeien, 
produceren tumorcellen dan ook groeifactoren die vorming van nieuwe 
bloedvaten (angiogenese) in en direct rond de tumor induceren. Een van de 
meest belangrijke groeifactoren is vasculair endotheel groeifactor (VEGF). 
Via de bloedbaan kunnen tumorcellen zich verplaatsen naar, en uitgroeien in, 
weefsels en organen elders in het lichaam (metastasering op afstand). Naast 
bloedvaten, zijn ook lymfevaten betrokken bij het metastaseringsproces, 
namelijk naar lymfeklieren die nabij de tumor zijn gelokaliseerd (regionale 
metastasering). In muizenstudies zijn er reeds duidelijke aanwijzingen 
gevonden dat tumorcellen ook bepaalde groeifactoren (zoals VEGF-C en VEGF-
D) kunnen aanmaken die de uitgroei van nieuwe lymfevaten (lymfangiogenese) 
in de tumor (en daarmee de lymfogene metastasering) kunnen stimuleren. Of 
lymfangiogenese ook in humane tumoren voorkomt is echter nog onduidelijk. 
Nieuwvorming van bloed- en lymfevaten is het gevolg van de interactie 
tussen de tumorcellen en de endotheelcellen die de bloed- en/of lymfevaten 
bekleden. Inmiddels is er steeds meer wetenschappelijk bewijs dat er tussen 
de tumorcellen en aanwezige andere celtypen inderdaad talrijke onderlinge 
interacties plaats vinden. Deze interacties worden bewerkstelligd door 
verschillende soorten ‘signaalstoffen’ (zoals VEGF, VEGF-C en VEGF-D) die 
zowel door de tumorcellen en andere celtypen aangemaakt en uitgescheiden 
worden in de ECM. 
In melanomen, zowel van de huid als het oog, zijn bepaalde patronen van 
ECM afzetting (depositie) aanwezig die in ongeveer 40 tot 50% van de gevallen 
een soort netwerk lijken te vormen. Hoewel men weet dan de aanwezigheid 
van deze patronen voorspellend is voor het optreden van metastasen (en dus 
een slechte prognose), is er weinig tot geen kennis van morfologische en 
functionele eigenschappen van dit netwerk. 
Uit het voorafgaande blijkt dat kennis van de eigenschappen van de ECM in 
het melanoom noodzakelijk is om het mechanisme van tumorgroei en 
metastasering te begrijpen. In dit proefschrift hebben we dan ook de rol van de 
ECM in het huid- en oogmelanoom bestudeerd met bijzondere aandacht voor 
de bloed- en lymfvasculatuur, voor de belangrijke mediatoren die angiogenese 
en lymfangiogenese veroorzaken (hoofdstuk 2, 3 en 4) en voor de 
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morfologische en functionele eigenschappen van de netwerkpatronen 
(hoofdstuk 5, 6 en 7). 
 
ECM: relatie tussen lymfe- en bloedvaten 
Hoewel de rol van bloedvaten bij tumorgroei en metastasering uitgebreid is 
bestudeerd, is er weinig bekend over de rol en anatomische lokalisatie en 
functie van lymfevaten in tumoren. Dit wordt veroorzaakt door het ontbreken 
van specifieke merkstoffen voor lymfevaten. In hoofdstuk 2 hebben we een in 
het eigen laboratorium ontwikkelde immunohistochemische dubbelkleuring die 
het mogelijk maakte om bloed- en lymfevaten van elkaar te onderscheiden in 
verschillende soorten normale en tumor weefsels. Het bleek dat lymfevaten 
vooral lokaliseerd zijn aan de rand van tumoren. Overtuigende (tekenen van) 
lymfangiogenese hebben we echter niet gevonden. In het oogmelanoom zijn 
lymfevaten zelfs compleet afwezig, hoewel VEGF-C en zijn receptoren KDR en 
Flt-4 (waarvan Flt-4 expressie essentieel is voor lymfangiogenese) wel tot 
expressie kwamen (hoofdstuk 4). Deze gegevens suggereren dat er meerdere, 
nog niet bekende, factoren een rol spelen bij de inductie van lymfangiogenese 
in (humane) tumoren. 
Nieuwvorming van bloed- en lymfevaten in tumoren zijn het gevolg van vele 
interacties tussen de tumorcellen en andere celtypen. Een voorbeeld van zo'n 
interactie is de inductie van Flt-4 expressie op bloedvaten in tumoren. Onder 
normale, niet-pathologische, omstandigheden komt Flt-4 tijdens het volwassen 
leven alleen tot expressie op lymfevaten. Flt-4 expressie blijkt echter te 
verschijnen op bloedvaten die in, of direct aan de rand van een tumor liggen 
(hoofdstuk 2, 3 en 4). Bij deze inductie lijkt VEGF een belangrijke rol te spelen 
(hoofdstuk 3). De mate van Flt-4 expressie op de bloedvaten lijkt bovendien 
gerelateerd te zijn aan de graad van agressiviteit, althans bij goedaardige en 
kwaadaardige melanocytaire huidafwijkingen (hoofdstuk 2). 
 
ECM patronen in het oogmelanoom 
Aanvankelijk in het oogmelanoom, en later ook in het huidmelanoom, werden 
in het begin van de jaren 90 verschillende patronen van ECM deposities 
beschreven. Deze patronen kunnen zichtbaar gemaakt worden m.b.v. de 
zogenaamde PAS-kleuring. In hoofdstuk 5 en 6 zijn deze netwerkpatronen 
morfologisch en functioneel gekarakteriseerd in het humane oogmelanoom en 
in een muizenmodel met onderhuids gelegen melanomen. De netwerkpatronen 
zijn opgebouwd uit ECM (hoofdzakelijk bestaand uit collageen, laminine en 
verschillende typen heparansulfaatproteoglycanen) met verspreid daarin 
ingebed bloedvaten. Intraveneuze injectie van een merkstof (gelabeld 
albumine) in muizen zulke melanoom lesies toonde aan dat in de tumor de 
merkstof de bloedvaten kon verlaten en zich via deze netwerkpatronen te 
verspreiden. Echter open kanalen in de netwerkpatronen waren buiten de 
bloedvaten niet aantoonbaar m.b.v. electronenmicroscopie. Dit patroon van 
merkstofverspreiding kan worden verklaard door aan te nemen dat er transport 
via ruimtes gelegen tussen collagene en laminine vezels optrad, als het ware 
door een zeef. We denken dat de ECM netwerkpatronen dus een 
“vloeistofgeleidend zeefnetwerk” vormen. Verdere functionele analyse toonde 
aan dat kleine moleculaire stoffen relatief snel werden getransporteerd door 
deze netwerkpatronen (hoofdstuk 6). Daarnaast zijn er aanwijzingen dat de 
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netwerkpatronen ook betrokken zijn bij de afvoer van (afval)stoffen (hoofdstuk 
5 en 6), en daarom wat betreft functie lijken op lymfevaten. 
Behalve tumorcellen zijn er langs de netwerkpatronen verschillende andere 
celtypen aanwezig, waaronder macrofagen (hoofdstuk 5, 6 en 7). Hun 
aanwezigheid die vrijwel beperkt is tot de netwerkpatronen, suggereert dat ze 
deze patronen gebruiken als soort geleider om de tumor binnen te komen. Het 
is onbekend wat de macrofagen naar de tumor doet komen. Verschillende 
chemotactische eiwitten kunnen hierbij een rol spelen, zoals endotheel-
monocyt activerend polypeptide-II (EMAP-II). EMAP-II expressie is gerelateerd 
aan de aanwezigheid van macrofagen langs de netwerkpatronen in het 
oogmelanoom (hoofdstuk 7). Het is dus mogelijk dat de tumor macrofagen 
actief naar zich toetrekt door EMAP-II tot expressie te brengen. Wellicht dat 
dan ook tumorcellen deze patronen kunnen gebruiken om de tumor te verlaten 
en om via de bloed- en lymfevaten vervolgens te metastaseren. 
Concluderend hebben we in dit proefschrift duidelijke aanwijzingen gevonden 
dat de ECM van essentieel belang is voor tumorgroei en metastasering van het 
huid- en oogmelanoom. Met name de interactie met bloed- en lymfevaten, de 
expressie van (lymf)angiogene groeifactoren en de vorming van specifieke ECM 
netwerkpatronen zijn belangrijk voor deze processen. Deze netwerkpatronen 
zijn betrokken bij het transport van voedingstoffen vanuit het bloed de tumor 
in, bij transport van (afval)stoffen vanuit de tumor naar de lymfe- en 
bloedbaan, migratie van de tumor door verschillende andere celtypen (met 
name macrofagen) en bij het verlaten van tumorcellen uit de tumor. Met name 
deze laatste drie functies zijn kenmerkend voor lymfevaten. Kortom: de ECM 
netwerkpatronen zijn mogelijk een functioneel alternatief voor het ontbrekende 
lymfevatstelsel in het oogmelanoom. 
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Chapter 2, figure 1 (page 28): Immunohistochemical analysis of the vasculature 
in serial sections of preputial skin (a,c,e) and of squamous cell carcinoma of the 
larynx (b,d,f) (magnification: 200x). a,b: differential staining of capillary and 
venous blood vessels and lymph vessels. Blood vessels (arrows) are stained red by 
mAb PAL-E, lymph vessels (arrowheads) and arteries blue by anti-CD31 (note that 
the blue blood vessel (except arteries) endothelial staining by anti-CD31 is 
overruled by the red staining by PAL-E 7). c,d: adjacent sections stained with the 
mAb QBEnd/10 (CD34). Numerous stromal cells are CD34-positive. e,f: adjacent 
sections stained with the mAb 9D9 (Flt-4). No staining is observed of the blood 
vessel (arrow) whereas lymphatics are positive (arrowhead) in the preputial skin 
(e). Both Flt-4 positive (left arrow) near the tumor cells (T) and negative blood 
vessels (right arrow) at a greater distance from the tumor were observed (f). The 
arrowheads in figure a, c, e and b, d, f mark identical lymph vessels, and the 
arrows identical blood vessels. In c-f, the QBEnd/10 and 9D9 stainings were 
counterstained with Harris' haematoxylin. 
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Chapter 2, figure 2 (page 
30): Immunohistochemical 
analysis of the Flt-4 expression 
using the 9D9 mAb (a,c). Flt-4 
expression was localized on the 
vasculature by comparison to a 
serial section stained by the 
PAL-E/CD31 double staining 
protocol (b,d) in the common 
acquired melanocytic nevus 
(a,b) and dysplastic nevus 
(c,d) Blood vessels are stained 
red by mAb PAL-E, lymph 
vessels and arteries blue by 
anti-CD31 (b,d). Flt-4 is 
present on lymphatic 
endothelium (corresponding 
arrowheads, a,b) whereas 
blood vessels are negative (a-
d). Flt-4 positivity of 
Langerhans cells is indicated by 
the arrows (a). Sections in a 
and c were counterstained with 
Harris' haematoxylin. Magni-
fication:100x. 
Chapter 2, figure 3 (page 
30): Immunohisto-chemical 
analysis of the Flt-4 
expression using the 9D9 mAb 
(a,c,e). Flt-4 expression was 
localized on the vasculature 
by comparison to a serial 
section stained by the PAL-
E/CD31 double staining 
protocol (b,d) and anti-CD34 
MAb (f). Blood vessels are 
stained red by mAb PAL-E, 
lymph vessels and arteries 
blue by anti-CD31. (b,d). In 
primary nodular melanoma 
lesions (a,b) and cutaneous 
metastatic (c,d) melanoma 
lesions, Flt-4 is present on the 
blood vasculature. Flt-4 is 
expressed on blood vessels in 
areas of regression in a 
superficial spreading 
melanoma (horizontal growth 
phase) (e,f). Melanoma cells 
(e, asterisk) sometimes 
expressed Flt-4 as well. 
Sections in a,c,e and f were 
counterstained with Harris' 
haematoxylin. Magnification 
a-b:100x; c-f: 200x 
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Chapter 3, figure 1 (page 42): Immunohistochemical analysis of the 
vasculature (a), Flt-4 (b,d,f) and VEGF-A (c,e) expression in a lymph node 
metastasis (a,b) and cutaneous metastatic lesions (c-e) of cutaneous melanoma 
in a human patient. Blood vessels are stained red by blood vessel marker PAL-E, 
lymph vessels blue by the pan-endothelial marker CD31 as previously 
described.10,18 Blue blood vessel endothelial staining by the anti-CD31 mAb is 
overruled by the red staining by PAL-E and thereby not visible. In a and b, the 
lymphatic endothelial wall of the marginal sinus containing tumor cells and 
lymphocytes (LS, a) is indicated by the arrowhead. CD31-positivity was also 
observed occasionally on lymphocytes (*, a). Blood vessel in the tumor lesion 
were strongly positive for Flt-4 (b). Strong VEGF-A staining of tumor cells co-
localised with VEGF-A (arrowhead, c) and Flt-4 (d) on endothelial cells. A 
number of cells, likely inflammatory cells, adhere to the endothelium (arrow, c) 
which are also positive for Flt-4 (d). In e and f, VEGF-A expressing tumor cell 
islets (T) are surrounded by stroma. At some distance of these tumor cells, a 
blood vessel (indicated by the asterisk in its lumen, e) is hardly positive for VEGF 
and Flt-4. Two lymphatic vessels are Flt-4 positive (arrows, f). Magnification a,b: 
200x, c-e: 250x. Sections in b-e were counterstained with Harris' haematoxylin. 
Appendix 
 129
Chapter 4, figure 2 (page 
54): (Immuno)histochemical 
analysis of the vasculature in 
a preputial skin section 
shows differential staining of 
blood and lymph vessels. 
Blood vessel capillaries and 
venules are stained red by 
the PAL-E mAb, lymph 
vessels and arteries blue by 
the anti-CD31 mAb (a). 
Corresponding lymphatics in 
a, b and c are indicated by 
asterisks, two arteries by 
arrows and a remaining vein 
by arrowheads. In b, staining 
by an anti-alpha-smooth 
muscle actin mAb 
demonstrated the absence of 
smooth muscle cells in 
lymphatics, whereas all blood 
vessels are positive. In c, 
anti-CD34 staining is 
selectively confined to the 
blood vasculature including 
arteries (arrows). Numerous stromal cells are CD34-positive as well. In d, Masson 
trichrome histo-chemistry of the boxed area (a) is depicted, showing that evident 
differences in vessel morphology are present (using a modified protocol, connective 
tissue stains green instead of blue): in the lymphatic vessel wall (asterisk) only 
endothelial cells are present. Stainings in b and c were counterstained with Harris' 
haematoxylin. Magnification a,b,c: 100x; d: 250x. 
 
Chapter 4, figure 3 (page 54): 
Immunohistochemical analysis of the 
vasculature in serial sections of the 
choroidal layer of the ocular wall. a: 
differential staining of blood and lymph 
vessels. Blood capillaries and venules are 
stained red, lymph vessels and arteries 
blue. By comparison with the anti-CD34 
staining (b) and on basis of previous 
results,27 the blue vessel was classified 
as an arterial vessel. No lymphatics were 
present. b: adjacent section stained with 
the mAb QBEnd/10 (anti-CD34), 
counterstained with Harris' 
haematoxylin. Magnification: 200x. 
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Chapter 4, figure 4 (page 53): Immunohisto-chemical analysis of the 
vasculature in cutaneous (a) and uveal (b,c,d) melanoma. Blood capillaries 
and venules are stained red by mAb PAL-E, lymph vessels and arteries blue by 
anti-CD31 (a,b,c). The arrow indicates staining of the basal membrane by 
mAb PAL-E. No lymphatics or large arteries are present in the uveal 
melanoma (b). Details in the area marked in b are depicted in c and d. The 
vasculature in c is clearly stained red by mAb PAL-E. Macrophages (arrow) 
containing melanin are present along the vasculature. In an adjacent section 
(d), the anti-CD34 mAb produced a weaker staining signal than the PAL-E 
mAb (corresponding arrowheads in c and d). Magnifications: a: 200x, b: 100x 
and c,d: 250x. CD34 staining in d was counterstained with Harris' 
haematoxylin. 
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Chapter 5, figure 2 (page 67): Evaluation of extracellular matrix and blood vessels in 
human primary melanoma (a,b) and xenografts of cutaneous melanoma (c,d) in serial 
paraffin-embedded sections. Extracellular matrix is stained blue, nuclei of tumor cells 
red and erythrocytes intensely red by Azan histochemistry (a,c). Arcs and back-to-back 
loop network patterns were clearly visualized. Blood vessels were detected by CD34 (b) 
and ASD-13 (d) immunohistochemistry. Parts of the matrix patterns were also CD34-
positive (arrow, b). Within the matrix patterns, no lumina were observed except where 
blood vessels were present. Erythrocytes were exclusively observed in association with 
endothelial immunostaining. In e-i, the distribution of i.v. administered tracer (FITC-
BSA) in cryosections of xenografts of Mel57 melanoma cells was evaluated. In serial 
sections, the distribution of endothelium (e) and laminin (f) was visualized by 
immunostaining demonstrating a similar pattern as observed by Azan and endothelial 
(immuno) histochemistry in paraffin-embedded tissues (see also figure 1,3 (pages 70-
71). In Mel57-xenografts, the tracer (green, h) is distributed in and outside the blood 
vasculature stained red by endothelial marker Mec 7.46 mAb (g), along the 
extracellular matrix, stained red by laminin Abs (i). A space between the laminin sheets 
surrounding coherent groups of tumor cells is indicated by the arrow. CD34, ASD-13, 
Mec 7.46 (e) and laminin (f) stained sections were counterstained with Harris' 
haematoxylin. Bar = 0.1 mm. 
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Chapter 6, figure 2 (page 
82): Distribution of FITC-I 
(b) and FITC-D20 at 2 min 
(e) and FITC-D2,000 at 60 
min (h) after i.v. injection. 
Endothelial cells were 
detected by CD31 (in red: 
a,d,g) and the ECM 
patterns by laminin (in 
blue: c,f,i) immuno-
fluorescence. FITC-I and 
FITC-D20 rapidly distri-
buted in- and outside the 
vasculature along the ECM 
patterns. The fuzzy 
fluorescence pattern seen 
with FITC-I or FITC-D20 
may indicate leakage 
between tumor cells 
outside the ECM patterns 
(arrowheads b,e). In e, 
tumor cell nuclei are visible 
(arrowhead). To show 
FITC-D2,000 in more 
detail, tracer distribution in 
the boxed area (g) 
containing a large vessel is 
depicted in the boxed area 
in h by digitally 
superimposing g on h. Endothelial CD31 staining in the boxed area in e has been 
superimposed on tracer staining (inset, h). FITC-D2,000 leaked into the perivascular 
space (arrowhead, h) whereas only minimal leakage into matrix structures occurred in 
the neighbourhood of major vessels (arrow, h). Magnification: 400x In j, Tracer 
distribution data in the course of time after i.v. injection is summarized. Dashed boxes 
indicate intra- or directly perivascular presence of tracer (as shown in figure 2e); boxes 
with gray to black filling indicate increasing amounts of tracer present in the ECM 
patterns (as shown in figure 2d,e,g). White boxes represent absence of tracer. NT: not 
tested.  
 
 
 
Chapter 6, figure 3 (page 84): DNA 
in situ hybridization analysis of a 
melanoma xenograft lesion using total 
human DNA (labeled blue) and total 
murine DNA (labeled red) for 
simultaneous differential detection of 
human and murine cells. Murine cells 
were associated with the ECM 
patterns (arrowhead) and formed the 
endothelial lining of the 
microvasculature (asterisks). 
Sporadically, murine cells infiltrated 
inside tumor cells nests (arrow). 
Magnification: 400x. 
